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Animal venoms and toxins from snakes, scorpions, spiders and bees, 
have been widely applied in both traditional medicine and current 
biopharmaceutical research. Possessing anticancer potential is another novel 
discovery for animal venoms and toxins. An increasing number of studies 
have shown the anticancer effects of venoms and toxins of snakes, scorpions 
and others in vitro and in vivo, which were achieved mainly through the 
inhibition of cancer growth, arrest of cell cycle, induction of apoptosis and 
suppression of cancer metastasis.  However, more evidence is needed to 
support this concept and the mechanisms of anticancer actions are still not 
clearly understood.  Therefore, in this study, several scorpion venoms were 
screened and the anticancer potential of Hottentotta hottentotta scorpion 
venom (BHV) and the L-amino acid oxidase (LAAO) from Crotalus adamanteus 
snake venom were extensively evaluated and investigated in NUGC-3 human 
gastric cancer cells and xenograft model.  
Crude venoms of Mesobuthus martensi karsch, Hottentotta 
hottentotta, Heterometrus longimanus and Pandinus imperator scorpions, 
were screened for their anti-proliferative effects to gastric cancer cells, with 
results showing that BHV was the most inhibitory to NUGC-3 cell proliferation 
with low IC50 (8.12 µg/ml). Further studies indicated that BHV decreased the 
cell viability of NUGC-3 cells by cell cycle arrest at sub-G1 phase and 
 xi 
 
induction of apoptosis. In NUGC-3 gastric cancer mouse xenograft model, 
BHV inhibited tumor growth, histologically disrupted tumor homogeneity and 
induced apoptosis in situ. Interestingly, at low concentration (2 µg/ml), BHV 
also suppressed NUGC-3 cell migration and invasion.  
BHV crude venom was partially purified and characterized by HPLC, 
SDS-PAGE and mass spectrometry, with the identification of L-amino acid 
oxidase (LAAO) as an active molecule. However, as crude BHV was almost 
used up and the supplier was not able to continue the supply, a commercially 
available LAAO from Crotalus adamanteus snake venom was applied to 
investigate the anticancer potential of LAAO in gastric cancer cells. Similarly, 
it was observed that LAAO decreased the cell viability of gastric cancer cells 
dose-dependently, arrested cell cycle at G2/M phase, induced cell apoptosis 
and inhibited cell migration at low concentration. These functional studies 
revealed (for the first time) that BHV and LAAO from Crotalus adamanteus 
snake venom exert anticancer effects in gastric cancer via cell cycle arrest, 
induction of apoptosis and inhibition of cancer metastasis.  
Another contribution from this work is the clarification of the 
mechanisms for BHV and LAAO`s anticancer actions. A caspase-independent 
apoptosis (CIA) induced by BHV and LAAO was confirmed by western blot, 
caspase-3 activity assay and the presence of pan caspase inhibitor z-VAD-fmk. 
Increase of intracellular ROS, with permeabilization of mitochondrial 
membrane and the translocation of AIF from mitochondria to nucleus were 
 xii 
 
also observed in LAAO induced CIA. Moreover, using genomic and 
transcriptomic approaches, the MAPK/ERK pathway was found to be 
inhibited by both BHV and LAAO treatment. Finally, several gene and protein 
candidates were elucidated from microarray and SILAC data, such as EIF, 
HNRNP and HSP families as well as TUBB, TOP2A and SDHA, which could be 
good anticancer targets and deserve further investigations.  
Taken together, this study evaluated and confirmed the anticancer 
potential of BHV and LAAO from Crotalus adamanteus snake venom using 
gastric cancer model. The MAPK/ERK pathway was identified as the 
mechanistic pathway responsible for the anticancer activities of BHV and 
LAAO. The novel findings shed light on the development of anticancer agents 
from scorpion venoms and L-amino acid oxidases, and provided biological 
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1.        INTRODUCTION 
1.1     Gastric cancer 
1.1.1  Epidemiology 
According to the World Health Organization (WHO), cancer has 
surpassed heart disease to become the leading cause of death worldwide, 
accounting for 14.1 million new cases and 8.2 million deaths in 2012. Lung, 
liver, stomach, colorectal and breast cancers are the most common causes of 
cancer death. More than 60 percent of new cancer cases come from less 
developed regions such as Africa and Asia.  
Gastric cancer, also called stomach cancer, refers to the tumors that 
arise from any part of the stomach, which is a J-shape gastrointestinal organ 
consisting of 5 parts: cardia, fundus, body, antrum and pylorus. The inner 
lining of the stomach has four layers: serosa, muscularis, submucosa and 
mucosa (Fig 1.1) (Clayburgh et al., 2004).  
 
 
Fig 1.1 Structures of human stomach (modified from stomach: structure. Art. 
Encyclopædia Britannica,2010). Left, regions of the stomach; Right, the inner 






Due to the high incidence and mortality rates, gastric cancer has 
become a major health burden for most countries in the last few decades. In 
2012, gastric cancer accounted for 952,000 new cases, which makes it the 5th 
most common cancer worldwide. More perturbing is the fact that it causes 
723,000 cancer deaths and ranks as the 3rd leading death of cancer in 2012, 
only behind lung and liver cancers (Ferlay et al., 2013). Gastric cancer mostly 
occurs in patients between ages of 60 to 80 and shows a male 
preponderance with an approximate male: female ratio of 2:1. As most 
patients are diagnosed at advanced stages, the 5-year survival rate is low, at 
only about 20 percent (Nagini, 2012). From the geographical perspective, 
there are high incidence rates in Eastern Asia, Eastern Europe, and South 
America. In contrast, low incidence rates are documented in North America 
and most parts of Africa. Males in China, Korea and Japan now predominate 
with up to 30 new diagnosed cases per 100,000 population per year (Jemal et 
al., 2011). This regional variation is attributed to genetic differences, dietary 
patterns and the high association of Helicobacter pylori infection (Parkin, 
2006).  
In Singapore, even though there is a declining trend in gastric cancer,  
it remains the 7th most frequent cancer in males and 8th most frequent 
cancer in females respectively, leading to  1611 cancer deaths for both 
gender (data 2008-2012) (Singapore Cancer Registry, 2014). Moreover, there 
is a difference between various ethnic groups in Singapore. Chinese males 






000 population per year) of 25.7. Whereas, Malay and Indian males have 
lower incidence rates as ASR decreases to 8.4 and 6.6, respectively (Look et 
al., 2001).  
 
1.1.2  Risk Factors 
Gastric cancer is a multifactorial disease with complex interactions 
and combination effects between different risk factors. Helicobacter pylori (H. 
pylori) bacterial infection is considered as one primary risk factor for gastric 
cancer. Several meta-analyses performed in gastric cancer has proven that H. 
pylori chronic infection is associated with a two-fold increased risk of 
developing distal gastric carcinoma and gastric mucosal lymphoma in human 
(Eslick, 2006). In 1994, based on the evidences from numerous 
epidemiological and animal studies, the WHO International Agency for 
Research on Cancer has characterized H. pylori as a "Group 1 human 
carcinogen" (IACR, 1994). However, even though over 50% of the world 
population is infected by H. pylori, only 2 percent of the infected individuals 
progress to gastric cancer and H. pylori does not increase the risk of proximal 
or cardia gastric cancers (Group, 2001; Suerbaum et al., 2002). Therefore, a 
combination of a virulent bacterial strain, environment factors (i.e. smoking 
and dietary factors) and the host genetic susceptibility is established to be 
responsible for H. pylori -induced gastric cancer (Kim et al., 2011). Studies 
show that strains possessing the cytotoxin-associated gene A (CagA) are more 






driving forces for H. pylori-induced gastric carcinogenesis include generation 
of oxidative stress, DNA damage and cell cycle dysregulation as well as 
changes in epithelial gene expression (described in section 1.1.5) and loss of 
gastric acidity (Kim et al., 2011). Preclinical and clinical data show that the 
eradication of H. pylori can inhibit or even regress the progression of 
precancerous lesions, shedding light on the potential to prevent gastric 
cancer by early screening and removal of H. pylori in patients. However, the 
time the H. pylori infection is detected should be taken into account as 
atrophic gastritis and intestinal metaplasia are irreversible where genetic 
changes have already occurred (Malfertheiner et al., 2006).  
Another important risk factor for gastric cancer is diet. High 
consumption of salt and salt-preserved foods is strongly associated with the 
increased risk of developing gastric cancer. It is found that salt intake will 
enhance H. pylori colonization, cause direct damage to gastric mucosa, and 
eventually lead to gastritis (Wang et al., 2009; D'Elia et al., 2012). Also, 
dietary nitrates and nitrites from processed meat, smoked foods as well as 
animal foods being grilled, baked, roasted and barbecued, can increase 
gastric cancer risk, because all these practices enhance the formation of 
carcinogenic N-nitroso compounds. On the other hand, non-starchy 







Other risk factors include tobacco, alcohol and family history. The 
European Prospective Investigation into Cancer and Nutrition (EPIC) project 
observed a significant association between cigarette smoking and gastric 
cancer risk, with 1.45 hazard ratio (HR) for smokers (Gonzalez et al., 2010). 
The risk is increased by two to three folds if the patient has first-degree 
relatives with gastric cancer (Dhillon et al., 2001).  
 
1.1.3  Classification 
1.1.3.1  Types of gastric cancer 
In terms of the origins of neoplastic cells, gastric cancers can be divided into 
different types. About 90% to 95% of gastric cancers are adenocarcinomas 
and   generally the term "gastric cancer" refers to adenocarcinoma of the stomach 
(Lawrence, 2004). Stomach adenocarcinoma indicates the cancer starting in the 
glandular tissue that lines the lumen of the stomach. Other types of cancerous 
tumors that originate from the stomach include lymphoma, squamous cell cancer, 
gastrointestinal stromal tumour (GIST) and carcinoid tumors (Hu et al., 2012). With 
respect to anatomical location, stomach cancers are classified into cardia (proximal) 
stomach cancer, non-cardia (distal) stomach cancer and diffused stomach cancer.  
1.1.3.2  Histological classification of gastric cancer 
Several classification systems have been proposed for gastric cancer based 
on microscopic-morphological features (Table 1.1). The two most commonly used 
systems are Lauren`s classification and WHO classification. The Lauren`s 






cell adhesion between tumor cells, defines gastric cancer as two major types: 
intestinal and diffuse (Lauren, 1965). The intestinal type is characterized by cohesive 
cells that form gland-like structure, whereas in diffuse type, cell adhesion is absent 
so that the individual cell can infiltrate and thicken the stroma wall. The 
development of intestinal type gastric cancer normally involves sequential 
histopathological changes in gastric mucosa, including atrophic gastritis, intestinal 
metaplasia and dysplasia that ultimately progresses to carcinoma (Correa et al., 
2012).  
Table 1.1 Gastric cancer classification systems 
WHO (2010) Lauren (1965) Ming (1977) 
Tubular adenocarcinoma 
Intestinal type Expanding type Papillary adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
Diffuse type Infiltrating type 
Other poorly cohesive carcinomas 
 
One detailed classification system is provided by WHO in which gastric 
cancers are recognized as four major histologic patterns: tubular 
adenocarcinoma, papillary adenocarcinoma, mucinous adenocarcinoma, 
signet-ring cell adenocarcinoma and others (Hu et al., 2012). Tubular 
carcinoma and papillary carcinoma are two common types in early gastric 
carcinoma, which are characterized by irregular-shaped and fused neoplastic 
glands and epithelial projections supported by fibrovascular cores. Mucinous 






In signet-ring cell carcinoma, the nucleus of tumor cells is compressed to the 
edge of the cell by the unsecreted mucous in the cytoplasm. 
Another practical classification was proposed by Ming in 1977 (refer 
to Table 1.1) on the basis of different growth and invasiveness patterns of the 
cancer: the expanding type contains discrete tumor nodules and is 
prognostically favourable, whereas the infiltrating type contains individually 
invaded tumor cells and has a poor prognosis (Ming, 1977).  
 
1.1.4  Early screening, diagnosis and prognosis 
One reason for the low 5-year survival rate of gastric cancer is that 
this disease is usually detected in late stage as most patients experience 
vague and nonspecific symptoms in the early period. Anemia, weight loss, 
weakness or fatigue, abdominal pain, vomiting may accompany tumor 
invasion and metastasis (Axon, 2006). There is a long period for the stomach 
epithelial lining to become cancerous and the development of early gastric 
cancer is slow (Tsukuma et al., 2000). Thus, screening and early diagnosis are 
of great importance for gastric cancer intervention. In Japan, one third of 
gastric cancer cases are detected at an early stage due to rigorous screening 
processes (White et al., 1985).  
Radiographic investigation of upper gastrointestinal tract (barium 
meal) and endoscopy are two useful tools to screen pre-malignant gastric 






and convenient for initial screening. Endoscopy followed by pathologic 
assessments can provide higher detection sensitivity and is increasingly used 
for gastric cancer screening. However, the limitation is the dependence on 
the skills of the endoscopist and the instrument availability, which makes it 
unfeasible for mass screening (Leung et al., 2008). Endoscopic ultrasound 
(EUS), computed tomography (CT) and magnetic resonance imaging (MRI) are 
now frequently used to facilitate diagnosis of gastric cancer, which provide 
more detailed information about tumor infiltration and metastasis.  
Over the past years, many efforts have been made to search for 
biological markers for early detection and diagnosis of gastric cancer. 
Measurement of serum pepsinogen (PG) is considered as a convenient and 
non-invasive test for gastric cancer. Pepsinogen contains two types: PGI and 
PGII and the PG I/II ratio is a good indicator of atrophic gastritis. Based on the 
studies on Japanese, the combination of H. pylori serology and pepsinogen 
test has good prediction for intestinal gastric cancer (Watabe et al., 2005).  
The clinicopathologic stage is the most important indicator of 
resectability and prognosis for gastric cancer. The most commonly used 
system is the TNM classification (tumor stage, lymph node status and 
presence of metastasis) by the American Joint Committee on Cancer (AJCC) 
(Edge et al., 2010). Early gastric cancer (EGC) is defined as adenocarcinoma 






metastasis. Thus, compared with the TNM classification, EGC refers to any 
gastric cancer with tumor stage less than T2.  
 
1.1.5  Molecular changes in gastric cancer: genetic and epigenetic 
alterations 
Gastric cancer is a heterogeneous disease and it is estimated that 80-
90% gastric cancers are sporadically developed (Al Saghie, 2013). 
Understanding the molecular changes in gastric tumorigenesis is critical for 
the early detection and the identification of novel therapeutic targets. 
Studies from past few decades have shown that a number of genetic and 
epigenetic alterations occur in the multistep processes of gastric 
carcinogenesis. Such changes include point mutation, chromosome instability 
(loss of heterozygosity, translocation and amplification), microsatellite 
instability and hypermethylation, which are involved in the regulations of  cell 
cycle, cell apoptosis, DNA repair, inflammation, invasion and angiogenesis 
(Hamilton et al., 2006).  
 Microsatellite instability: 
Microsatellites are short repetitive DNA sequences (2-7 nt) in the 
genome. Microsatellite instability (MSI) occurs in DNA replication as a result 
of defective DNA mismatch repair. MSI was initially reported in colorectal 
cancer and became a hallmark of the hereditary non-polyposis colorectal 






gastric cancers (Ottini et al., 2006). Mutation or epigenetic inactivation of 
mismatch repair genes leads to MSI phenotype, such as hMLH1 and hMSH2. 
In gastric cancer, more than 50% of patients showing high levels of MSI, are 
due to the hypermethylation of hMLH1 promoter. The affected genes by MSI 
are normally tumor suppressor genes in cell cycle, apoptosis and DNA repair, 
including TGFβ RII, IGFIIR, BAX, MSH6, MSH3, et al. (Hudler, 2012). All these 
genomic alterations further enhance genomic instability and promote gastric 
carcinogenesis. However, one interesting finding is that high MSI is reported 
to be associated with unique clinical-pathological features, favourable 
prognosis and better survival outcome. Patients with high MSI display a 
higher frequency of intestinal histotype, antral location, and a decreased 
prevalence of nodal metastasis (Iacopetta et al., 1999; Beghelli et al., 2006; 
Corso et al., 2009). This phenomenon is proposed to be related to the 
increased host immune response (Chiaravalli et al., 2006).  
Involvement of p53:   
p53, a tumor suppressor gene, regulates cell growth and apoptosis in 
response to DNA damage. More than 50% of human cancers contain p53 
gene mutation. Similarly, mutation and inactivation of p53 by loss of 
heterozygosity, missense mutation or frameshift deletion, are widely 
documented in gastric cancer and its precursor lesions: intestinal metaplasia 
(38%), dysplasia (58%) and gastric carcinoma (67%), suggesting its critical role 






Although the p53 mutation is more frequent in patients with H pylori 
infection, the mechanism of p53 mutagenesis by H pylori infection has not 
been elucidated (Kubicka et al., 2002).  
HER-2: 
Human epithelial growth factor receptor 2 (HER-2), also called c-erbB-
2, is a membrane receptor of the tyrosine kinase family. With IHC and FISH 
techniques, it is found that HER2 is over-expressed in approximately 20% of 
gastric cancer, especially in intestinal type gastric carcinoma (Gravalos et al., 
2008). Moreover, according to clinical data, high level expression of HER2 is 
significantly associated with tumor size, serosal invasion, lymph node 
metastases as well as poorer prognosis and 10-year survival (Uchino et al., 
1993; Vizoso et al., 2004). All these evidence indicate that HER2 could be an 
effective prognostic marker and a target for molecular targeted therapy for 
intestinal gastric cancer. 
E-cadherin: 
E-cadherin is a protein that controls cell-cell adhesion and cell polarity. 
Abrogation of E-cadherin results in the loss of adherens junction, cellular 
polarity and contact inhibition, reduces cell adhesiveness and enhances 
cancer cell migration and invasion (Vleminckx et al., 1991; Handschuh et al., 
1999). The germline mutation of E-cadherin gene, CDH1, has been described 
in a subset of hereditary diffuse gastric cancers and  CDH1 mutations are the 






about 50% of cases or more (Graziano et al., 2003). In susceptible individuals 
with CDH1 germline mutation in one allele, the loss or inactivation of the 
other normal allele is achieved by deletion of the whole gene or promoter 
hypermethylation. Finally, loss of function of E-cadherin is linked with 
enhanced metastasis and poor survival, further highlighting its importance in 
the pathogenesis of diffuse gastric cancer (Kawanishi et al., 2000).   
Other molecular abnormalities and research interests include K-ras 
and K-sam (oncogenes), RUNX3 and SMAD4 (tumor suppressors), APC/β-
catenin (cell adhesion), COX-2 (inflammatory mediator), EGFR and VEGF 
(invasion and angiogenesis), p16, p21, p27 and Cyclin E (cell cycle regulation), 
Bcl-2 and Bax (apoptosis regulation), as well as matrix metalloproteinases 
(MMPs) and microRNAs (miRNAs)  (Hamilton et al., 2006; Nobili et al., 2011; 
Resende et al., 2011; Nagini, 2012). The molecular alterations in the 




Fig 1.2 Diagrammatic representations of the molecular alterations in the 
progress of gastric carcinogenesis. , genes mainly involved in the 
progression of intestinal GC; , genes involved in both intestinal and 
diffuse GC; , genes mainly involved in diffuse GC. ↑ indicates over-
expression or up-regulation; ↓ indicates inactivation, reduced-expression 







1.1.6  Treatment of gastric cancer: conventional and targeted therapies 
With the advances in surgical and adjuvant chemo- or radio-therapy, 
treatment of gastric cancer has improved over the last 30 years. Nevertheless, 
the overall survival rate is still low for gastric cancer, because the majority of 
patients are diagnosed at advanced stages with locally advanced tumors, 
regional lymphnode involvement, or metastasis to distant organs. Endoscopic 
mucosal resection and submucosal dissection can be only applied in very 
early stage, when the primary tumor is small and limited to the mucosa 
(Gotoda et al., 2013). Surgical gastrectomy remains the mainstay of 
treatment to remove localised tumors. 30-50% of gastric cancer patients are 
fortunate to receive a curative-intent surgery, with 5-year survival rates of 60% 
and 34% for stage I and stage II diseases, respectively (Morabito et al., 2009). 
Preoperative, perioperative and postoperative chemotherapy or 
radiotherapy are normally conducted to reduce the tumor size, lower the risk 
of recurrence and improve survival and life quality of patient.  
Results from meta-analyses show a significant benefit of adjuvant 
chemotherapy in the treatment of completely resected gastric cancer (Earle 
et al., 1999; Panzini et al., 2002). The efficacy of neoadjuvant therapy 
(chemotherapy, chemoradiotherapy and immunotherapy) for locally 
advanced tumors and those with high risk of recurrence after surgery is 
under investigation. For unresectable locally advanced or metastatic gastric 






treatment. Combination chemotherapy with docetaxel, cisplatin and 5-FU 
(DCF) has been shown to improve the overall survival (OS) and has advantage 
compared with single drug or CF (Van Cutsem et al., 2006).  New generation 
of cytotoxic drugs in systemic chemotherapy include S1 (block thymidine 
synthesis), oxaliplatin (crosslink DNA) and irinotecan (topoisomerase inhibitor) 
(Power et al., 2010).  
However, poor outcome of survival of advanced gastric cancer shows 
that conventional therapies are still not optimum. Moreover, toxicity to 
normal tissues, resistance to treatment and recurrence of tumors are needed 
to be taken into account. Therefore, the emergence of targeted therapy 
opens a new way for researchers and doctors to treat gastric cancer. An 
increased understanding of gastric cancer biology such as genetic and 
epigenetic alterations and signal transduction pathways that are involved in 
cell proliferation, apoptosis and metastasis, has lead to the development of 
molecular targeted drugs. A number of targeted molecule-based drugs, which 
target vascular endothelial growth factor (VEGF), epidermal growth factor 
receptor (EGFR) and HER-2, cyclin-dependent kinase (CDK), mammalian 
target of rapamycin (mTOR) and matrix metalloproteinase (MMP) (Fig 1.3), 
are in clinical phase II/III trial and giving promising outcome (Zagouri et al., 





















For targeted therapies, two common strategies are being used for 
drug development, viz. monoclonal antibodies and small molecule inhibitors. 
Antibodies can directly bind and block signal factors and receptors in cancer 
cells or trigger the immune system mediated-cell killing (Scott et al., 2012). 
Such examples in gastric cancer targeted therapies include trastuzumab and 
pertuzumab (anti-HER-2), cetuximab (anti-EGFR), bevacizumab and 
ramucirumab (anti-VEGF). Small molecule inhibitors are compounds that can 
enter cancer cells and interfere with the enzymatic function of receptor 








Fig 1.3 A diagrammatic representation of novel target-based drugs in 
gastric cancer treatment (redrawn with reference to Morabito et al., 
2009). 
Drugs used in targeted 






tyrosine kinases or intracellular signaling molecules to inhibit or stop 
aberrant signal transduction. Most inhibitors will compete with ATP binding 
in the catalytic domain of the respective target (Zhang et al., 2009a). The 
small molecule inhibitors under investigation in gastric cancer therapy 
include erlorinib and gefitinib (anti-EGFR), lapatinib (dual inhibitor of EGFR 
and HER-2), sunitinib and sorafenib (anti-VEGF), everolimus (mTOR inhibitor), 
bortezomib (proteasome inhibitor) (Yamada, 2012). 
Trastuzumab (Herceptin®, Genentech), is a humanized 
immunoglobulin G1 monoclonal antibody against the HER-2/neu receptor. It 
has been approved by FDA in combination with chemotherapy as adjuvant 
treatment of HER-2 positive breast cancer (Smith et al., 2007). More than 20 
percent of gastric cancers show HER-2 overexpression, predominantly in 
intestinal type (Albarello et al., 2011). One phase III clinical trial, ToGA, has 
been conducted to evaluate the combination effect of trastuzumab with 
cisplatin/5-FU in the treatment of metastatic HER-2 positive 
gastroesophageal and gastirc cancers. Results have shown that trastuzumab 
can significantly increase the objective response rate (ORR), median 












1.2  Scorpion venoms and toxins and their effects on cancer 
1.2.1  Animal venoms and toxins, an introduction 
Venomous animals produce venoms/toxins from specialized organs 
named venom glands. Venomous animals have long history of evolution and 
cover a wide range of species, e.g. snakes, scorpions, spiders, bees, lizards, 
cone snails and sea anemones. The venoms can be secreted from teeth, 
stingers, claws or even skins of these animals, to paralyze and kill the prey or 
to protect themselves from predation and other dangers.  
Venomous animals often have negative reputations because of the 
morbidity and mortality inflicted by their bites or stings. The signs and 
symptoms after exposure to venoms vary from mild allergic reactions, itch, 
pain, swelling to respiratory arrest, paralysis, necrosis or even death 
(Weinstein et al., 2009). Envenomation has become a global health concern 
and the antivenom strategies are needed to be established and developed.  
Nevertheless, animal venoms and toxins are also beneficial to human 
beings in terms of their applications in medical and pharmaceutical research 
and industry. The usage of animal venoms in folk medicine has been 
documented since long-time ago in some countries, like China, India and 
Middle East. For example, Chan Su, the dried toad venom from skin glands, 
first recorded in traditional Chinese medicine more than 1,000 years ago, has 






2009). Animal venoms are complex cocktails with various bioactive proteins 
and peptides and they are quite variable between different species, making 
animal venoms a rich source for drug discovery. For the last 30 years, animal 
venoms and toxins have been widely investigated in the treatment of  human 
disorders, such as diabetes,  hypertension, chronic pain, HIV, cancer, etc. Up 
to now, six FDA-approved drugs are derived from venom proteins or peptides, 
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1.2.2  Scorpion biology 
Scorpions are among the most well-known venomous arthropod 
animals, which belong to the order Scorpiones under the class Arachnids. 
Evolutionarily, scorpions are one of the oldest creatures and have existed on 
earth for more than 400 million years since the middle Silurian period. 
Scorpions are widely distributed all over the world which mostly occupy 
temperate, desert, and tropical habitats except for Antarctica. Over 1,500 
species have been reported so far and assigned to 13 families according to 
the current higher classification after 2003: Bothriuridae, Buthidae, 
Caraboctonidae, Chactidae, Chaerilidae, Euscorpiidae, Hemiscorpiidae, 
Iuridae, Microcharmidae, Pseudochactidae, Scorpionidae, Superstitioniidae 
and Vaejovidae (Williams, 2009). The family Buthida is the largest, the most 
widespread and more importantly the most studied in biomedical research. 
The Buthida family contains more than 500 species and  is represented by the 
genera Androctonus, Buthus, Mesobuthus, Buthotus, Parabuthus and Leirus, 
which are located in North Africa, Asia, the Middle East, and India (Loret et al., 




























Fig 1.4 Representative geographic distribution of Buthida scorpions around 
the world (redrawn with reference to Loret et al., 2001). Dashed lines 
indicate equator and 50° latitude north and south. Aah, Androctonus 
australis hector; Amm, Androctonus mauretanicus mauretanicus; Be, 
Buthus epeus; BmK, Buthus martensi Karsh; Bom, Buthus occitanus 
mardochei; Bot, Buthus occitanus tunetanus; Bt, Buthus tamulus; Clt, 
Centruroides limpidus; Cn, Centruroides noxius; Cs, Centruroides 
sculpturatus; Css, Centruroides suffuses suffuses; Lqh, Leiurus 








The scorpion has a variable size of approximately 1-20 cm and is 
characterized by its segmented morphology. Scorpion comprises 3 parts: the 
head (prosoma, with a pair of chelae for prey immobilisation, defence and 
sensory purposes); the abdomen (mesosoma, with 4 legs on each side); the 




Fig 1.5 Anatomy of scorpion represented by the Heterometrus spinifer 






A pair of venom glands is located in the telson, which are segregated 
by a muscle septum. Each gland has a tortuous lumen, surrounded by folded 
glandular epithelium. Upon stimulation, the muscle will contract and the 




1.2.3  Scorpion venoms and toxins 
Scorpion venoms are produced and secreted by the venom glands for 
offensive or defensive purposes, which are normally milked and collected by 
electrical stimulation in the laboratory.  Scorpion venoms are a complex 
mixture of water, salts, mucoproteins, lipids, nucleotides, glycoaminoglycans, 
histamine, serotonin, biogenic amines, low M.W peptides (e.g. neurotoxins), 
high M.W. proteins (e.g. enzymes), and others (Andreotti et al., 2010). Each 






scorpion has its own component profile in the venom and the number varies 
from dozens to hundreds. 
Small peptides (<10 kDa) are the most important components in 
scorpion venoms, which are believed to be responsible for the intoxication 
and are widely investigated for biomedical and scientific applications. They 
are often considered as neurotoxins because the majority of peptides target 
and modify the ion channels of the excitable cells (e.g. neurons), which 
makes them valuable tools for ion channel research in neuroscience. Based 
on the types of targeted ion channels, scorpion venom peptides can be 
classified into four groups: sodium (Na+) channel toxins, potassium (K+) 
channel toxins, calcium(Ca2+) channel toxins and chloride (Cl-) channel toxins.  
1.2.3.1  Sodium channel toxins (NaScTxs) from scorpion venoms 
The scorpion Na+ channel toxins (NaScTxs) are polypeptides of 60-76 
amino acid residues in length (6.5-8.5 kDa), tightly bound by four disulfide 
bridges (Possani et al., 1999). Current database covers around 200 sequences 
of putative NaScTxs, which can be found in World Wide Web: SCORPION 
(Srinivasan et al., 2002a). As Na+ channel comprises one α subunit and two β 
subunits, Na+ toxins are divided into two categories: α- NaScTxs and β- 
NaScTxs, based on the binding sites and physiological effects. α-NaScTxs bind 
to the receptor site 3 (a domain in α subunit) in a voltage dependent mode 
and inhibit the fast inactivation process of sodium channel (Couraud et al., 






independently of voltage and shift the threshold of channel activation to a 
more hyperpolarized membrane potential. The phyletic preference has been 
reported among NaScTxs, which principally categorizes NaScTxs into two 
groups: "Classical"-highly active on mammalian sodium channels, and "anti-
insect"- highly active on insect sodium channels. The later toxins are further 
subdivided into excitatory and depressant insect toxins (Quintero-Hernández 
et al., 2013). 
 1.2.3.2  Potassium channel toxins (KTxs) from scorpion venoms 
Scorpion venoms are rich sources of potassium channel toxins (KTxs), 
which block several types of K+ channels, e.g. voltage-gated K+ channels 
(Kv1.x), Ca2+ activated K+ channels of small, intermediate and high 
conductance. KTxs are structurally categorized into four families: α-, β-, γ- 
and κ-KTxs, most of which share a conserved cysteine-stabilized α-helical and 
β-sheet structural motif (CSαβ) (Tytgat et al., 1999; Rodriguez de la Vega et 
al., 2004). The α-KTx family is considered as the largest in number, with 
about 140 peptides falling in 26 subfamilies, termed α-KTx1-26 and new 
peptides are described continuously (Diego-García et al., 2013). These 
peptides are composed of 23-42 amino acid residues with 3 or 4 disulfide 
bridges. This family of toxins are important blockers of voltage-gated 
potassium channels and attract much attention in the studies of Kv channel 
structure-function and Kv  related channelopathies (Castle, 2010). The β-KTxs 






interesting short chain peptides mainly targeting hERG channels, which are 
associated with the cell cycle and proliferation of several cancers (Corona et 
al., 2002; Asher et al., 2010). The κ-KTxs toxins are characterized by two 
parallel α-helices linked by two disulfide bridges CSαα, represented by the 
well known κ-Hefutoxin isolated from Heterometrus fulvipes scorpion venom 
(Srinivasan et al., 2002b). Scorpion potassium channel toxins have improved 
our understanding of the physiological and patho-physiological functions of 
potassium channels and contributed to the identification of therapeutic leads 
for Kv related diseases. 
1.2.3.3  Calcium  and Chloride channel toxins from scorpion venoms 
Different from NaScTxs and KTxs, scorpion venom peptides that target 
calcium and chloride channels, are scarcely known and have variable amino 
acid lengths (Possani et al., 2000). Imperatoxin A (IpTxa), purified from 
Pandinus imperator scorpion venom, was the first peptide that was reported 
to have high affinity to ryanodine receptor (RyR, one type of ligand-activated 
calcium channels). IpTxa increases the binding of [3H] ryanodine and induces 
a fast release of calcium from sarcoplasmic reticulum (Valdivia et al., 1992). 
Subsequently, several IpTxa-like peptides were identified from other scorpion 
venoms, including Maurocalcin, Hemicalcin and Hadrucalcin (Quintero-
Hernández et al., 2013). Kurtoxin, a 63 amino acid peptide from the venom of 
the scorpion Parabuthus transvaalicus, was initially shown to bind with high 






that it can also interact with T-, L-, N-, and P-type Cav channels in central and 
peripheral neurons (Chuang et al., 1998; Sidach et al., 2002).  
So far, some small peptides that target chloride channels have been 
identified and characterized. Chlorotoxin (CTX/ClTx), a 36 amino acid small 
peptide purified from the Leiurus quinquestriatus scorpion venom, was 
initially described as a chloride channel blocker that acts as a paralytic agent 
for small insects (DeBin et al., 1993). One remarkable finding and application 
of this toxin is that CTX can specifically bind to the chloride channel on glioma 
cells and inhibit glioma progression (Lyons et al., 2002). Because of its high 
affinity, specificity and low toxicity, CTX is considered as a promising agent 
for imaging and targeted therapies for gliomas. A phase II clinical trial is in 
progress with 131I-TM-601, a synthetic CTX coupled with radioactive iodine 
isotope (Mamelak et al., 2006). Other chloride channel inhibitors from 
scorpion venoms include BmKCT from Mesobuthus martensi, Chlorotoxin-like 
peptide Bs 14 from Buthus sindicus, Toxin PBITx1 from Parabuthus schlechteri, 
et al. (Ali et al., 1998; Tytgat et al., 1998; Zeng et al., 2000).  
1.2.3.4  Scorpion venom peptides with no disulfide bridges 
Apart from the ion channel targeted peptides with disulfide bridges, 
there are a number of non disulfide-bridged peptides (NDBPs) in scorpion 
venoms (Almaaytah et al., 2014). These peptides show high diversity in both 
structure and bioactivities. To date more than 40 scorpion venom NDBPs 






antimicrobial peptides with a board spectrum of activity against bacteria, 
yeast, fungi and viruses (Hancock et al., 2006). Hadruin, a 41 amino acid 
peptide isolated from Hadrurus aztecus,  was the first to show antimicrobial 
activities against both Gram-positive and Gram-negative bacteria at low 
micromolar concentration (10-50 uM) (Torres-Larios et al., 2000). 
Mucroporin-M1, a modified antimicrobial peptide from scorpion Lychas 
mucronatus, was demonstrated to have antibacterial activity against 
antibiotic-resistant pathogens (Dai et al., 2008). Another small group of 
NDBPs are the so called bradykinin potentiating peptides (Bpps). Bradykinin is 
a vasoactive peptide that plays an important role in the regulation of blood 
pressure, which can be inactivated by one enzyme, angiotensin converting 
enzyme and the Bpps are the inhibitors of this enzyme. Peptides T from 
Tityus serrulatus, K-12 from Buthus occitanus and BmKbpp from Mesobuthus 
martensi Karsch are examples in this group (Almaaytah et al., 2014).  
1.2.3.5  High molecular weight enzymes  
The high M.W. proteins in scorpion venoms are mainly diverse 
enzymes, which are believed to contribute to the venom cytotoxicity or 
potentiate the envenomation process. Therefore, a good understanding of 
these enzymes` structures and functions is helpful for anti-venom strategy. In 
contrast to spider and snake venoms, scorpion venoms exhibit low levels of 






venoms include hyaluronidase, phospholipase A2, L-amino acid oxidase and 
proteases (Petricevich, 2010).  
Hyaluronidase: 
Hyaluronidase can be found in several venomous species like snake, 
bee, spider and scorpion. This enzyme can degrade the hyaluronan, an 
extracellular matrix protein in the soft connective tissues around blood 
vessels and increase the diffusion of toxins (Girish et al., 2007). 
Hyaluronidase has been purified from a few scorpion venoms, e.g., 
Heterometrus fulvipes, Tityus serrulatus and Palamneus 
gravimanus.  BmHYA1, a hyaluronidase isolated from Mesobuthus martensi, 
was shown to remove hyaluronan and modulate the expression of CD44 
variant in MDA-MB-231 breast cancer cell (Feng et al., 2008).  
Phospholipase A2 (PLA2): 
Phospholipases A2 (PLA2) are a group of enzymes that hydrolyze the 
ester bonds of phospholipids into lysophospholipid, fatty acids and others 
(Burke et al., 2009). PLA2 can be divided into 4 subfamilies: secretory PLA2 
(sPLA2), cytosolic PLA2 (cPLA2) calcium-independent PLA2 (iPLA2) and 
lipoprotein PLA2 (LpPLA2) (Six et al., 2000). All the PLA2s described in scorpion 
venoms belong to sPLA2, which have low molecular weight (13-15 kDa) and 
are involved in tissue destruction and inflammation during the action of 
scorpionism (Valentin et al., 2000). Several scorpion sPLA2 have been 






venom of the African scorpion Pandinus imperator, Phaiodactylipin from 
wood scorpion (Anuroctonus phaiodactylus) and Heteromtoxin from 
Heterometrus laoticus scorpion venom (Zamudio et al., 1997; Incamnoi et al., 
2013). These enzymes have diverse biological and pharmacological potentials 
like anti-coagulant and anti-bacterial activities (Perumal Samy et al., 2007).  
Proteases: 
Proteases are important proteins in venoms that are involved in the 
post-translational processing of toxins and promote the spreading of toxins 
via degradation of matrix proteins (Almeida et al., 2002). Proteases found in 
scorpion venom glands are quite recently reported with the help of 
proteomic and transcriptome studies. Two main types of proteases are 
identified in scorpion venoms: serine proteases and metalloproteases 
(Valdez-Velázquez et al., 2013). The first metalloprotease purified from 
scorpion venom was named antarease from Brazilian scorpion Tityus 
serrulatus, which cleaves the vesicle-associated membrane proteins 2 and 8 
(VAMP2 and VAMP8) (Fletcher et al., 2010). A serine protease-like protein 
(BMK-CBP) was also isolated from Chinese red scorpion Mesobuthus martensi 







1.2.3.6   L-amino acid oxidases (LAAOs) from scorpion and snake venoms 
L-amino acid oxidases (LAAOs) are a group of flavoenzymes that 
catalyze oxidative deamination of L-amino acid substrates and form the 
corresponding α-keto acids, hydrogen peroxide and ammonia (Du et al., 
2002). LAAOs can be widely found in nature, including bacteria, fungi, 
seaweeds and snake venoms. Normally, LAAOs are homodimeric, FAD-
binding glycoproteins with 3-4% carbohydrate with molecular weight range 
110-150 kDa. However, the de-glycosylation has no effect on enzymatic 
activities of LAAOs from several snake venoms.  
The presence of LAAOs in scorpion venoms is not widely reported 
while our group and another study showed the LAAO activity in the Chinese 
red scorpion venom Mesobuthus martensi (Ahn et al., 2000). Snake venoms 
are the richest source of LAAOs, which are responsible for the yellowish 
colour for the venoms (de Vieira Santos et al., 2008). Recently, LAAOs have 
become a research interest in biomedicine because they have multi-
biological activities, such as anti-microbial, anti-HIV, anti-coagulant,  
apoptosis-inducing, edema-inducing and hemorrhagic activities (Tan et al., 
2008). Interestingly, some snake venom LAAOs can induce platelet 
aggregation, like LAAOs from B. moojeni, Bothrops atrox and Trimeresurus 
jerdonii. While LAAOs from snake venoms of Vipera berus berus, Naja naja 
oxiana and others, were reported to inhibit platelet aggregation. The 
mechanisms of such controversial actions on platelet aggregation are not 






The application of LAAOs in cancer research is another recent 
scientific attempt, by applying the cytotoxic effects of H2O2 generated from 
LAAO enzymatic reaction. It was found that LAAOs from snake venoms of 
Ophiophagus hannah, Agkistrodon acutus, Bothrops jararaca, Bothrops atrox, 
Naja naja atra, etc., inhibited cancer proliferation and induced cancer cell 
apoptosis in bench studies or in animal experiments. This will be discussed in 
detail in discussion part.  
1.2.4  The anticancer potential of scorpion venoms and toxins 
Scorpion envenomation is a risk for public health in tropical and 
subtropical regions and there is a clear need for the improvement in specific 
(antivenom) and systematic treatments.  However, each coin has two sides 
and the medical significance of scorpion venoms should not be ignored. 
Scorpions and scorpion venoms have been applied in traditional medicine for 
long periods in China, India and Africa. For example, in one Chinese famous 
pharmacopoeia book "Ben Cao Gang Mu" (Compendium of Materia Medica, 
A.D. 1578), the dried whole body of scorpion was described as an 
antiepilepsy and analgesic agent (Shao et al., 2007). Meanwhile, scorpion 
venoms have the antimicrobial functions against bacteria, fungi, yeasts and 
viruses.  Studies show that scorpion venoms-derived protein Mucroporin-M1 
can inhibit the amplification of hepatitis virus B and another peptide Kn2-7 






The anticancer potential is another recently observed biological 
property of scorpion venoms and toxins. A number of experimental and 
preclinical studies have shown that scorpion venoms and toxins can impair 
cancer growth, induce apoptosis and inhibit cancer metastasis in vitro and in 
vivo. Several active molecules with anticancer activities have been purified 
from scorpion venoms in terms of inhibition of proliferation, cell cycle arrest, 
induction of apoptosis and decreasing cell migration and invasion. The 
investigated cancer types include glioma, neuroblastoma, leukemia, 
lymphoma, breast, lung and prostate cancers (refer to Table 1.3) (Ding et al., 
2014).  
Among all the scorpions tested in cancer research, Mesobuthus 
martensi Karsch (BmK) scorpion venom is probably the first to be reported to 
possess antitumor properties. Early in 1980s, a Chinese researcher Zhang 
Futong extracted a solution from the dried whole body of BmK and 
administered this to mice with reticulum cell Sarcoma and MA-737 mammary 
carcinoma. Results showed that the BmK solution can significantly inhibit the 
tumor growth and decrease DNA content in tumor tissues (Zhang et al., 1987). 
This innovative study paved the way for the investigation of BmK and other 
scorpion venoms in cancer therapy. BmK scorpion venom was the most 







Polypeptide extract from the scorpion venom (PESV), a group of 
partially purified  polypeptides with 50-60 amino acids from the crude venom 
of BmK, was reported to inhibit cell proliferation and induce cell apoptosis of 
DU 145 human prostate cancer cells (Zhang et al., 2009b). AGAP, an 
analgesic-antitumor peptide isolated from BmK with a molecular mass of 
6,280 Da, was shown to exert antitumoral activity against mouse S-180 fibro 
sarcoma and Ehrlich ascites tumor (Liu et al., 2002). AGAP was subsequently 
indentified as a voltage gated sodium channel scorpion toxin (Cui et al., 2010). 
A fusion protein SUMO-AGAP, which connected a small ubiquitin-related 
modifier to AGAP, inhibited cell proliferation and migration of SHG-44 human 
malignant glioma cells via interfering with the p-AKT, NF-κB, BCL-2, and MAPK 
signaling pathways (Zhao et al., 2011).  
The most notable evidence regarding the anticancer effects of 
scorpion venoms comes from Chlorotoxin (CTX, mentioned in sention 3.1.3) 
used in the treatment of glioma. Based on electrophysiological evidence, the 
chloride ion channel was initially considered to be responsible for the affinity 
and specificity of CTX to glioma. However, further studies by protein 
interaction approaches with a recombinant His-CTX, revealed that the 
principle receptor of CTX is matrix metalloproteinase-2 (MMP-2), a protease 
that is over-expressed on the surface of glioma cells (Deshane et al., 2003). 
131I-TM-601, a synthetic CTX coupled with radioactive iodine isotope 






FDA, to perform clinical trials imaging and diagnosis of gliomas (Mamelak et 
al., 2006).  
In recent years, several scorpion venoms have been screened for the 
apoptosis inducing action against cancer cells and some active molecules 
have been identified and characterized. Bengalin, a 72 kDa protein isolated 
from the Indian black scropion Heterometrus bengalensis koch, was shown to 
induce apoptosis of human leukemic cells without cytotoxicity to normal 
human lymphocytes. The damaged nuclei, DNA fragmentation was observed 
to be accompanied by decreased expression of heat shock protein (HSP) 70 
and 90, activation of caspase-3,9 and induced cleavage of poly (ADP-ribose) 
polymerase (PARP) (Gupta et al., 2010). Two novel apoptogenic peptides with 
molecular mass of around 30 kDa were purified from Tityus discrepans 
scorpion venom, named Neopladine 1 and Neopladine 2, respectively. 
Immunohistochemistry studies demonstrated that Neopladines can bind to 
the cell surface of SKBR3 breast cancer cells, induce the expression of Fas 
ligand (FasL) and triger cell apoptosis. Whereas, Neopladines had a negligible 
effect on non-malignant MA104 monkey kidney cells, indicating their 
potential in the development of anticancer drugs (D'Suze et al., 2010). 
Another two crude scorpion venoms were also evaluated for the anticancer 
effects including Odontobuthus doriae and Androctonus crassicauda against 
SH-SY5Y human neuroblastoma cells and MCF-7 breast cancer cells. The 
oxidative stress was proposed to contribute to the cell cycle arrest at S phase 






To sum up briefly, the anticancer potential of scorpion venoms and 
toxins has been screened on various carcinomas, in vitro and in vivo 
(summarized in Table 1.3).  
Table 1.3  Molecules purified from scorpion venoms with anticancer potential 
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It can be concluded that two mechanisms have been described for 
scorpion venoms in their actions against cancer cells. I), targeting the ion 
channels to inhibit cell proliferation and metastasis; II), induction of apoptosis 
by cell cycle arrest, caspase activation, mitochondria depolarization or 
oxidative stress.  
Nevertheless, as a novel search field, much more efforts should be 
made to extensively evaluate the anticancer effects of scorpion venoms and 
toxins and understand the mechanisms of action. Currently, only a few 
scorpion species have been tested and most work is performed in cell culture, 
not in animal model. Furthermore, the mechanisms are not clearly elucidated 
and the purification and characterization of active molecules remain a 
challenge. 
1.3  Scope of study 
The application of animal venoms and toxins as anticancer agents is a 
novel frontier in cancer research. Few scorpion venoms have been 
investigated and the mechanisms are not quite clear. The hypothesis of this 






scorpion venom, and L-amino acid oxidase from snake venom have 
antitumoral potential in gastric cancer, based on our preliminary studies. 
Objectives of this study: 
1. Perform a preliminary screening of the anti-proliferative effects of several 
crude scorpion venoms in gastric cancer and breast cancer cell lines 
2. Evaluate the anticancer effects of Hottentotta hottentotta scorpion 
venom in gastric cancer in vitro and in vivo. 
3. Purify and characterize the anticancer component from Hottentotta 
hottentotta scorpion venom (BHV). 
4. Investigate the anticancer effects of L-amino acid oxidase (LAAO) from 
Crotalus adamanteus snake venom in gastric cancer cells. LAAO was the 
active molecule identified from BHV but there was difficulty in processing 
BHV from the same source. 
5. Elucidate and understand the mechanisms that account for the anti-
cancer actions of Hottentotta hottentotta scorpion venom and L-amino 
acid oxidase, including cellular responses, gene and protein targets and 















Materials and Methods 
2.      MATERIALS AND METHODS 
2.1    Scorpion venom preparation, purification and characterization  
2.1.1  Scorpion venom preparation 
Crude Hottentotta hottentotta scorpion venom was purchased from 
Latoxan (Valence, France), which was extracted from the scorpions in Mali. 
Methbuthus martensii karsch scorpion venom was purchased from a supplier 
in Zhejiang Province, P.R. China. Aqueous L-amino acid oxidase from Crotalus 
adamanteus snake venom was purchased from Sigma (Sigma-Aldrich, St. 
Louis, MO, USA), whose enzymatic activity was described to be more than 15 
unit/ml. Heterometrus bengalensis and Pandinus imperator scorpion venoms 
were stocks in the laboratory, which were previously lyophilized and kept at 
4 °C. The lyophilized crude scorpion venom was dissolved in ice-cold 1 x PBS, 
pH=7.4. The venom was centrifuged for 30 min at 100,000 rpm to remove 
any undissolved particles. The supernatant (crude venom solution) was 
collected and filtered through 0.22 µm syringe filter (Sartorius Stedim Biotech, 
Goettingen, Germany). The sterile venom solution can be kept at 4 °C for one 
or two weeks. Otherwise, it was aliquoted into 100 µl/tube and kept at -20 °C 
for long time storage.  
 
2.1.2  Protein concentration measurement 
Protein concentration for scorpion venoms and cell lysate was 
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Laboratories, Hercules, CA, USA) (Bradford, 1976). This assay is based on the 
colormetric change of Coomassie Brilliant Blue in response of various 
concentrations of protein. Briefly, 10 µl of protein samples and protein 
standards (0.05, 0.1, 0.2, 0.3, 0.4, 0.5 mg/ml BSA) were pipetted into a 96 
well plate in triplicates. Subsequently, 200 µl diluted dye reagent (1 part dye 
diluted with 4 parts distilled water) was added into each well with multi-
channel pipet. The protein and dye were mixed well and incubated in dark at 
room temperature (RT) for 5 to 10 min. At last, the absorbance was 
measured at 595 nm using SpectraMax® M5 Microplate Reader (Molecular 
Devices, Sunnyvale, CA, USA). The concentration of protein sample was 
deduced from the standard curve generated from BSA standards. 
 
2.1.3  Sodium dodecyle sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
10% resolving gel and 5% stocking gel were prepared following the 
recipe in Table 2.1. Appropriate amounts of protein sample (normally 20 µg 
for western blot and 50 µg for venom sample) was mixed with 6 x 
biomophenol blue loading dye and denatured at 95 ºC for 5 min. SDS-PAGE 
was run with Mini-Protean 2 apparatus electrophoresis system (Bio-Rad) in 
0.25 M Tris-glycin buffer (pH=8.3) at 70 V for 45 min followed by run at 100 V 
until the loading dye reached the bottom of the resolving gel. PageRuler 
Prestained Protein Ladder (Pierce, Rockford, IL, USA) was applied to indicate 
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was transferred onto PVDF membrane for western blot or stained by GelCode 
Blue Stain Reagent (Pierce) according to manufacturer`s instruction and 
visualized with Bio-Rad GS-800 calibrated imaging densitometer. 
Table 2.1 Recipe of resolving gel and stocking gel 
 
Reagent 10% resolving gel (ml) 5% stacking gel (ml) 
dd H2O 4 3.4 
30% acylamide 3.3 0.83 
1.5 M Tris pH8.8 2.5 - 
1.0 M Tris pH6.8 - 0.67 
10% SDS 0.1 0.05 
10% APS 0.1 0.05 
TEMED 0.004 0.005 
Total 10 5 
 
2.1.4  Size exclusive gel filtration 
Size exclusive gel filtration chromatography normally provides the 
preliminary separation of proteins based on their molecular size. The 
prepared crude venom was loaded onto Superdex G75 Hi-load 16/60 gel 
filtration column (GE healthcare, Buckinghamshire, UK), and the venom 
fractions were eluted with 50 mM ammonium bicarbonate, pH=8.0, at a flow 
rate of 1mL/min. The absorbance was monitored at 215, 254, 280 nm 
simultaneously. Each fraction was collected by pooling the eluted solution 
together and lyophilized using Modulyo® freeze dryer (Thermo Scientific, 
Wilmington, DE, USA). Protein concentration of each fraction was 
determined by the Bradford method and the molecular weight (M.W.) 
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2.1.5  Cation exchange chromatography  
Based on the cell viability assay, the anticancer component was 
determined in fraction 1 (BHV-F1). Therefore, the BHV-F1 was processed for 
secondary purification using 7x35 mm UNOS1 cation exchange column (Bio-
Rad). Desalting and buffer exchange was accomplished with Amicon Ultra-15 
centrifugal filter device (Millipore, MA, USA). The column was equilibrated 
with 50 mM sodium acetate, pH=5.0, at a flow rate of 1ml/min, and the 
elution buffer was 1M NaCl in starting buffer with a gradual increase of 
gradient from 0% to 100%. The absorbance was monitored at 215, 254 and 
280 nm simultaneously. 
 
2.1.6  MALDI-TOF Mass spectrometry  
MALDI-TOF-MS (Matrix-Assisted Laser Desorption/Ionization Time of 
Flight Mass Spectrometry) was applied to determine the protein identity. 
After BHV was partially purified and separated by SDS-PAGE, the bands of 
interest were carefully cut out from gel. Next, the samples were submitted to 
the Protein and Proteomics Center, NUS for further analysis. First, the gel was 
cut into small pieces, washed, dehydrated and digested into peptides with 
11ng/µl trypsin in 25mM ammonium bicarbonate. The peptides were then 
extracted and eluted with elution solution (0.1% TFA/50% acetonitrile). 
Peptides extracts were dried on a speed-vac at RT and re-dissolved in 1 µL of 
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TFA, 50% acetonitrile in MilliQ water). Next, the sample was spot onto the 
MALDI target plate, allowed to air dry and analyzed by ABI 4800 Proteomics 
Analyzer MALDI-TOF/TOF Mass Spectrometer (Applied Biosystems, Foster 
City, CA, USA). The GPS explorer™ software v3.6 (Applied Biosystems) was 
used to retrieve data and create reports. The peptide and protein 
identification was analyzed using MASCOT search engine v2.1 (Matrix Science) 
with reference to NCBInr Protein Database. 
 
2.2  Cell culture 
MKN-7, MKN-74 and NUGC-3 gastric cancer cell lines were purchased 
from Japanese Riken Cell Bank (Tsukuba, Japan). MDA-MB-231, T-47D, MCF7 
and MCF-12A breast cancer cell lines were obtained from American Tissue 
Culture Collection (ATCC, Manassas, VA, USA). In this study, the cell 
maintenance and subculture conditions are listed in Table 2.2. The medium 
RPMI-1640, DMEM/High Glucose and fetal bovine serum (FBS) came from 
HyClone (Logan, Utah, US). DMEM F12 plus supplements and trypsin were 
purchased from Invitrogen (Carlsbad, CA, USA). The cells were grown in an 
incubator at 37 ºC with 5% CO2 air flow. Upon reaching 90% confluency, cells 
were washed with 1 x PBS and detached by trypsin. The enzymatic reaction 
was stopped by adding complete culture medium and the cells were 
harvested by centrifugation at 1000 rpm for 5 min. The cells were 
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1:4 was used. For cell seeding in 96- and 6-well plate, cells were counted with 
hemocytometer.  
For cryopreservation, cells were harvested and resuspended in the 
respective culture medium containing 20% FBS and 10% dimethylsulfoxide 
(DMSO). The cells were kept in Cryo 1 ºC Freezing Container (Nalgene, 
Rochester, NY, USA) and put in -80 ºC freezer overnight before transferring 
into a liquid nitrogen tank.  
 
Table 2.2 Cell lines, cell maintenances and subculture conditions 
Gastric cancer cells 
Cell line Medium receipt Subculture condition 
NUGC-3 RPMI + 10%FBS 2 x trypsin* 6-8 min 
MKN-7 RPMI + 10%FBS 2 x trypsin 15 min 
MKN-74 RPMI + 10%FBS 2 x trypsin 8 min 
Breast cancer cells 
Cell line Medium receipt Subculture condition 
MDA-MB-231 RPMI + 10%FBS 1 x trypsin 2 min 
MCF-7 DMEM + 10%FBS 1 x trypsin 5 min 
T-47D RPMI + 10%FBS 1 x trypsin 5-7 min 






*cocktail indicates 5% FBS + 20 ng/ml epidermal growth factor (EGF) + 100 
ng/ml cholera toxin + 0.01 mg/ml insulin + 500 ng/ml hydrocortisone + 40 
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2.3  Functional studies to evaluate the anticancer effects of scorpion venom 
and LAAO in vitro   
2.3.1  Cell proliferation/viability assay 
Cell proliferation/viability was determined by alamarBlue® Cell 
Viability Reagent (Invitrogen). The alamarBlue Reagent is an oxidized form of 
redox indicator that is blue in colour and non-fluorescent. When incubated 
with viable cells, the reagent change colour from blue to red and become 
fluorescent because the viable cells provide a reducing environment. Briefly, 
10,000 cells per well were seeded in a 96-well plate.  After 24 h of settlement, 
cells were treated with various concentration of venom or LAAO for another 
24 h. Next, cells were washed once with warm PBS and 100 µl new medium 
containing 10 µl alamarBlue was added to each well. After 1 h-4 h of 
incubation at 37 ºC in dark, fluorescence was measured with the 
SpectraMax® M5 Microplate Reader (Molecular Devices) at 570/585nm 
excitation/emission. 
 
2.3.2  Cytotoxixity determination by Lactate Dehydrogenase (LDH) assay 
Cytotoxicity of scorpion venom and LAAO to cancer cells was 
determined using Cytotoxicity Detection Kit (Roche, Basel, Switzerland) based 
on the measurement of lactate dehydrogenase (LDH) from damaged cells. 
Briefly, 10,000 cells per well were seeded in a 96-well plate and received drug 
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prior to assay as a positive control. The microplate was centrifuged at 250 x g 
for 10 min and 100 µl of supernatant from each well was transferred into a 
new plate. 100 µl of freshly prepared reaction mixture (250 µl of 
Diaphorase/NAD+ mixture in 11.25 ml of Indotetrazolium chloride + sodium 
lactate) was added and mixed with the supernatant. The mixture was 
incubated at RT for 30 min and the absorbance of each sample was read at 
492 nm. The cytotoxicity of drugs was calculated using the following formula:  
                
                            
                            
      
 
2.3.3  Cell cycle analysis 
Both floating and adherent cells after treatment with scorpion venom 
or LAAO were harvested by trypsin-EDTA and centrifugation at 1000 rmp for 
5 min.  Cells were washed twice with ice-cold PBS, followed by fixation with 
70% cold ethanol overnight at 4 °C. Next, the fixed cells were collected and 
washed twice again.  The cell pellet was resuspended in 1 ml propidium 
iodide (PI) staining reagent, which contains 20 µg PI, 0.2mg RNase A, and 0.1% 
Triton-X dissolved in PBS. The cells were incubated in the dark for 15 min at 
RT and analyzed by flow cytometry with CyAn™ ADP Analyzer (Beckman 
Coulter, Brea, CA, USA) or  BD LSRFortessa™ cell analyzer (BD Biosciences, 
Franklin Lakes, NJ, USA). The data obtained were analyzed using the Summit 
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2.3.4  Cell apoptosis detection by Annexin V & PI staining 
Cells exposed to scorpion venom or LAAO were harvested by the 
trypsin-EDTA method and washed twice with ice-cold PBS. FITC Annexin V 
Apoptosis Detection kit I (BD Bioscience) was applied to detect the cell 
apoptosis. In apoptotic cells, the membrane phospholipid phosphatidylserine 
(PS) is translocated from the inner to the outer leaflet of the plasma 
membrane. The FITC conjugated Annexin V is a 35-36 kDa Ca2+ dependent 
phospholipid-binding protein that has a high affinity for PS and thus serves as 
a sensitive probe of cell apoptosis analysed by flow cytometry. Since 
externalization of PS occurs in the earlier stages of apoptosis, the FITC 
Annexin V staining is used to identify early apoptosis. Briefly, the washed 
cells were collected by centrifugation and resuspended in 100 µl 1 X Binding 
Buffer. Then, 5 µl of FITC Annexin V and 5 µl PI were added into each solution. 
Meanwhile, unstained, Annexin V staining alone and PI staining alone were 
set as controls, respectively. The cell solution was gently vortex and 
incubated at RT for 15 min in dark. Finally, 400 µl of 1 X Binding Buffer was 
added to each tube to stop the reaction and cells were analyzed by flow 
cytometry within 1 h with CyAn™ ADP Analyzer (Beckman Coulter) or BD 
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2.3.5  Transmission electron microscopy (TEM)  
NUGC-3 cells were seeded on Nunc™ Lab-Tek™ 4-Chambered 
Coverglass (Thermo Scientific) at a density of 8 x 104 cells/well. After 24 h of 
settlement, cells were treated with BHV for 24 h or LAAO for 12h, 
respectively.  After treatment, medium was removed and cells were washed 
twice with ice-cold PBS, followed by fixation with 2.5% glutaraldehyde for 1 h 
at 4 °C.  Cells were washed 3 times with ice-cold PBS and post-fixed with 1% 
osmium tetroxide and potassium  ferrocyanide  for 1 h at room temperature. 
Subsequently, cells were dehydrated through an ascending series of ethanol 
and embedded in araldite for 24 h. 99 nm ultrathin sectioning of samples was 
performed using the Reichert Ultracut E ultramicrotome. The last step of 
sample preparation was mounting the cells onto copper grids and doubly 
stained with uranyl acetate and lead citrate. NUGC-3 cellular ultrastructure  
was observed under the EM280S  transmission electron microscope (Philips, 
Amsterdam, Netherlands) at a voltage level of 100.0 KeV. 
 
2.3.6  Scanning electron microscopy (SEM)  
Lab-Tek™ 4-Chambered Coverglass (Thermo Scientific) was used for 
seeding NUGC-3 cell at a density of 8 x 104 cells/well. NUGC-3 cells were 
treated with 1.0 µg/ml LAAO for 12 h and washed with 1 x PBS at RT. Cells 
were then fixed with 2.5% glutraldehyde for 1 h at RT, followed by 3 times of 
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an ascending series of ethanol (in 25%, 50%, 75%, 95% ethanol for 3 min and 
in 100% ethanol twice for 5 min, respectively). Samples were then 
transferred into the Balzers CPD 030 critical point drier (Bal-tec, Liechtenstein) 
for 1 h as per the manufacturer’s instruction. The cover slides were mounted 
onto the metal stubs with silver paint. Finally, samples were coated with gold 
for conductivity in a sputter way before being viewed under JSM-6701F, cold 
field-emission scanning electron microscope (JEOL, Tokyo, Japan) at a voltage 
level of 10.0 KeV. 
 
2.3.7  Cell migration and invasion assay 
NUGC-3 cell migration assay was conducted using 6.5 mm Transwell 
with 8.0 μm pore polycarbonate membrane inserts (Corning, MA, USA). 
Firstly, the inserts were re-hydrated by adding 600 µl RPMI 1640 medium 
containing 20% FBS into lower chamber and 200 µl RPMI 1640 medium into 
upper chamber and incubating at 37 °C with 5% CO2 overnight. After re-
hydration, the medium was carefully removed. NUGC-3 cells (treated with 
non-cytotoxic dose of scorpion venom) were harvested by trypsin-EDTA 
method, pelleted and resuspended in appropriate volume of RPMI 1640 
medium to get the concentration of 4 X 105 cell/ml. Next, 200 µl of cell 
suspension containing 8 x 104 cells was placed into upper chamber and 600 µl 
of RPMI 1640 medium with 20% FBS was added into lower chamber as a 
chemoattractant to attract the cells to migrate through the insert 
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incubator at 37 °C with 5% CO2, the inserts were washed twice with 1 x PBS 
and fixed in 100% methanol for 15 min. Afterwards, the inserts were washed 
again and kept in the hood for air dry. The dried inserts were subsequently 
stained with 0.5% (w/v) crystal violate for 30 min. The excess dye was flushed 
off by rinsing the inserts in clean water twice and the non-migrated cells in 
the upper chamber were removed using cotton swab. Finally, the migrated 
cells that adhere to the bottom of the insert were viewed under SMZ 1500 
stereomicroscope (Nikon, Yurakucho, Tokyo, Japan). Five fields (1 in centre 
and 4 in periphery) were chosen to take photo and the cell number was 
counted using Adobe Photoshop CS5 software. 
The cell invasion assay was similar to migration assay using BD 
Biocoat™ Matrige Invasion Chamber with 8.0 µm PET membrane insert (BD 
Biosciences). The incubation time for cell invasion assay was 36 h.  
 
2.3.8  Evaluation of Caspase-3 activity  
Caspase-3 is a downstream effector caspase, that is activated when 
caspase-dependent cell apoptosis happens, and in turn executes apoptosis by 
cleaving various cytoplasmic or nuclear proteins including PARP. In this study, 
the caspase-3 activity was measured using Caspase-3 Colormetric Assay Kit 
(Genescript, NJ, USA) based on spectrophotometric detection of the 
chromophore pnitroanilide (pNA) after cleavage from the labeled substrate 
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preferentially recognized by caspase-3. Briefly, cell apoptosis was induced by 
treating NUGC-3 cells with 30 µg/ml BHV or 1 µg/ml LAAO for 24 h. 10 µM 
Doxorubicin was used as positive control. Cells were harvested by trypsin-
EDTA method and washed once with ice-cold 1x PBS. 5 x 106 cells were 
collected by centrifugation and lysed in 50 µl lysis buffer containing 10 mM 
DTT. The solution was incubated on ice for 40 min with vortex every 10 min. 
The cell lysate was obtained by collecting the supernatant after centrifuging 
at 10,000 rpm at 4 °C for 10 min. Protein concentration was then determined 
by the Bradford method. Next, 50 µl of supernatant containing 100 µg 
protein was transferred into 96-well plate and mixed with another 50 µl 2 x 
reaction buffer. 5 µl of caspase-3 substract (200 µM final concentration) was 
added to each sample and mixed well. The plate was incubated in dark at 
37 °C for 4 h and the absorbance was read with avSpectraMax® M5 
Microplate Reader (Molecular Devices) at 405 nm.  
 
2.3.9  Measurement of mitochondrial membrane potential 
Loss of mitochondrial membrane potential (MMP) is one of the key 
events happening during cell apoptosis (Ly et al., 2003). In this study, NUGC-3 
mitochondrial membrane potential was measured using JC-1 (5,5',6,6'-
tetrachloro-1,1',3,3'- tetraethyl-imidacarbocyanine iodide) (BioVison, Milpitas, 
CA, USA). JC-1 is a cationic dye that can stain mitochondria in living cells in a 
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spontaneously forms complexes called J-aggregates with red fluorescence. 
Whereas, in apoptotic cells with low MMP, JC-1 remains in the monomeric 
form and shows green fluorescence. Briefly, 4 x 105 NUGC-3 cells seeded in 6-
well plate were treated with 1.0 µg/ml LAAO for 0 h, 3 h, 6 h and 9 h, 
respectively. For the positive control, CCCP (carbonyl cyanide 3-
chlorophenylhydrazone) was applied to treat cells in 50 µM final 
concentration for 10 min. After treatment, cells were harvested by trypsin-
EDTA method and resuspended in 1ml warm medium containing 2 µM JC-1 
dye. Cells were incubated at 37 °C, 5% CO2 for 20 min followed by one time 
wash with 1 x PBS to remove the excess dye. Finally, cells were resuspended 
in 500 µl PBS and analyzed on BD Accuri™ C6 flow cytometer (BD Biosciences) 
with red and green fluorescence channels.  
 
2.3.10  Measurement of Oxidative stress  
NUGC-3 intracellular oxidative stress was evaluated with 2’,7’ –
dichlorofluorescein diacetate (DCFDA) (Sigma-Aldrich), a fluorogenic dye that 
measures the level of various reactive oxygen species (ROS) in the cell. After 
diffusion into the cell, DCFDA is deacetylated by cellular esterases to a non-
fluorescent compound, which is later oxidized by ROS into 2’, 7’ –
dichlorofluorescin (DCF). DCF is a highly fluorescent compound and can be 
detected and quantified by flow cytometry. Briefly, 4 x 105 NUGC-3 cells 
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and 6 h, respectively. Cells were harvested by trypsin-EDTA method and 
washed once with warm 1x PBS. Cells were pelleted by centrifugation at 
1,000 rpm for 5 min and resuspended in 1 ml PBS buffer containing 10 µM 
DCFDA. The solution was incubated in dark at 37 °C for 30 min. After that, the 
staining buffer was removed by centrifugation and cells were returned to 
pre-warmed medium and incubated in cell culture incubator for a short 
recovery (about 5 min) for cellular esterases to hydrolyze the acetate groups 
and render the dye which is responsive to oxidation. Finally, cells were 
collected and resuspended in 1 ml PBS and analyzed by BD Accuri™ C6 flow 
cytometer (BD Biosciences) with excitation spectra of 495nm. Meanwhile, in 
this experiment, 50 µM tert-butyl hydroperoxide, tBHP (Sigma-Aldrich) was 
used as positive control by incubating with NUGC-3 cells for 2 h prior to assay.  
 
2.3.11  Immunofluorescence analysis of AIF translocation 
8 x 104 NUGC-3 cells were grown in Lab-Tek™ 4-Chambered 
Coverglass (Thermo Scientific) up to 60-70% confluency and were treated 
with 1 µg/ml LAAO for 12 h. After treatment, cells were washed twice with 1 
x PBS and fixed in 4% paraformaldehyde at RT for 20 min.  The fixed cells 
were washed twice with 0.05% Teween-20 in PBS and treated with 0.2% 
Triton X-100 in PBS for 5 min at RT for permeabilization. Next, cells were 
blocked in 1% BSA in 1 x PBS at RT for 1 h, and subsequently incubated in 200 
µl AIF antibody (1:200 dilution, Cell signaling, Dancers, MA, USA) diluted in 
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20 in PBS, cells were incubated in 200 µl Cy5-conjugated anti-rabbit IgG 
(1:500 dilution, Sigma-Aldrich) for another 1 h at RT in dark. After incubation, 
cells were washed thrice again and nuclei conterstaining was performed by 
incubating cells with 4,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories, Burlingame, CA, USA) for 5 min at RT. Finally, cells were covered 
with 200 µl 1 x PBS and visualized under FluoView™ FV1000 confocal 
microscope (Olympus, Shinjuku, Tokyo, Japan). 
 
2.4  NUGC-3 xenograft model to assess the anticancer potential of scorpion 
venom  
2.4.1  Establishment of NUGC-3 xenograft model 
Female 4-week-old BALB/c-nu/nu mice were obtained from Biological 
Resource Centre (A∙STAR, Singapore). The animals were housed four per 
plastic cage with free access to water and food under controlled temperature, 
humidity and lightning (12-12 h light-dark cycle). All manipulations of mice 
were performed in accordance with the procedures outlined in the Guide for 
the Care and Use of Laboratory Animals of National University of Singapore. 
After one week of acclimatisation, 5 x 106 NUGC-3 cells in 0.1 ml PBS were 
inoculated subcutaneously into the left flank of the mice. The tumor growth 
was monitored and the tumor volume was calculated using the following 
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2.4.2  Intratumoral injection of venom 
After 3-4 weeks, the tumor has grown to palpable size (100-200 mm3 , 
shown in Fig 3.14). The mice were randomly divided into 3 groups. The 
experimental groups were injected intratumorally with BHV of 6.25 
µg/mouse and 12.5 µg/mouse, respectively. The control group were injected 
with equal volume of 1 x PBS. The mice were observed for another one week 
with measurement of tumor volume using a digital calliper every two days. At 
the endpoint, all mice were euthanized by CO2 and the tumor was harvested. 
A very small part of the tumor was cut and kept in RNAlater (Qiagen, Hilden, 
NRW, Germany) at -80 °C for RNA and protein use. The rest was put into 10% 
formaldehyde for following analysis. 
 
2.4.3  Tissue processing, paraffin embedding and microtome sectioning 
The animal tissues were automatically processed using ATP700 Tissue 
Processor (Histo-Line Laboratories, Milano, Italy) with the settings in Table 
2.3. Subsequently, the specimen was fixed with wax in the mould and cooled 
down on the Cryo Console. 5 µm sections of tumor specimens were obtained 
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Table 2.3 Program settings for tissue processing 
Step 
NO. 














Time/h 1.0 1.3 1.3 2.0 2.0 3.0 
Step 
NO. 
7 8 9 10 11 12 
Reagent Histoclear Histoclear Histoclear Wax Wax Wax 
Time/h 2.0 2.0 3.0 2.0 2.0 2.0 
 
2.4.4  Haematoxylin and Eosin staining 
The dewaxing of paraffin slides was conducted in accordance with the 
following steps: Histoclear (2 times)→100% alcohol→90% alcohol→70% 
alcohol→50% alcohol→ distilled water (3 times). 
After dewaxing, slides were kept in Shandon Instant Haematoxylin 
solution for 5 min followed by washing in distilled water. Differentiation was 
achieved by immersing slides in differentiating fluid (70% ethanol with a few 
drops of HCl) for 20 seconds. Then, slides were rinsed in distilled water and 
checked under a microscope to see if the differentiating process is completed. 
Sections were blued in tap water for 15 min and rinsed once in distilled water. 
Next, sections were immersed in 95% alcohol for a while before being stained 
in Alcoholic Eosin for 20 seconds. Dehydration was completed by quick 
immersion of slides in 95% alcohol and absolute alcohol for two changes. 
Finally, slides were cleaned in Histoclear for 3 changes and mounted with 
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2.4.5  In situ apoptosis detection 
The in situ apoptosis in tumor specimen was assessed by the 
detection of DNA fragmentation based on terminal deoxynucleotidyl 
transferase (TdT) dUTP nick end labeling (TUNEL) technique. The 
TumorTACS™ In Situ Apoptosis Detection Kit (Trevigen, MD, USA) was used 
for this purpose. Firstly, the tumor specimens were deparaffinized as 
mentioned in section 2.4.4. Secondly, the slides were washed in 1 x PBS for 
10 min and covered with 50 µl of diluted Proteinase K solution for 5 min. 
Thirdly, after washing the slides in distilled water twice for 2 min, the 
specimens were immersed in Quenching solution for 5 min. Fourthly, after 
being washed in 1 x PBS for 1 min, the specimens were immersed in 1 x TdT 
Labeling buffer for 5 min. Fifthly, The specimens were covered with 50 µl of 
Labeling Reaction Mix and incubated at 37 °C in a humidity chamber for 60 
min. Sixthly, the reaction was stopped by immersing specimens in 1 x TdT 
Stop buffer for 5 min. Seventhly, The specimens were washed twice again in 
1 x PBS, 2 min each, covered with 50 µl of Strep-HRP Solution and incubated 
for 10 min at RT in a humidity chamber. Eighthly, the specimens were washed 
twice in 1 x PBS for 2 min each and stained in DAB solution for 5 min before 
rinsing 4 times in distilled water for 2 min each and staining in 1% Methyl 
Green solution for 30 sec. Finally, the slides were dipped 10 times each in 
distilled water→ distilled water→95% alcohol→100% alcohol → Histoclear→ 
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2.5  Transcriptomic and proteomic analysis 
2.5.1  Quantitative real-time polymerase chain reaction (qRT-PCR) 
RNA isolation: 
Total RNA was isolated from NUGC-3 human gastric cancer cells using 
the commercially available RNeasy mini kit (Qiagen) based on the 
manufacturer’s instructions. Cell monolayer grown in 6-well plate was 
washed once with ice-cold PBS to completely remove the culture medium. 
350 μl of Buffer RLT buffer containing 1% of β-mercaptoethanol was added to 
each well to lyse the cells. Cell scraper may be used to disrupt the cells. Then, 
the cell lysate was homogenized by being passed through a 23-gauge needle 
for 5 times. A volume of 70% ethanol was mixed with the lysate and the 
whole mixture was transferred to an RNeasy spin column and centrifuged for 
15 sec at 13,000 rmp. Flow-through was discarded and 700 µl Buffer RW1 
was added to spin column to wash RNA, followed by the same centrifugation. 
The RNA sample was further concentrated by adding 500 µl Buffer RPE to the 
column and centrifuging at the same speed for 15 sec and 2 min, respectively. 
Finally, the purified RNA was eluted in 30 µl RNase-free water by 
centrifugation. The RNA concentration was determined by nanodrop ND-100 
spectrophotometer (Thermo Scientific). The quality of RNA was assessed by 
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cDNA synthesis: 
Complementary DNA (cDNA) was synthesized using SuperScript® 
VILO™ cDNA Synthesis Kit (Invitrogen) following the product protocol. Briefly, 
a 20 µl of reaction system was prepared by mixing 5x VILO Reaction Mix (4 µl), 
10x SuperScript Enzyme Mix (2 µl), RNA (up to 2.5 µg), as well as DEPC-
treated water. Then, the master mix was incubated at 25 °C for 10 min, 
followed by 42 °C for 60 min. The reaction was terminated at 85 °C for 5 min. 
The resultant cDNA was stored at -20 °C until use.  
qRT-PCR: 
Real time PCR was performed on the HT7900 FAST Real-Time PCR 
System using FAST SYBR® Green Master Mix (Applied Biosystems). Primers 
were designed with PRIMER3 software (http://frodo.wi.mit.edu/) and their 
specificities were verified by the NCBI’s Basic Local Alignment Search Tool 
(BLAST) database (http://blast.ncbi.nlm.nih.gov). The sequences of 
synthesized primers (1st BASE, Singapore) are listed in Table 2.4. 10 µl PCR 
reaction mix consisted of 5 µl SYBR green cocktail, 0.5 µl forward primer, 0.5 
µl reverse primer, 1 µl cDNA and 3 µl DEPC-treated water. The reaction 
mixture was added into a 96-well PCR plate. The thermal-cycling conditions 
were programmed as follows: polymerase activation at 95 °C for 20 sec, 
followed by 40 cycles of denature at 95 °C for 1 sec and annealing/extension 
at 60 °C for 20 sec. The dissociation curve was applied to check the specificity 
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were analyzed using the ΔΔCt and 2-ΔΔCt method to calculate the relative gene 
expression (Livak et al., 2001). 
 
Table 2.4  Sequences of primers used in real-time PCR 
Gene Forward Primer Sequence 
(5'→3') 
Reverse Primer Sequence 
(5'→3') 
ASNS CGTGTGTCTCCAGCACTGTT ATCAGCTTGTTTGCCGTCTT 
BIRC3 ATGCTTTTGCTGTGATGGTG TGGGCTGTCTGATGTGGATA 




TNFSF15 CAGGAGTTTGCACCTTCACA CCAGGCCTAGTTCATGTTCC 
SART1 AACCAAAAGCTGGGGAAGAT CTCCACCAGAGTGCTGACAC 
TOP2A CAGCCCATTGGTCAGTTTGG AGGACCACCCAGTACCGATT 
TUBB CTGGACCGCATCTCTGTGTA GTTACCTGCCCCAGACTGAC 
ERK1 ACAGTCTCTGCCCTCCAAGA CTCATCCGTCGGGTCATAGT 
ERK2 CCAGACCATGATCACACAGG CTGGAAAGATGGGCCTGTTA 
RSK TGCACAGCCTGGGTATCATTT CTGTCCCGCAGAAAGAATAGG 
MEK1 CTATGGTGCGTTCTACAGCGA CCCACGGGAGTTGACTAGGAT 
MEK2 CCAAGGTCGGCGAACTCAAA TCTCAAGGTGGATCAGCTTCC 
Raf1 AGTTCAGCAGTTTGGCTATCAG CACTGTTCTTTGCTTGTTCGG 
P70 TTTGAGCTACTTCGGGTACTTGG CGATGAAGGGATGCTTTACTTCC 
Tpl-2 CTCCCCAAAATGGACGTTACC GGATTTCCACATCAGATGGCTTA 
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2.5.2  Western blot 
Protein extraction: 
Cell monolayer or cell pallet was washed twice with ice-cold PBS prior 
to protein extraction. The extraction buffer consisted of M-PER® Mammalian 
Protein Extraction Reagent (Pierce), Halt™ Protease and Phosphatase 
Inhibitor Cocktail (Pierce) and 0.5 M EDTA at a ratio of 100:1:1. Appropriate 
amount of extraction buffer was added to the cells and the mixture was put 
on ice for 15 min with gentle shaking. Cell lysate was collected and 
transferred to a microcentrifuge tube. Then, the protein sample was 
centrifuged at 13,000 rpm for 10 min at 4 °C to remove debris. The protein in 
the supernatant was collected and stored at -80 °C. 
Western blot: 
The extracted proteins were quantified (refer to section 2.1.2), 
separated on SDS-PAGE gel and transferred onto a polyvinyl difluoride 
membrane (PVDF, Bio-Rad) via semi-dry transfer method. First, the 
membrane was rehydrated with absolute methanol and equilibrated in 
transfer buffer. A sandwich structure was made by putting the gel onto 
membrane and laying them in between two filter pads. Air bubble between 
each layer was removed using a glass rod and the protein was transferred at 
15 V for 60 min. After protein transfer, the membrane was blocked in 5% 
non-fat milk for 1 h at RT and washed thrice with 1 x TBST. Diluted primary 





Materials and Methods 
The membrane was then washed thrice with 1 x TBST followed by incubation 
with corresponding secondary antibody for 2 h at RT. After washing with 
TBST and two changes of 1 x TBS, the protein bands were developed with 
Supersignal West Pico Chemiluminescent substrate (Pierce) and finally 
visualized on blue X-ray films in dark room. The protein bands were scanned 
with Bio-Rad GS-800 densitometer and quantified with Quantity-One Image 
Analysis software (Bio-Rad). The relative expression of target protein was 
calculated by the ratio of optical density (OD) of target protein to the OD of 
β-actin. The primary and secondary antibodies used in this study are listed in 
Table 2.5 
Table 2.5  Antibodies used in western blot 
Antibody Source Host species Dilution 
Cleaved PARP Cell Signaling Rabbit 1:1000 
Cleaved caspase-3 Cell Signaling Rabbit 1:1000 
Cleaved caspase-8 Cell Signaling Rabbit 1:1000 
Cleaved caspase-9 Cell Signaling Rabbit 1:1000 
Phospho-ERK1/2 Cell Signaling Rabbit 1:1000 
Phospho-MEK1/2 Cell Signaling Rabbit 1:1000 
Phospho-Elk-1 Cell Signaling Rabbit 1:1000 
Phospho-MSK-1 Cell Signaling Rabbit 1:1000 
Phospho-p90RSK Cell Signaling Rabbit 1:1000 
Bcl-2 Cell Signaling Rabbit 1:1000 
Bax Cell Signaling Rabbit 1:1000 
Bcl-xl Cell Signaling Rabbit 1:1000 
Polyclonal 
Malondialdehyde (MDA) 
Abcam Cambridge, UK Rabbit 1:5000 
β-actin Sigma-Aldrich Mouse 1:6000 
Anti-rabbit IgG Cell Signaling Goat 1:2000 
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2.5.3  Affymetrix Gene Chip® Human Gene 2.0 ST Array 
To investigate the gene expression profile after BHV scorpion venom 
treatment, the cDNA microarray was conducted using Gene Chip® Human 
Gene 2.0ST Array (Affymetrix, Santa Clara, CA, US). NUGC-3 cells were 
treated with 5 µg/ml BHV-F1 for 24 h. Total genome RNA was extracted as 
mentioned in section 2.5.1. After that 6 total RNA samples were submitted to 
Origen Labs (Singapore) for following analysis.  
First, the RNA integrity and quality were checked using 
spectrophotometric measurement (BioSPEC-Mini, Shimadzu, Nakagyo-ku, 
Tokyo, JP) and RNA gel electrophoresis analyzed with Agilent Bioanalyzer 
(Santa Clara, CA, US), according to SOP of Origen Labs. Next, for each sample, 
100 ng total RNA was reverse transcribed to cDNA/mRNA, which was 
subsequently converted to double strand cDNA with a unique DNA/RNA 
heteroduplex on one end. The cDNA was then amplified via SPIA (Single 
Primer Isothermal Amplification) and post-SPIA Modification to generate 
sense target cDNA. Finally, the target cDNA was fragmented, biotin labelled 
and hybridized to Affymetrix Human Gene 2.0 ST array for 18 h at 45 °C with 
rotation at 60 rpm. Arrays were then washed and stained using the 
FS450_0002 fluidics protocol and scanned with an Affymetrix 3000 7G 
scanner.  
For results interpretation, probe intensity data in CEL file were 
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and imported into Expression Console 1.3 software for array quality control. 
List of target genes was created using Gene Spring GX software (Agilent) with 
requirement of fold change above 2 and p value less than 0.05. Functional 
clustering was accomplished with the online Database for Annotation, 
Visualization and Integrated Discovery (DAVID). The flow chart of whole 




2.5.4  Cancer 10-Pathway Reporter Array 
The Cancer 10-Pathway Reporter Array (Qiagen) is a commercial 
reporter array to measure the activities of ten cancer-related signaling 
pathways. All reporter assays are based on dual-luciferase technology. Each 
reporter consists of a mixture of a pathway-focused transcription factor-
responsive firefly luciferase construct and a constitutively expressing Renilla 
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luciferase construct (shown in Fig 2.2). Briefly, first, 50 µl of Opti-MEM® was 
added to each well to resuspend reporter constructs. Second, 50 µl of diluted 
Attractene was mixed with resuspended reporter constructs and the mixture 
was incubated at RT for 20 min. Third, NUGC-3 cells after treatment with 
scorpion venom were harvested by trypsin method, counted and suspended 
in 50 µl Opti-MEM containing 10% of FBS. Then, 2 x 104 cells were seeded to 
each well and transfected for 24 h. Forth, after transfection, each well was 
replaced with complete growth medium and the Dual-Glo® Luciferase Assay 
was performed (Promega). 
Fig 2.2  Plate components for Cancer 10-Pathway Reporter Array 
 
2.5.5 Stable Isotopic Labeling using Amino acids in Cell culture (SILAC) 
Stable Isotopic Labeling using Amino acids in Cell culture (SILAC) is a 
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cells were cultured in light and heavy medium systems to incorporate the 
isotopes for labeling. Light medium contained L- Lysine : 2HCl and L-
Arginine:HCl (Sigma-Aldrich). Heavy medium contained L- Lysine : 2HCl (U-
13C6, U15N2) and L-Arginine:HCl (U-13C6, U15N4) (Cambridge Isotope 
Laboratories, MA, US). Dialyzed FBS was used in this experiment (Therom 
Scientific). After 6 passages of cell culture for isotope incorporation, cells in 
heavy medium were treated with 1.0 µg/ml LAAO for 8 h and cell lysates 
from both culture mediums were harvested using RIPA buffer (Pierce).  
Protein concentration was determined by Bradford method and samples 
were mixed in 1:1 ratio. Subsequently, samples were analyzed by 
Quantitative Proteomics Group in IMCB (A·STAR, Singapore) using LTQ-
OrbiTrap (Classic) Mass Spectrometer (Thermo Scientific). The protein 
quantification was performed with MaxQuent software (Version 1.3.0.5).  
 
2.6  Statistical analysis 
In this study, GraphPad Prism 5 (GraphPad Prism, San Diego, CA, USA) 
was applied for statistical analysis. The Student`s t-test was used to compare 
the difference between two groups. One way ANOVA with a post-hoc Tukey’s 
Test was performed for the data with 3 or more groups. Two way ANOVA 
analysis was used in two-factorial experiments. Data were presented as 
mean+SEM and p value less than 0.05 was considered significant. In this 
thesis, two levels of significance were shown. * indicates p<0.05 and ** 
















3.     RESULTS 
3.1  Preliminary screening of the anticancer activities of scorpion venoms  
3.1.1 The anti-proliferative effects of Mesobuthus martensi scorpion venom 
This study started with preliminary screening of the anticancer effects 
of Mesobuthus martensi karsch (synonym: Buthus martensi karsch, BmK) 
scorpion venom. The alamarBlue cell viability assay was conducted to 
evaluate the anti-proliferative effects of BmK to cancer cells. The cell 
viability/proliferation of 3 cancer cell lines were analyzed after treatment 
with 0, 1.25, 2.5 and 5 mg/ml BmK crude venom for 24 h, respectively. 
Results showed that BmK venom only inhibited the viability/proliferation of 
NUGC-3 human gastric cancer cells significantly at 5 mg/ml while had no 






Fig 3.1  AlamarBlue cell viability/proliferation assay of cancer cells after 
BmK venom treatment. The cell viability of NUGC-3 human gastric cancer 
cells (A), MDA-MB-231 human breast cancer cells (B) and MCF-7 human 
breast cancer cells (C) was analyzed after treatment for 24 h and cell 
viability was normalized with control group. Data are presented as 
means + SEM. N=3. *, p < 0.05. 








Since the BmK scorpion venom had inhibitory effect on the NUGC-3 
cell proliferation at 5 mg/ml, cell cycle and apoptosis of NUGC-3 cells were 
examined to further investigate the anticancer effects of BmK in gastric 
cancer cells. As shown in Fig 3.2, after treatment with 5 mg/ml BmK venom 
for 24 h, the cell cycle profile changed with 6 percent increase in sub-G1 
phase (2.3% vs 8.2%), 9 percent increase in G1 phase (51.1% vs 60.3%) and 11 
percent decrease in G2/M phase. Meanwhile, 5 mg/ml of BmK venom 





Fig 3.2  Representative profiles of NUGC-3 cell cycle (A) and cell apoptosis (B) analysis 
by flow cytometry. Cells were treated with 5 mg/ml BmK venom for 24 h. R1, R2, R3 
and R4 in (A) indicate sub-G1, G1, S and G2/M phase, respectively. R11 and R9 in (B) 











All these findings indicate that BmK scorpion venom had a significant 
inhibitory effect on NUGC-3 cell proliferation via cell cycle arrest at sub-G1 
and G1 phases and apoptosis enhancement. However, the administrated 
concentration of BmK venom was high and the anti-proliferative effects were 
limited.  
 
3.1.2 The anti-proliferative effects of crude venom from Hottentotta 
hottentotta, Heterometrus longimanus and Pandinus imperator scorpions 
Another three crude scorpion venoms were screened using 
alamarBlue cell viability/proliferation assay to compare their anti-
proliferative effects on NUGC-3 cells, including Pandinus imperator, 
Heterometrus longimanus and Hottentotta hottentotta scorpion venoms 
(short for PIV, HLV and BHV, respectively). Results showed that all these 
three venoms could decrease NUGC-3 cell viability/proliferation in a dose 
dependent way (Fig 3.3). The IC50 for 24 h treatment in 96-well plate was 0.9 
mg/ml for PIV, 0.3 mg/ml for HLV and 8.1 µg/ml for BHV. Compared with 
BmK scorpion venom, it can be seen that these three venoms have stronger 
inhibition activity even at much lower concentration. BHV has the lowest 
effective concentration and seems the most promising to be developed as 
anticancer agent. Therefore, BHV was selected for further investigation of the 























3.2  Evaluating the anticancer potential of Hottentotta hottentotta scorpion 
venom in gastric cancer  
3.2.1 BHV`s inhibition to cell viability/proliferation of gastric cancer cell 
lines 
Based on the observations in the preliminary screening work, the 
anticancer potential of BHV in gastric cancer will be the focus of this study. 
First, the cell viability/proliferation of another two gastric cancer cells (MKN-7 
Fig 3.3  AlamarBlue cell viability/proliferation assay of NUGC-3 cells after 
treatment with PIV, HLV and BHV for 24 h, respectively. The intensity of 
alamarBlue was read by fluorescence with excitation at 570 nm and 








and MKN-74) were validated after receiving BHV treatment. Similar to NUGC-
3, BHV decreased their cell viability/proliferation dose dependently. Whereas, 









3.2.2 Evaluation of the cytotoxicity of BHV to NUGC-3 cells by LDH assay  
The cytotoxicity of BHV to NUGC-3 cells was evaluated by measuring 
the release of lactate dehydrogenase (LDH) enzyme.  Cells were treated with 
different dose of BHV for 24 h prior to LDH study. Results showed that there 
was no increase in the amount of released LDH after treatment with less than 
8 µg/ml BHV (p>0.05), even though the cell viability decreased dose 
dependently. However, treatment with 10 µg/ml BHV significantly induced 
the LDH release, indicating the loss of membrane integrity (Fig 3.5). The 
percentage cytotoxicity was calculated as 49.5% for the 10 µg/ml BHV group.  
Fig 3.4  AlamarBlue cell viability/proliferation assay of gastric cancer cells 










3.2.3  NUGC-3 cell cycle profile after treatment with BHV  
To determine BHV`s effect on NUGC-3 cell cycle profile, the fixed cells 
were stained with PI and analyzed by flow cytometry after treatment with 
different concentrations of crude venom for 24 h. It was shown that BHV 
treatment resulted in an increase in sub-G1 phase, which indicates the 
occurrence of DNA fragmentation. With 7.5 µg/ml of BHV treatment, sub-G1 
phase increased from 2.25% to 29.5%. Concomitantly, G2/M phase decreased 
from 39.5% to 20.7%, and there was a slight decrease in G1 phase (Fig 3.6). 
Such observations suggested that BHV could induce DNA fragmentation at 






Fig 3.5 BHV cytotoxicity to NUGC-3 cells by LDH assay. Cells were treated 
for 24 h. 2% (w/v) Triton X was used as positive control. Data are 
























3.2.4  Morphological changes induced by BHV treatment in NUGC-3 cells 
3.2.4.1  NUGC-3 morphology under fluorescence microscope 
Acridine orange/Ethidium bromide (AO/EB) staining is a simple way to 
detect cell morphology using fluorescence light microscope, which is 
commonly used in the differentiation of early and late apoptosis. In this study, 
Fig 3.6  BHV treatment induced changes of NUGC-3 cell cycle profile 
(A): Representative images of NUGC-3 cell cycle profiles. R1, R2, R3 and 
R4 indicate sub-G1, G1, S and G2/M phase, respectively.  (B): Cell 
fractions in different cell cycle phases. Data are presented as means + 















NUGC-3 cells were treated with 20 µg/ml BHV for 12 h and 24 h, respectively. 
Different stages of apoptotic morphologies were observed. The control cells 
were uniformly green from the staining of AO (Fig 3.7-A). Fig 3.7-B showed 
typical features of early apoptotic cells.  Cells were stained green with bright 
yellowish dots as a consequence of chromatin condensation and nuclear 
fragmentation. Moreover, the formation of membrane blebbing was also 
observed. The late apoptotic cells were stained orange red because the cells 
have lost membrane integrity and EB was incorporated to stain DNA. In 
addition, late apoptotic cells displayed more condensed nuclei and cell 











(A): Control (C): BHV 24 h (B): BHV 12 h 
Fig 3.7  NUGC-3 morphological changes after BHV treatment by AO-EB 
staining. Photos were taken at 200 X magnification. Arrows indicate 
apoptotic features including yellowish and red colour changes, membrane 








3.2.4.2  NUGC-3 morphology under transmission electron microscope (TEM) 
TEM was used to visualize the ultrastructural changes induced by BHV 
treatment. NUGC-3 cells were treated with 20 µg/ml BHV for 24 h. As shown 
in Fig 3.8-A, the cytoplasmic and nuclear integrity in the control cell was well 
preserved. For example, chromatin was evenly distributed in nucleus and the 
cell membrane was intact.  The subcellular organelles such as mitochondria 
could also be seen in the cytoplasm. Comparatively, in BHV treated cells (Fig 
3.8-B), the cell integrity was remarkably disrupted. The chromatin was 
condensed with margination along the nuclear envelope with membrane 






3.2.5  NUGC-3 apoptosis detection by Annexin-V and PI staining 
Annexin-V and PI staining is a sensitive method to detect and quantify 
cell apoptosis based on the externalization of phosphatidylserine (PS). NUGC-
Fig 3.8 Morphological changes seen in NUGC-3 cells after BHV treatment 
under TEM. (A): untreated NUGC-3 cell. (B): NUGC-3 cell treated with 20 
µg/ml BHV for 24 h showing condensed chromatin, membrane blebbing and 







3 cells were treated with 15 µg/ml BHV for 24 h prior to staining with 
Annexin-V-FITC and PI. Results showed that Annexin-V-FITC signal was 
considerably increased after BHV treatment, which indicated the occurance 
of cell apoptosis (Fig 3.9). Compared with untreated cells, late apoptosis (R9) 
increased significantly from 3.37% up to 29.9% (p<0.01) and there was a 















Fig 3.9 Flow cytometric analysis of NUGC-3 cell apoptosis with Annexin V 
and PI staining. (A): Representative profiles of Annexin-V-FITC and PI 
signals from flow cytometry. R11 (Annexin-V positive/PI negative) 
indicates early apoptosis; R9 (Annexin-V positive/PI positive) indicates 
late apoptosis. (B): Bar chart of the percentage of cells undergoing early 
and late apoptosis, respectively. Data are presented as means + SEM. 










3.2.6  Detection of caspase activation after BHV treatment 
3.2.6.1 Western blot analysis of cleaved caspases  
Apoptosis is commonly considered to be mediated by the activation 
of a family of cysteine-containing aspartate-directed proteases called 
caspases. To prove this hypothesis, the cleaved caspase antibodies were 
applied in western blot to identify the activation of caspase family members 
during BHV induced apoptosis. PARP, caspase-3 caspase-8 and caspase-9 are 
key regulators in the caspase apoptosis pathway. NUGC-3 cells were treated 
with 30 µg/ml BHV for 24 h and cell lysate was collected for western blot. 
Unexpectedly, results showed that no cleaved bands were detected for 
caspase-3, caspase-8 and caspase-9 after BHV treatment and a faint but non-
significant cleaved PARP was visualized (Fig 3.10).  However, in the positive 
control group (NUGC-3 treated with Doxorubicin, a chemotherapy drug), 
obvious bands were seen. Such findings suggested that the apoptosis induced 




























Fig 3.10 Western blot of caspase proteins in NUGC-3 cells after treatment 
with BHV. β actin was used to normalized the protein loading. BHV, 20 
µg/ml. Dox, doxorubicin, 25 µM. Data were representative of two 
replicates.  
 







3.2.6.2 Caspase-3 activity assay and the influence of pan-caspase inhibitor 
on NUGC-3 cell viability 
To confirm the apoptosis induced by BHV was caspase independent, 
the caspase-3 activity was measured based on the reaction between caspase-
3 and its substrate DEVD-pNA. Results showed that there was no increase in 
caspase activity in NUGC-3 cells after treatment with BHV (Fig 3.11-A). NUGC-
3 cells were pre-treated with the pan-caspase inhibitor z-VAD-fmk for 1 h to 
inhibit caspase pathway prior to the administration of BHV. However, the 
pre-treatment with z-VAD-fmk did not have influence on the cell viability, 
indicating that the inhibition of caspase pathway had no effect on the BHV 
induced reduction of cell viability (Fig 3.11-B, p=0.16 by Two-way ANOVA). 
These two experiments further concluded that BHV induced a caspase 









Fig 3.11 Confirmation of caspase independent apoptosis induced by BHV 
treatment. (A): caspase-3 activity assay. NUGC-3 cells were treated with 
30 µg/ml BHV for 24 h. Dox, 25 µM doxorubicin as positive control. (B): 
NUGC-3 cell viability study after treatment with different concentration of 
BHV. BHV+z-VAD-fmk indicates cells were pre-treated with 50 µM z-VAD-
fmk for 1 h prior to the administration of BHV. Data are presented as 













3.2.7  BHV`s effects on NUGC-3 cell migration and invasion 
Cell migration and invasion are pivotal cell behaviours involved in 
cancer metastasis. The effect of BHV treatment on NUGC-3 cell migration was 
investigated by transwell study. Based on the cell viability study, a non-toxic 
concentration 2 µg/ml was used in this assay to eliminate the interference of 
cell viability as influencing migration. Results showed that 2 µg/ml of BHV 
reduced the cell migration ability through the polycarbonate membrane 






Fig 3.12 NUGC-3 gastric cancer cell migration assay after treatment with 
BHV. (A): Representative images of migrated NUGC-3 cells. Images were 
taken at 80 X magnification. (B): Bar chart of migrated cell number. 
Numbers are the average of 5 counting areas. Data are presented as 






Similarly, NUGC-3 cell invasion activity was examined using Matrigel 
assay. There was a significant decreased number of cells that invaded 
through the matrigel and polycarbonate membrane after crude BHV 







Fig 3.13 NUGC-3 gastric cancer cell invasion assay after treatment with 
BHV. (A): Representative images of invaded NUGC-3 cells. Images were 
taken at 80 X magnification. (B): Bar chart of invaded cell number. 
Numbers are the average of 5 counting areas. Data are presented as 








3.2.8  The effects of BHV in NUGC-3 xenograft in vivo model 
NUGC-3 xenograft model was established on BALB/c-nu/nu mice by 
subcutaneous injection of cancer cells. After 4 weeks, the tumor grew to 
palpable size (100-200 mm3, Fig 3.14-A). The non-lethal dose of BHV to mice 
was determined as lower than 12.5 µg/mouse. The inhibition effect of BHV 
following injection was evaluated by monitoring the tumor growth. Results 
showed that 6.25 µg/mouse BHV did not inhibit tumor growth (p=0.06) while 
12.5 µg/mouse BHV significantly inhibited tumor growth (p=0.008) (Fig 3.14-
B1). The finding was confirmed with a repetitive experiment with injection of 
12.5 µg/mouse BHV and the partially purified fraction BHV-F1 (5 µg/mouse) 





















Fig 3.14 Tumor growth rate of NUGC-3 xenograft after BHV treatment 
(A): Representative image of BALB/c-nu/nu mice bearing NUGC-3 
xenograft on the left flank, as shown with arrow. The photo was taken 4 
weeks after cancer cell injection.  
(B1) and (B2): Tumor growth rate of NUGC-3 xenograft after BHV 
treatment. Data are presented as means + SEM. N=5 (For group B2-12.5 














3.2.9  Tumor histology by Haematoxylin and Eosin staining 
Histology of tumor sections was observed after staining with 
Haematoxylin and Eosin. As shown in Fig 3.15, BHV treatment disrupted the 





Fig 3.15 Tumor histology with H & E staining. (A) and (B) are 
representative images of tumor tissues with H&E staining. A, control; B, 
12.5 µg/mouse BHV injection. Photos were taken at 12.5 X magnification. 
Scale bar=2000 μm; (C) and (D) are higher magnified images of the framed 
area in (A) and (B), respectively. Photos were taken at 200 X 










3.2.10  Apoptosis detection in tumor tissues 
Apoptosis in situ was detected in paraffin embedded tumor sections 
based on the TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay. 
Apoptotic cells were stained into brown colour and the healthy cells were 
stained green. As shown in Fig 3.16, much more apoptosis positive staining 
was observed in BHV injected tumor specimens. This finding indicated that 
BHV impaired tumor growth and disrupted tumor histology by the induction 









control 1 control 2  control 3  BHV 1 BHV 2 BHV 3 
control 2  BHV 2 
Fig 3.16 Apoptosis in situ analysis in tumor sections after BHV treatment.  
(A): Gross view and comparison between control and BHV treated tumor 
slides. (B): Magnified images showing the apoptotic cells (dark brown) 
after BHV treatment. Photos were taken at 400 X magnification. Scale 








3.3  Investigation of  possible mechanisms of BHV anticancer actions  
3.3.1  Cancer 10-pathway Reporter Array  
Cignal Finder Cancer 10-Pathway Reporter Array was carried out to 
investigate the activity of ten important pathways in NUGC-3 cancer cells (as 
described in section 2.5.4). Results showed that among the ten pathways, the 
activity of five pathways was detected and the rest did not respond. The 
responsive pathways were NFκB, Myc/Max, Hypoxia, MAPK/ERK and 
MAPK/JNK, respectively. After BHV treatment, there was a significant 
decrease in the activity of MAPK/ERK pathway (p=0.02). Whereas, the other 
four pathways were not significantly changed.  
 Fig 3.17 Activity of pathways in NUGC-3 cells after BHV treatment by 
Cancer 10-Pathway Reporter Array. Cells were treated with 20 µg/ml BHV 








3.3.2  Expression of genes in MAPK/ERK pathway after BHV treatment  
The MAPK/ERK pathway plays an important role in the regulation of 
cell proliferation and cell apoptosis. The expression of some selected genes in 
the MAPK/ERK pathway was quantified by real-time PCR. Results showed 
that most of the genes were down regulated after treatment with BHV, such 
as ERK1, ERK2, MEK1, Raf1, p70 and RSK. These results indicated the 














Fig 3.18  Expression of genes in MAPK/ERK pathway by reat-time PCR. 
NUGC-3 cells were treated with 20 µg/ml BHV for 24 h. GAPDH was used 
for normalization. Date are presented as means + SEM. N=3. p values 
were calculated based on each gene expression of untreated cells and the 








3.3.3  Regulation of phosphorylated proteins in MAPK/ERK pathway by BHV 
treatment  
The expression of phosphorylated proteins plays an critical role in the 
regulation of one pathway`s activity. In this study, the phosphorylated 
protein expression of several important regulators in MAPK/ERK pathway 
was validated by western blot. NUGC-3 cells were treated with 30 µg/ml BHV 
for 24 h and the cell lysates were collected for western blot. Results showed 
that most of the selected proteins were down regulated. After BHV 
treatment, the expression of MEK 1/2, MSK-1 and Elk-1 significantly 
decreased (p<0.05) whereas the expression of ERK 1/2 and p90RSK showed a 




























Fig 3.19  Regulation of MAPK/ERK pathway in NUGC-3 cells by BHV analyzed 
by western blot. NUGC-3 cells were treated with 30 µg/ml BHV for 24 h. β 
actin was used as loading control. Molecular mass: MEK 1/2 - 45 kDa, ERK 
1/2 - 42, 44 kDa, p90RSK - 90 kDa, MSK 1 - 90 kDa, Elk-1 -47 kDa,  β actin - 42 













3.3.4  Affymetrix gene microarray of NUGC-3 cells after BHV-F1 treatment 
To better understand the genomic changes induced by BHV, the 
Affymetrix Gene Chip® Human Gene 2.0 ST Array was performed. NUGC-3 
cells were treated with 5 µg/ml BHV-F1 for 24 h and the total RNA was 
extracted for gene chip. Based on One-Way ANOVA analysis, 140 
transcription IDs were considered as differentially expressed (fold change >2 
and p value <0.05). The hierarchical clustering of these transcripts is shown in 
Fig 3.20, which indicates the standardized gene expression level of each gene 
in each sample. High consistency of the gene expressions of 3 samples in the 
same group (control or BHV-F1 treated) was observed. Moreover, the 
differential expression pattern between control and BHV-F1 treated group 

















Fig 3.20  Hierarchical clustering of differentially expressed genes from microarray. The gene expression was standardized by shifting 
genes to mean of zero and scaling to standard deviation of one. Genes with no changes are displayed as a value of zero and colored 
gray. Up-regulated genes have positive values and displayed in red, whereas down-regulated genes have negative values and displayed 








The microarray data were also analyzed by volcano plot to see the 
distribution of differentially regulated genes, as shown in Fig 3.21. The results 
showed that the majority of genes were not changed by BHV-F1 treatment 
with fold change less than two and among those genes with fold change 
above two, most were not significant as their p values were more than 0.05. 
After removing the repetitive and invalid transcription IDs, 65 genes were 
confirmed as differentially regulated by BHV-F1 treatment. Among these 
genes, 22 genes were up regulated and 43 genes were down regulated 




Fig 3.21 Volcano plot of microarray data. The significant genes are 
indicated out by one horizontal bold blace line (p=0.05) and two vertical 
bold black lines (fold change > 2 or < -2). The down regulated genes are 









Table 3.1 List of differentially expressed genes in NUGC-3 cells after BHV-F1 










ANAPC5 51433 anaphase promoting complex subunit 5 -14.9854 0.000446 
ANGPT2 285 angiopoietin 2 11.49494 0.001509 
ANKRD1 27063 ankyrin repeat domain 1 -3.63879 0.018007 
ANLN 54443 anillin, actin binding protein -2.17062 0.008509 
ANP32E 81611 acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member E 
-2.18441 0.02323 
ASNS 440 asparagine synthetase 2.589586 0.003469 
ASPM 259266 asp (abnormal spindle) homolog, 
microcephaly associated 
-2.35799 0.026867 
ATP6V1G2 534 ATPase, H+ transporting, lysosomal 
13kDa, V1 subunit G2 
-2.774 0.001193 
BIRC3 330 baculoviral IAP repeat-containing 3 2.389077 0.027975 
C6orf48 26797 chromosome 6 open reading frame 48 4.328741 0.004102 
CANX 821 calnexin -7.05307 0.011419 
CBX3 11335 similar to chromobox homolog 3 -4.26086 0.004875 
CHMP4C 92421 chromatin modifying protein 4C 2.04211 0.014596 
COX7B 1349 cytochrome c oxidase subunit VIIb -2.04037 0.002444 
DDX5 1655 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
5 
-4.41702 0.011417 
DNAJA1 3301 DnaJ (Hsp40) homolog, subfamily A, 
member 1 
-3.15604 0.000129 
DSCC1 79075 defective in sister chromatid cohesion 1 
homolog 
-2.08955 0.00115 
EGR1 1958 early growth response 1 4.184436 0.001438 
EIF3D 8664 eukaryotic translation initiation factor 3, 
subunit D 
-2.85451 0.04928 
EIF3F 390282 eukaryotic translation initiation factor 3, 
subunit F 
-3.11397 0.040692 
EIF4G2 1982 eukaryotic translation initiation factor 4 
gamma, 2 
-3.9618 0.030402 
ESCO1 114799 establishment of cohesion 1 homolog 1 2.130514 0.026444 
FNTA 2339 farnesyltransferase, CAAX box, alpha 5.199527 0.032174 
FTH1 2495 ferritin, heavy polypeptide 1 4.362973 0.003489 
FTL 2512 ferritin, light polypeptide 2.400792 0.037392 
GATC 283459 glutamyl-tRNA(Gln) amidotransferase, 
subunit C homolog 
3.314797 0.027889 
GDI2 2665 GDP dissociation inhibitor 2 -3.05096 0.000612 
HNRNPA1 3178 heterogeneous nuclear ribonucleoprotein 
A1-like 3 
-6.72359 0.027009 
HNRNPD 3184 heterogeneous nuclear ribonucleoprotein 
D 
-2.07645 0.035162 






HSP90AB1 3326 heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
-3.07199 0.046848 
HSPA8 3312 heat shock 70kDa protein 8 -3.85441 0.000141 
HSPH1 10808 heat shock 105kDa/110kDa protein 1 -2.76811 0.001413 
ILF2 3608 interleukin enhancer binding factor 2, 
45kDa 
-10.4436 0.005072 
KDM2B 84678 lysine (K)-specific demethylase 2B -2.85705 0.007626 
KYNU 8942 kynureninase (L-kynurenine hydrolase) 2.308296 0.046193 
LOC285359 285359 phosducin-like 3 pseudogene -2.93047 0.011587 
LOC389765 389765 similar to KIF27C 2.159745 0.033027 
LOC648771 648771 similar to 60S ribosomal protein L12 -3.69463 0.029502 
NAMPT 10135 nicotinamide phosphoribosyltransferase 4.892851 0.004212 
NBEAL1 65065 neurobeachin-like 1 -3.69463 0.029502 
ND1 4535 NADH-ubiquinone oxidoreductase chain 1 -2.68821 0.039377 
NEAT1 283131 non-protein coding RNA 84 2.997719 0.006362 
NONO 4841 non-POU domain containing, octamer-
binding 
-6.04071 1.89E-05 
PARK7 11315 Parkinson disease (autosomal recessive, 
early onset) 7 
-7.18922 0.042892 
PRPF8 10594 PRP8 pre-mRNA processing factor 8 
homolog 
-4.27161 0.008261 
PSMB2 5690 proteasome (prosome, macropain) 
subunit, beta type, 2 
-2.48659 0.005686 
RIOK3 8780 RIO kinase 3 2.790354 0.00825 
RPL10A 4736 ribosomal protein L10a 2.253678 0.016353 
RPL18 6141 ribosomal protein L18 -2.57181 0.005058 
RPL4 158345 ribosomal protein L4 2.673675 0.001257 
SART1 9092 squamous cell carcinoma antigen 
recognized by T cells 
-3.71279 0.001753 
SART3 9733 squamous cell carcinoma antigen 
recognized by T cells 3 
-7.01067 0.027671 
SBNO1 55206 strawberry notch homolog 1 -2.03721 0.034587 
SERPINB2 5055 serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 
2.747522 0.047249 
SNORD18C 595098 small nucleolar RNA, C/D box 18C 2.673675 0.001257 
STARD7 56910 StAR-related lipid transfer (START) 
domain containing 7 
-2.22616 0.021743 
TAF1D 684959 TATA box binding protein (TBP)-
associated factor, RNA polymerase I, D,  
2.086967 0.011563 
TMSB4X 7114 thymosin beta 4, X-linked -2.12485 0.027562 
TNFSF15 9966 tumor necrosis factor (ligand) 
superfamily, member 15 
2.470492 4.98E-05 
TOP2A 7153 topoisomerase (DNA) II alpha 170kDa -2.22287 0.000971 
TUBB 203068 tubulin, beta; -2.15314 0.027179 
UBE2L1 7330 ubiquitin-conjugating enzyme E2L 1 -2.27259 0.038651 
ZFAS1 441951 ZNFX1 antisense RNA 1 -2.62715 0.003335 






The functional classification was accomplished using DAVID functional 
annotation clustering analysis. These genes were involved in different 
biological processes including cell cycle, cell apoptosis, membrane 
organization, cytoskeleton, stress response, DNA repair, oxidation reduction 
and so on (Table 3.2).  
Table 3.2  Functional classification of differentially expressed genes 
from Affymetrix microarray 
Biological processes Related genes 
cell cycle ANAPC5, ANLN, ASPM, DSCC1, EIF4G2,  
PSMB2, SART1, TUBB, ESCO1 
cell apoptosis SART1, TOP2A, TUBB, ASNS, BRIC3, 
FNTA, SERPINB2, TNFSF15, LOC285359 
cytoskeleton ANLN, ASPM, FNTA, CBX3,  
TMSB4X, TOP2A, TUBB 
stress response HSPH1, HSPA8, HSP90AB1 
DNA repair NONO1, TOP2A, ESCO1 
Oxidation reduction ND1, FTH1, KDM2B, FTL 














3.3.5  Validation of apoptosis related genes by real-time PCR 
Considering the importance of cell apoptosis induced by BHV in 
functional studies, real-time PCR was performed to verify the reliability of 
results of apoptosis related genes obtained from microarray. It was found 
that the expression of all 8 genes by real-time PCR was in concordance with 
the microarray data and more up-regulation of ASNS and TNFSF15 was 
















Fig 3.22  Validation of apoptosis related genes from microarray data by real-
time PCR. NUGC-3 cells were treated with 5 µg/ml BHV-F1 for 24 h. The RNA 
samples were as the same as those sent for cDNA microarray. GAPDH was 








 3.4  Purification and characterization of the antitumoral agent in BHV 
3.4.1  Characterization of crude BHV by SDS-PAGE 
The lyophilized crude BHV was dissolved in 1 x PBS and protein 
concentration was measured with Bradford method, with finding that the 
proteins accounted for 60% of the total weight of the crude venom. The 10% 
SDS-PAGE results verified the molecular mass distribution of crude BHV (Fig 
3.23). More than 10 bands were separated on the gel with a wide range of 
M.W., which included small peptides (5~15 kDa), medium size proteins 
(15~55 kDa) and high M.W. proteins (55~130 kDa). 
 
  
Fig 3.23 10% SDS-PAGE pattern of crude BHV in two different separation 
conditions.  30 µg crude venom was loaded and M.W. unit is Da.  
(A): shorter time running with focus on low M.W. protein separation. Bio-
Rad protein ladder was used as standard. (B): longer time running with 
focus on high M.W. protein separation. PageRuler protein ladder was used 
as standard.  
(A) (B) 






3.4.2  Size exclusive gel filtration chromatography and SDS-PAGE of 
fractions 
Superdex G75 gel filtration column was used to perform the 
preliminary separation of crude BHV. Five fractions were obtained, named F1 
to F5, respectively (Fig 3.24). Among which, F2 was the most abundant and 
F5 had the fewest contents. All fractions were collected and lyophilized and 
each fraction was characterized by SDS-PAGE (Fig 3.25). Results showed that 
F1 mainly contained high M.W. proteins (>32.5 kDa) with few small bands as 
well. F2 contained wide range of small and medium proteins (5~32.5 kDa). F3 












Fig 3.24 Superdex G75 gel filtration chromatography of crude BHV.   
100 µg crude venom was loaded each time. Fractions were eluted with 50 
mM ammonium bicarbonate, pH=8.0, at a flow rate of 1 mL/min. Five 










3.4.3  Test of the inhibition effect of each fraction to NUGC-3 cell viability 
To find out which fraction has the anticancer effect and contain the 
cytotoxic protein, NUGC-3 cell viability study was performed after treatment 
with each fraction (10 µg/ml). The results showed that F1 almost killed all 
NUGC-3 cells with viability reduction more than 90%. F2 and F3`s inhibition 
effect was also significant but were negligible compared with F1`s effect (Fig 
3.26-A). Therefore, the cytotoxic protein was confirmed to be located in F1, 
which deserved further investigations. To verify this finding, different 
concentration of F1 was applied and a corresponding cell viability inhibition 
was observed (Fig 3.26-B) with calculated IC 50 around 3 µg/ml.  
Fig 3.25 10% SDS-PAGE profile of gel filtration fractions.  For crude BHV, 
F1 and F2, 30 µg protein was loaded. For F3 and F4, 2 µg protein was 
loaded. F5 contained too low protein and was not applied in this 











3.4.4  Cation exchange chromatography, SDS-PAGE and cell viability test 
BHV-F1 was further separated with UNO S1 cation exchange 
chromatography column (Bio-Rad). A liner NaCl gradient elution resolved the 
BHV-F1 into another 5 peaks, named BHV-F1-A to BHV-F1-E, respectively (Fig 
3.27). BHV-F1-A was the unbound fraction and the rest peaks were eluted 
fractions.  Similarly, 10% SDS-PAGE was performed to characterize protein 
M.W. distribution in each peak (Fig 3.28) and the inhibition effect of each 
fraction to NUGC-3 cell viability was examined by alamarBlue assay. Results 
showed that among all 5 fractions, both fraction 3 and 4 decreased cell 
viability of NUGC-3 cells, indicating that the targeted proteins were in both 
fractions (Fig 3.29). This was possibly because BHV-F1-C and BHV-F1-D were 










Fig 3.26 NUGC-3 cell viability assay after treatment with gel filtration 
fractions. (A): NUGC-3 cell viability study after treatment with each 
fraction after gel filtration (10 µg/ml for 24 h). (B): NUGC-3 cell viability 
study after treatment with different concentrations of F1 for 24 h. Data 












































Fig 3.27 UNO S1 cation exchange chromatogram of BHV-F1.  BHV-F1 was 
lyophilized and re-dissolved in starting buffer (50 mM sodium acetate, pH 
5.0). The column was equilibrated with starting buffer and the elution was 
achieved with a liner gradient of 1 M NaCl.  





























Fig 3.28 10% SDS-PAGE profile of fractions after BHV-F1 separation.  
 20 µl of each fraction was loaded. Protein concentration: F1-A, 0.04 







Fig 3.29 NUGC-3 cell viability assay after treatment with fractions after 
cation exchange chromatography. 10 µl of each fraction was added to 100 
ul cell medium and treatment time was 24 h. Protein concentration: F1-A, 
0.04 µg/ml; F1-B, 0.31 µg/ml; F1-C, 0.31 µg/ml; F1-D, 0.88 µg/ml; F1-E, 







3.4.5  Preliminary protein identification results with MALDI-TOF-Mass 
Spectrometry 
Based on the information from SDS-PAGE (Fig 3.28), several suspected 
bands were cut down from the gel and sent for MALDI-TOF-MS/MS analysis 
to identify the protein, including a mixed protein band from BHV-F1 named 
F1-a, two bands from BHV-F1-C named F1-C-a and F1-C-b, and one band from 
BHV-F1-D, named F1-D-a (Fig 3.30). Mass spectrometry results showed that 
F1-a contained 3 types of protein, which were Coagulation factor X-activating 
enzyme heavy chain, Acetylcholinesterase and L-amino acid oxidase. 
Consistently, the individual band protein identification results indicated that 
F1-C-a was Acetylcholinesterase, F1-C-b was L-amino acid oxidase and F1-D-a 
was Coagulation factor X-activating enzyme heavy chain. From the literature 
review, the L-amino acid oxidase was reported to possess anticancer effect 
and became our research interest for further study. The mass spectrum of F1-




Fig 3.30 Indication of the bands that were cut from PAGE gel for mass 
spectrometry analysis. The bands cut down from each lane were indicated 
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Fig 3.32  Probability Based Mowse Score and protein summary report. 
Ions score is -10*Log(P), where P is the probability that the observed 











3.4.6 Detection of LAAO enzymatic activity in crude BHV and BHV-fractions 
As the results from mass spectrometry and protein ID blast can only 
putatively identify the protein, the enzymatic activity test was performed to 
double confirm that the anticancer protein was LAAO. LAAO can oxidaze L-
leucine and form hydrogen peroxide, which can be degraded by horseradish 
peroxidase (HRP) and produce the absorbance at 490 nm. The results are 
shown in Fig 3.33. The LAAO enzymatic activity was observed in crude BHV, 
fraction 1 after gel filtration and BHV-F1-C after BHV-F1 cation exchange 








Fig 3.33  LAAO enzymatic activity assay in BHV fractions. 10 µl of samples 
mixed in 90 µl 50mM Tris-Hcl buffer (pH 8.0) containing 5 mM L-leucine, 2 
mM o-Phenylenediamine and 2.5 unit HRP. Reaction mixture was 
incubated at 37 °C for 1h and terminated by adding 50 µL 2 M H2SO4. 









3.5  Investigating the anticancer effects of L amino acid oxidase (LAAO) in 
gastric cancer 
3.5.1  LAAO`s inhibition to cell viability/proliferation of gastric and breast 
cancer cell lines 
Because of the non-availability of LAAO from scorpion venom, LAAO 
purified from Crotalus adamanteus snake venom was used in the following 
studies. Firstly, its effect on the viability/proliferation of gastric cancer cells 
(MKN-74, MKN-7, NUGC-3) was analyzed, with results showing that LAAO 
decreased the cell viability dose dependently. Moreover, an extended study 
using breast cancer cells (MDA-MB-231, T-47D, MCF-7) and normal breast 
cells (MCF12A) was also done, showing that LAAO induced more reduction of 
cancer cell viability, compared with normal cells.  
 
  
Fig 3.34  AlamarBlue cell viability/proliferation assay of gastric and breast 
cancer cells after treatment with LAAO for 24 h. Data are presented as means 






3.5.2 LAAO cytotoxicity to NUGC-3 cells by LDH assay  
The cytotoxicity of LAAO to NUGC-3 cells was evaluated by LDH assay. 
Results showed that more than 0.5 µg/ml LAAO induced a significant increase 
of LDH release from cytoplasm to culture medium, which indicated that the 
plasma membrane had lost its integrity. The cytotoxicity was up to 53.4% for 













Fig 3.35 LAAO cytotoxicity to NUGC-3 cells by LDH assay. Cells were 
treated for 24 h. 2% (w/v) Triton X was used as positive control. Data are 
presented as means + SEM. N=3. *, p < 0.05; **, p<0.01.  
* 






3.5.3  NUGC-3 cell cycle profile after treatment with LAAO 
LAAO`s effect on NUGC-3 cell cycle was examined by flow cytometry 
after fixing and staining with PI. NUGC-3 cells were treated with 1.0 µg/ml 
and 1.5 µg/ml LAAO for 24 h. Results showed that LAAO treatment induced a 
percentage increase in G2/M phase (27.3% vs 34.8% vs 38.5%) and a 
percentage decrease in G1 phase (51.1% vs 42.5% vs 37.5%), indicating a 
G2/M cell cycle arrest (Fig 3.36). However, no sub-G1 peak was observed for 










Fig 3.36 LAAO treatment induced the changes of NUGC-3 cell cycle profile 
(A): Representative images of NUGC-3 cell cycle profiles. P3, P4, P5 and P6 
indicate sub-G1, G1, S and G2/M phase, respectively. (B): Cell fractions in 
different cell cycle phases. Data are presented as means + SEM. N=3. *, p < 







3.5.4  NUGC-3 cell apoptosis  analysis after treatment with LAAO 
The apoptosis induced by LAAO treatment was confirmed and 
quantified by flow cytometry analysis after staining with Annexin-V-FITC and 
PI. NUGC-3 cells were treated with 1.0 µg/ml LAAO for 12 h prior to staining 
with Annexin-V-FITC and PI. Compared with untreated cells, LAAO treatment 
induced both early apoptosis (2.8% vs 8.1%) and late apoptosis (5.8% vs 

















Fig 3.37 Flow cytometry analysis of NUGC-3 cell apoptosis with LAAO 
treatment. (A): Representative profiles of Annexin-V-FITC and PI signals 
from flow cytometry. Q4 (Annexin-V positive/PI negative) indicates early 
apoptosis; Q2 (Annexin-V positive/PI positive) indicates late apoptosis. (B): 
Bar chart of the percentage of cells undergoing early and late apoptosis, 








3.5.5  Morphological changes induced by LAAO treatment in NUGC-3 cells 
In order to detect the morphological changes of NUGC-3 induced by 
LAAO treatment, with special attention on early characteristics,  cells were 
treated with 1.0 µg/ml LAAO for 12 h. Different approaches were taken to 
investigate both extracellular and intracellular structure changes, including 
fluorescence light microscopy, transmission electron microscopy and 
scanning electron microscopy.  
Fluorescence microscopy: 
Fig 3.38 reveals the morphological changes of NUGC-3 cells after 
LAAO treatment under fluorescence light microscope with AO/EB staining.  
Such changes included nuclear condensation, membrane blebbing and the 





Fig 3.38 NUGC-3 morphological changes after LAAO treatment by AO-EB 
staining. Photos were taken at 200 X magnification. (A): control; (B): LAAO 
treated. Arrows indicate apoptotic features such as membrane blebs and 







Scanning electron microscopy (SEM): 
SEM was applied to visualize NUGC-3 cell surface structures. As shown 
in Fig 3.39, the untreated cell had fusiform shape with smooth surface and 
lots of small contacts. In contrast, after treatment with LAAO, cell became 

















Fig 3.39  Morphological changes of NUGC-3 cells after LAAO treatment under 
SEM.(A): untreated NUGC-3 cells. (B): a magnified image of the rectangle-
framed cell in (A). (C): NUGC-3 cells treated with 1.0 µg/ml LAAO for 12 h. (D): 
a magnified image of the rectangle-framed cell in (C). Scale bar is 20 μm for (A) 






Transmission electron microscopy (TEM): 
The nuclear and cytoplasmic structure changes induced by LAAO 
treatment were identified by TEM. For untreated cell, nuclear and cytoplasm 
integrity was well maintained with loosed chromatins and organelle 
structures. After treatment with LAAO, obvious chromatin condensation and 












Fig 3.40  NUGC-3 morphological changes after LAAO treatment under TEM 
(A): untreated NUGC-3 cell. (B): NUGC-3 cells treated with 1.0 µg/ml LAAO 







3.5.6  Detection of caspase activation after LAAO treatment 
Similar approaches were taken to detect the caspase activation after 
LAAO treatment. In the western blot, a very faint cleaved band was observed 
for PARP and caspase-3 in both control and LAAO treated groups. There was 
no increase in caspase-3 activity in the substrate colourmetric assay (p=0.248) 
and the pre-treatment with pan-caspase inhibitor z-VAD-fmk did not change 
the pattern of NUGC-3 cell viability with LAAO treatment (p=0.93 by Two-way 
ANOVA) (Fig 3.41). All these findings were consistent with BHV work and 








Fig 3.41 Confirmation of caspase independent apoptosis induced by LAAO 
treatment. (A): western blot of cleaved PARP and caspase-3. β-actin was used to 
normalized the protein loading. Cells were treated with 1.0 µg/ml LAAO or 25 
µM doxorubicin (Dox) for 24 h. Data were representative of two replicates. (B): 
caspase-3 activity assay. NUGC-3 cells were treated with 1.0 µg/ml BHV for 24 h. 
Dox, 25 µM doxorubicin as positive control. (C): NUGC-3 cell viability study after 
treatment with different concentration of LAAO. LAAO+z-VAD-fmk indicates cells 
were pre-treated with 50 µM z-VAD-fmk for 1 h prior to the administration of 
LAAO. Data are presented as means + SEM. N=3. 
 









3.5.7  Translocation of apoptosis inducing factor induced by LAAO  
Some studies have revealed that caspase independent cell apoptosis 
could be induced by other factors such as apoptosis inducing factor (AIF), 
Endonuclease G (Endo G) and apoptotic protease activating factor-1 (Apaf-1) 
(Tait et al., 2008). The translocation of AIF from mitochondria to nucleus has 
been reported to play an important role in caspase independent apoptosis. 
Therefore, in this study, the role of AIF in LAAO induced caspase independent 
apoptosis of NUGC-3 cells was investigated by immunofluorescence.  Shown 
in Fig 3.42, in untreated NUGC-3 cells, there was no overlap between AIF-Cy5 
labelling and DAPI labelling, which indicated that AIF localized in the 
cytoplasm not in nucleus. In contrast, after treatment with LAAO, the purple 
merged colour was observed, suggesting the translocation of AIF from 
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Control 
LAAO 
Fig 3.42  Immunofluorescence staining of NUGC-3 cells after LAAO treatment. 
Cells were treated with 1.0 µg/ml LAAO for 12 h. Photos were taken at 200 X 
manification. AIF antibody dilution was 1:200 and Cy5-conjugated anti-rabbit 
IgG dilution was 1:500. Arrows indicate the AIF translocation of AIF from 







3.5.8  Loss of mitochondrial membrane potential  of NUGC-3 cells after 
LAAO treatment  
Since the translocation of AIF was observed, it was hypothesized that 
the mitochondria function may also be impaired by LAAO. Thus, the 
mitochondrial membrane potential (MMP) was measured by JC-1 staining. 
Shown in Fig 3.43, there was an increase in the JC-1 green fluorescence signal 
after LAAO treatment, which indicated an increasing percentage of NUGC-3 
cells that lost MMP and became depolarized.  After 9 h of LAAO treatment, 













Fig 3.43  Flow cytometry analysis of NUGC-3 cells with JC-1 staining  
Cells were treated with 1.0 µg/ml LAAO for 0 h, 3 h, 6 h and 9 h respectively. cccp, 
carbonyl cyanide m-chlorophenylhydrazone was used as positive control. (A): 
Representative images of flow cytometry analysis of JC-1 fluorescence. P3 
indicates JC-1 red fluorescence and P4 indicates JC-1 green fluorescence. (B): Bar 
chart of the percentage of MMP depolarized cells (P4). Data are presented as 












3.5.9  Measurement of NUGC-3 oxidative stress induced by LAAO 
NUGC-3 intracellular oxidative stress was measured by flow cytometry 
after staining with DCF-DA, the indicator of reactive oxygen species (ROS). 
Results showed that there was a significant increase in intracellular oxidative 
level after 3 h of LAAO treatment. However, the DCF signal decreased to the 
baseline at 6 h time point. This could be because that after 6 h of LAAO 
treatment, NUGC-3 cells had lost the plasma membrane integrity and the DCF 
dye has leaked out. This result suggested that LAAO treatment increased the 









Fig 3.44  Flow cytometry analysis of NUGC-3 cells stained with DCF-DA 
Cells were treated with 0.5 µg/ml LAAO for 0 h, 1.5 h, 3 h and 6 h, 
respectively. tBHP, tert-butyl hydroperoxide, was used as positive control. 
(A): Representative images of flow cytometry analysis of DCF fluorescence 
(FL1-A, 480 nm). The increase shift of DCF peaks was indicated. (B): Bar chart 
of DCF fluorescence of sample with different treatment time. Data are 










Lipid peroxidation is another indicator of cellular oxidative stress. In 
this study, lipid peroxidation was evaluated by analyzing the 
malondialdehyde (MDA) modified protein adducts in western blot, which is a 
byproduct of lipid oxidation and ROS. NUGC-3 whole cell lysate western blot 
against MDA was shown in Fig 3.45-A. A significant increase of MDA protein 
adducts was observed after LAAO treatment, particularly the band around 70 
KDa.  The overall OD values for different duration after LAAO treatment 















Fig 3.45  Whole cell lysate western blot against MDA. Cells were treated 
with 0.5 µg/ml LAAO for 0 h, 3 h 6 h and 9 h, respectively. (A): Western blot 
of MDA protein adducts. MDA antibody dilution was 1: 5000.  (B): Bar chart 
of overall OD values of MDA modified protein adducts in each lane . Data 














3.5.10  Effects of LAAO on NUGC-3 cell migration and invasion 
The effects of LAAO on NUGC-3 cell migration and invasion were 
explored using Transwell assay. The cells were treated with 0.25 µg/ml LAAO 
for 24 h prior to migration and invasion assays, a concentration that would 
not affect NUGC-3 cell proliferation (refer to section 3.4.1).  The results 
showed that LAAO treatment resulted in a 36.6% decrease in the number of 
migrated cells (Fig 3.46-A, p=0.04) and a 36.9% decrease in the number of 


















Fig 3.46 NUGC-3 gastric cancer cell migration (A) and invasion (B) assays after 
treatment with LAAO. Left panel, representative images of migrated NUGC-3 
cells. Images were taken at 80 X magnification. Right panel, bar chart of 
migrated and invaded cell number, respectively. Numbers are the average of 













3.6 Investigation of mechanism in LAAO treated NUGC-3 gastric cancer cells 
3.6.1  Expression of genes in MAPK/ERK pathway after LAAO treatment 
Based on the observations in BHV work, the regulation of MAPK/ERK 
pathway was also assessed in NUGC-3 gastric cancer cells after treatment 
with LAAO. The expression of selected genes in MAPK/ERK pathway was 
analysed by real time PCR, with the results showing that most of the main 
regulatory genes in this pathway were inhibited by LAAO treatment, such as 












Fig 3.47  Expression of genes in MAPK/ERK pathway by reat-time PCR.  
NUGC-3 cells were treated with 1.0 µg/ml LAAO for 24 h. GAPDH was 
used for normalization. Date are presented as means + SEM. N=3. p 
values were calculated based on each gene expression of untreated cells 








3.6.2 Regulation of phosphorylated proteins in MAPK/ERK pathway by 
LAAO treatment  
Similarly, the phosphorylated protein expression of the main 
regulators in MAPK/ERK pathway was also validated by western blot analysis. 
The results showed that, after LAAO treatment, the expression of MEK 1/2, 
MSK-1 and p90RSK was significantly inhibited and ERK 1/2 showed a non-
















Fig 3.48  Regulation of MAPK/ERK pathway in NUGC-3 cells by LAAO 
analyzed by western blot. NUGC-3 cells were treated with 1.0 µg/ml LAAO 
for 24 h. β actin was used as loading control. Molecular mass: MEK 1/2 - 45 
kDa, ERK 1/2 - 42, 44 kDa, p90RSK - 90 kDa, MSK 1 - 90 kDa, β actin - 42 kDa. 
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3.6.3  Regulation of Bcl-2 family by LAAO treatment 
Bcl-2 family play a critical role in mitochondria function and 
programmed cell death. Since the loss of mitochondrial membrane potential 
was observed after LAAO treatment, the expression of Bcl-2 family members 
was examined by western blot. Results showed that the anti-apoptotic 
protein Bcl-2 and Bcl-xl were significantly down-regulated and the pro-
apoptotic protein Bax was up-regulated with borderline significance (p=0.07) 








Fig 3.49  Regulation of Bcl-2 family in NUGC-3 cells by LAAO analyzed by 
western blot. NUGC-3 cells were treated with 1.0 µg/ml LAAO for 24 h. β 
actin was used as loading control. Molecular mass: Bcl-2, 26 kDa; Bax, 20 
kDa; Bcl-xl, 30 kDa; β actin, 42 kDa. Date are presented as means + SEM. 









3.6.4  Validation of apoptosis related genes from microarray data in LAAO 
treated NUGC-3 gastric cancer cells 
To further validate the role of apoptosis related genes from microarray data, 
real time PCR was conducted in NUGC-3 cells after treatment with 1.0 µg/ml LAAO 
for 24 h. The results showed that seven of the eight apoptosis related genes were 
differentially regulated (p<0.05) and presented the same trend as BHV-F1 treatment, 


















Fig 3.50  Validation of apoptosis related genes in LAAO treated NUGC-3 
cells by real-time PCR. NUGC3 cells were treated with 1.0 µg/ml LAAO for 









3.6.5  Proteomic regulation of NUGC-3 cells with LAAO treatment by SILAC 
assay 
To further understand the proteomic changes induced by LAAO 
treatment, the SILAC (Stable Isotopic Labeling using Amino acids in Cell 
culture) was performed in NUGC-3 cell lysate after treatment with 1.0 µg/ml 
for 8 h. Experiment was done in duplicate with labeling the LAAO treated 
cells with heavy and light isotopes, respectively. For results interpretation, up 
or down regulation with fold change larger than 1.5 was considered as 
significant. It was found that 9 proteins were up regulated and 108 proteins 
were down regulated by LAAO treatment.  
Table 3.3 List of differentially expressed proteins in NUGC-3 cells after LAAO 
treatment by SILAC assay. 
 
Protein name Gene name Fold change 
Putative heat shock protein HSP 90-beta 4 HSP90AB4P 2.1385 
Nuclear ubiquitous casein and cyclin-dependent 
kinase substrate 1 
NUCKS1 1.6213 
Histone H3.2 HIST2H3A 1.5779 





Histone H4 HIST1H4A 1.5327 
Retinoic acid-induced protein 3 GPRC5A 1.5313 
Putative ribosomal RNA methyltransferase NOP2 NOP2 1.5301 
Histone H3.3 H3F3A 1.5205 
Eukaryotic translation initiation factor 4E-binding 
protein 1 
EIF4EBP1 1.5139 
Cystatin-M CST6 0.65738 
BRCA1-associated ATM activator 1 BRAT1 0.65571 
Kinesin-like protein KIF22 KIF22 0.65531 
Replication factor C subunit 5 RFC5 0.65368 






F-actin-capping protein subunit alpha-1 CAPZA1 0.63878 
Pyrroline-5-carboxylate reductase 2 PYCR2 0.63655 
DNA polymerase delta catalytic subunit POLD1 0.63414 
Hepatocyte growth factor receptor MET 0.63411 
G patch domain-containing protein 8 GPATCH8 0.62832 
Enoyl-CoA hydratase, mitochondrial ECHS1 0.62552 
Glutamine-rich protein 1 QRICH1 0.62029 
Histone-lysine N-methyltransferase MLL;MLL 
cleavage product N320; 
MLL 0.61948 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
SDHA 0.6122 
28S ribosomal protein S35, mitochondrial MRPS35 0.60941 
Glutaredoxin-related protein 5, mitochondrial GLRX5 0.60612 
Isoleucine--tRNA ligase, mitochondrial IARS2 0.60568 
Neurolysin, mitochondrial NLN 0.60347 
Protein LAP2 ERBB2IP 0.60264 
3-ketoacyl-CoA thiolase, mitochondrial ACAA2 0.60133 
Pyruvate dehydrogenase E1 component subunit 
beta, mitochondrial 
PDHB 0.59244 
Methionine aminopeptidase 1; METAP1 0.58701 
Proteasome maturation protein POMP 0.58508 
Succinyl-CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial 
SUCLG1 0.58052 
Enoyl-CoA delta isomerase 1, mitochondrial ECI1;DCI 0.57272 
Heterogeneous nuclear ribonucleoprotein M HNRNPM 0.5697 
Glutathione peroxidase 1 GPX1 0.56895 
Melanoma-associated antigen 1 MAGEA1 0.56505 
Aspartate--tRNA ligase, mitochondrial DARS2 0.55745 
Serine/threonine-protein kinase PRP4 homolog PRPF4B 0.55638 
Pleckstrin-2 PLEK2 0.55386 
Presequence protease, mitochondrial PITRM1 0.55104 
Myosin IC MYO1C 0.54947 
Cytosol aminopeptidase LAP3 0.54576 
Protein transport protein Sec16A SEC16A 0.54294 
Dihydrofolate reductase DHFR 0.53233 
Cellular tumor antigen p53 TP53 0.53046 
Centromere protein F CENPF 0.53045 







component of pyruvate dehydrogenase complex 
DLAT 0.52825 
Ras GTPase-activating-like protein IQGAP3 IQGAP3 0.52385 
Acetyl-CoA acetyltransferase, mitochondrial ACAT1 0.52288 
Replication protein A 70 kDa DNA-binding 
subunit 
RPA1 0.51943 
Deoxyhypusine hydroxylase DOHH 0.5159 
Keratin, type II cuticular Hb1;Keratin, type II 








28S ribosomal protein S7, mitochondrial MRPS7 0.5083 
Myosin-9 MYH9 0.50814 
Zinc finger protein 36, C3H1 type-like 1 ZFP36L1 0.50441 
PCNA-associated factor KIAA0101;PAF 0.49908 
Desmoplakin DSP 0.49789 
Fibronectin;Anastellin;Ugl-Y1;Ugl-Y2;Ugl-Y3 FN1 0.49709 
Baculoviral IAP repeat-containing protein 5 BIRC5 0.49495 
Aurora kinase B AURKB 0.49336 
Lon protease homolog, mitochondrial; LONP1 0.48667 
Myosin-14 MYH14 0.48518 
Nucleobindin-2 NUCB2 0.48378 
Replication factor C subunit 1 RFC1 0.48251 
28S ribosomal protein S29, mitochondrial DAP3 0.48 
Polymerase delta-interacting protein 2 POLDIP2 0.47749 
Glutamine synthetase GLUL 0.47712 
UPF0160 protein MYG1, mitochondrial C12orf10 0.47384 
ESF1 homolog ESF1 0.46832 
Dimethyladenosine transferase 2, mitochondrial TFB2M 0.45689 
Succinyl-CoA ligase [ADP-forming] subunit beta, 
mitochondrial 
SUCLA2 0.44914 
Adenylate kinase isoenzyme 4, mitochondrial AK4 0.4412 
Pericentriolar material 1 protein PCM1 0.43745 
HD domain-containing protein 2 HDDC2 0.43556 
Receptor-type tyrosine-protein phosphatase F PTPRF 0.42992 
Protein FAM83H FAM83H 0.42756 






28S ribosomal protein S23, mitochondrial MRPS23 0.42442 
28S ribosomal protein S9, mitochondrial MRPS9 0.42306 
Cyclin-dependent kinases regulatory subunit 2 CKS2 0.4178 
Mitochondrial-processing peptidase subunit 
alpha 
PMPCA 0.41628 
Iron-sulfur cluster assembly enzyme ISCU ISCU 0.40652 
Melanoma-associated antigen 6;Melanoma-




28S ribosomal protein S2, mitochondrial MRPS2 0.39839 
Serine/arginine repetitive matrix protein 2 SRRM2 0.38479 
Isocitrate dehydrogenase [NAD] subunit alpha IDH3A 0.38292 
Isopentenyl-diphosphate Delta-isomerase 1 IDI1 0.37563 
Iron-sulfur cluster assembly 2 homolog, 
mitochondrial 
ISCA2 0.36781 
Protein SON SON 0.34983 
Tropomodulin-3 TMOD3 0.34788 
Antigen KI-67 MKI67 0.34436 
Protein TBRG4 TBRG4 0.33751 
Delta-1-pyrroline-5-carboxylate 
synthase;Gamma-glutamyl phosphate reductase 
ALDH18A1 0.33638 
Trifunctional enzyme subunit beta, 
mitochondrial;3-ketoacyl-CoA thiolase 
HADHB 0.33277 
Ubiquitin-like protein 5 UBL5 0.33193 
Isocitrate dehydrogenase [NAD] subunit beta IDH3B 0.33082 
Elongation factor Tu, mitochondrial TUFM 0.32626 
Putative ATP-dependent RNA helicase DHX30 DHX30 0.31263 
SRA stem-loop-interacting RNA-binding protein SLIRP 0.30718 
dCTP pyrophosphatase 1 DCTPP1 0.29616 
Ribonucleoside-diphosphate reductase subunit 
M2 
RRM2 0.29498 
Long chain 3-hydroxyacyl-CoA dehydrogenase HADHA 0.28884 
Glutaminase kidney isoform, mitochondrial GLS 0.27842 
Protein ETHE1, mitochondrial ETHE1 0.26047 
Monofunctional C1-tetrahydrofolate synthase MTHFD1L 0.25422 
ATP-dependent zinc metalloprotease YME1L1 YME1L1 0.24702 
Mitochondrial-processing peptidase subunit beta PMPCB 0.23348 
G antigen family D member 2 XAGE1A 0.22967 











AFG3-like protein 2 AFG3L2 0.17198 
FAST kinase domain-containing protein 5 FASTKD5 0.13476 
Elongation factor G, mitochondrial GFM1 0.13452 
 
These proteins were also functionally characterized using DAVID 
functional annotation clustering analysis, which were classified into different 
groups involved in several interests of cellular processes, such as regulation 
of cell apoptosis, cell cycle, chromosome organization, cytoskeleton 
organization, mitochondrial membrane integrity and oxidative reduction 
(Table 3.4). 





cell cycle CKS2, MKI67, AURKB, BIRC5, CENPF, ERBB2IP, KIF22, MLL, 
MYH9, POLD1, RPA1, TBRG4, TP53 












ADI 1, ALDH18A1, DOHH, DHFR, GPX1, HADHA, IDH3A, IDH3B, 
PYCR2, PDHB, RRM2, SDHA 
Mitochondrial 
membrane 
AFG3L2, ACAT1, ALDH18A1, DC1, HADHA, HDAHB, ACAA2, 









3.6.6  The validation of proteins involved in MAPK/ERK pathway from SILAC 
findings 
By literature research, it was found that protein EIF4EBP1 (eukaryotic 
translation initiation factor 4E-binding protein 1, fold change=1.51 after LAAO 
treatment), HNPNPM (heterogeneous nuclear ribonucleoprotein M, fold 
change=0.52) and IQGAP3 (IQ motifcontaining GTPase activating protein 3, 
fold change=0.57) are involved in MAPK/ERK signaling pathway. Consistently, 
EIF and HNRNP family were also observed to be down-regulated by BHV 
treatment. Briefly, IQGAP3 is the up-stream activator of ERK pathway and EIF 
and HNRNP protein family are down-stream translational targets of ERK 
pathway. EIF4EBP1 can bind with EIF4E protein and inhibit its function. Their 
background and involvement in ERK pathway will be further discussed in 
section 4.4.  
To double confirm the gene and protein expression of these 3 targets 
after LAAO treatment, real time PCR and western blot were conducted. 
Results indicated that EIF4EBP1 was up-regulated by LAAO in both gene and 
protein level. Both HNRNPM and IQGAP3 were down-regulated by LAAO in 
gene and protein level (Fig 3.51). Taken together, these evidence further 













Fig 3.51  Validation of proteins involved in MAPK/ERK pathway by real-
time PCR (A) and western blot (B). NUGC3 cells were treated with 1.0 
µg/ml LAAO for 24 h. GAPDH  and β actin were used for normalization. 





















4.     DISCUSSION 
4.1  Anticancer potential of Hottentotta hottentotta scorpion venom and L-
amino acid oxidase 
Animal venoms and toxins from snakes, scorpions, spiders, bees, 
wasps and ants, have shown wide applications in biopharmacological fields. 
They have provided rich sources for drug discovery to target various human 
diseases such as cancer, HIV, hypertension, diabetes, chronic pain, congestive 
heart failure, stroke, microbial infection, autoimmune disease, and so on 
(King, 2011). In addition, the peptides isolated from animal venoms, which 
act on the ion channels, can be applied as channel modulators in the 
neurophysiology research (Lewis et al., 2003).  
The anticancer potential is a new discovery platform for animal 
venoms and toxins. Over the last three decades, the anticancer activities of a 
number of crude venoms and the active components from snakes, scorpions, 
spiders and bees have been extensively investigated in laboratories. Snake 
venoms and isolated proteins are the earliest and the most studied in 
anticancer perspective. Several components in the snake venoms have been 
described to inhibit cancer proliferation, induce cell apoptosis or block 
angiogenesis, cell adhesion, migration and invasion, such as phospholipase A2, 
L-amino acid oxidase, metalloprotease, disintegrin, lectins and peptides 
(Cardiotoxin III, Cytotoxin P4) (Calderon et al., 2014). Other proteins and 






for drug screening, including Chlorotoxin and Bengalin from scorpion venoms, 
Mellitin from bee venom, Mastoparan from wasp venom, Gomesin and 
Psalmotoxin 1 from spider venoms, etc. (Heinen et al., 2011).  
All these findings have shown that animal venoms and toxins possess 
anticancer potential by the inhibition of cancer cell proliferation, arrest of cell 
cycle, induction of cell death, reduction of cancer angiogenesis, cell adhesion, 
migration or invasion. Such functional studies have been done in a set of 
malignancies in cell culture or in mouse xenograft model, including leukemia, 
glioma, melanoma, lymphoma, breast, lung, gastric, prostate cancers and 
others. The outcome from clinical trial regarding synthetic Chlorotoxin (TM-
601) in glioma diagnosis and treatment is also encouraging (Mamelak et al., 
2006). All together, it is very promising that animal venoms and toxins could 
be developed into anticancer agents and deserve further studies. 
4.1.1 The anticancer potential of scorpion venoms, in particular BHV  
Scorpion venoms and toxins are gaining increasing attention in the 
investigations of anticancer agents, given that they are rich in proteins and 
peptides, especially the neurotoxins that act on ion channels in the cell 
membrane. In this study, four scorpion venoms were screened in the 
beginning for their anti-proliferative effects on cancer cells (mainly on gastric 
cancer cells). Results showed that BmK had limitative inhibition effect on 
NUGC-3 cell proliferation at a high concentration (5 mg/ml), which was 






cell apoptosis. Whereas, other 3 scorpion venoms displayed much stronger 
inhibition effects on NUGC-3 cell proliferation with different IC50 values. 
Considering that BHV was shown to be the most effective against NUGC-3 
with very low IC50 (8.1 µg/ml), BHV was chosen to be further investigated for 
its anticancer potential in gastric cancer in vitro and in vivo.  
The Hottentotta hottentotta scorpion was first reported by Fabricius 
in 1787, and has been mainly found in Africa and Middle East (supp. Fig 1). 
The genus Hottentotta was originally recognized as Buthotus, a subgenus of 
Buthus, and was elevated to an independent genus in 1935 (Werner, 1935). 
That is why the Hottentotta hottentotta venom was abbreviated as BHV 
(Buthotus hottentotta venom) in this study. Only few studies have been 
performed on this scorpion venom, leaving much unknown with regard to its 
biological properties in medical usages. It was reported that BHV can activate 
ryanodine receptor Ca2+ release channels of sarcoplasmic reticulum (Valdivia 
et al., 1991). Another study reported that BHV can stimulate adrenergic 
nerves with consequent release of transmitter (Gwee et al., 1995). The 
present study could be one of the first to evaluate its anticancer potential in 
gastric cancer.  
In vitro: 
 The functional studies to evaluate the anticancer potential of BHV in 
gastric cancer cell lines in vitro included alamarBlue cell viability/proliferation 






morphological changes under fluorescence microscope and TEM, apoptosis 
identification by Annexin-V & Propidium iodide staining, cell migration and 
cell invasion assays. The results showed that BHV induced the apoptotic 
phenotypes of NUGC-3 cells, which were supported by decrease in cell 
viability/proliferation, sub-G1 cell cycle arrest, morphological changes like 
chromatin condensation, membrane blebbing and cell shrinkage, as well as 
the significant increase in Annexin-V labeling. It needs to mention that the 
IC50 of BHV from test in 96-well assay was less than 10 µg/ml, while the 
concentration used in apoptosis studies in 6-well assay was 15 -30 µg/ml. The 
reason could be that the 50 percent reduction in cell viability may not 
convert to 50 percent cell apoptosis. Obvious cell apoptosis was observed at 
higher concentration of BHV administration based on morphological and 
biochemical judgement. That was why we applied higher concentration of 
BHV in TEM and western blot experiments.  
The apoptosis induction by scorpion venoms and toxins has been 
widely reported. Wang and Ji observed that BmK crude induced apoptosis of 
U-251-MG glioma cells at 10 mg/ml (Wang et al., 2005). Another study 
showed that BmK arrested cell cycle and induced apoptosis of human Jurkat 
and Raji lymphoma cells (Gao et al., 2009). Polypeptide extract from scorpion 
venom (PESV), a mixture of 50-60 aa polypeptides purified from BmK venom, 
was reported to induce apoptosis of DU 145 human prostate cancer cells, 
which was confirmed by TUNEL assay (Zhang et al., 2009b). Another group of 






and Androctonus crassicauda scorpion venoms on SH-SY5Y human 
neuroblastoma cells and MCF-7 breast cancer cells, together with the up-
regulation of caspase-3 activity and reactive nitrogen intermediates (Zargan 
et al., 2011b, a; Zargan et al., 2011c). Other evidences could be the cell 
apoptosis induced by Bengalin and Neopladine 1 and 2, as described in detail 
in section 1.2.4. In this study, the NUGC-3 cell apoptosis induced by BHV was 
not only identified by conventional approaches like cell cycle and Annexin V 
staining, but also confirmed based on morphological changes. The application 
of TEM and SEM techniques clearly revealed the structural changes of 
chromatin and cytoplasm, as well as the membrane blebbing. Membrane 
blebbing is one early morphological characteristic of apoptosis and is 
associated with the cytoskeleton disruption which leads to the contraction of 
the actin-myosin complex and the surface protrusion (Mills, 2001; Song et al., 
2002).  
 It was found that different scorpion venoms or toxins induced cell 
apoptosis with different mechanisms or various intracellular signaling 
transduction pathways. For example, Bengalin activated mitochondria-
caspase apoptotic cascades and inhibited HSP 70 and 90.  Neopladine 1 and 2 
induced the expression of Fas ligand and triggered cell apoptosis, whereas, 
BmK killed Jurkat cells by the inactivation of PI3K/Akt pathway via increasing 
PTEN expression. Moreover, the cell cycle arrest induced by scorpion venoms 
treatment was found to be distributed in diverse phases of the cell cycle, 






crassicauda). These different mechanisms could be due to the difference in 
venom components among different scorpions and the response from cancer 
cells would be varied.  
On the other hand, when the concentration of BHV was controlled as 
low as not affecting the cell viability/proliferation, BHV revealed another 
aspect of anticancer potential, the inhibition of NUGC-3 cell migration and 
invasion. The effects of scorpion venoms and toxins on cancer cell migration 
and invasion were seldom reported. SUMO-AGAP, a modified voltage gated 
sodium channel toxin from BmK venom by combining a small ubiquitin-
related modifier, was shown to inhibit the migration of SHG-44 glioma cells 
by wound healing assay (Zhao et al., 2011). CTX and BmKCT, the two 
anticancer peptides purified from scorpion venoms that can block the 
chloride ion channels, were reported to inhibit the migration and invasion of 
glioma cells by Transwell assays and the metastasis of glioma in rat model, 
respectively (Soroceanu et al., 1999; Fan et al., 2010). It could be inferred 
that scorpion toxins could reduce cancer metastasis maybe by the 
modulation of ion channels in the membrane of cancer cells and  
Targeting cancer metastasis is considered as an effective and 
promising strategy for cancer therapeutics, as neoplastic metastasis is a 
critical final step in cancer progression and indicates a poor prognosis and 
intervention efficacy. Recently, a growing body of studies have suggested 






channels and cancer migration and invasion (Prevarskaya et al., 2010). A 
variety of experiments have discussed the involvement of Ca2+, Na+, K+, Cl- 
and some transporters in the processes of cancer migration and invasion. The 
mechanisms are poorly understood and one hypothesis was proposed that 
these ion channels facilitate cancer migration/invasion by the regulation of 
cell volume and motility (Cuddapah et al., 2011). Specifically, ion channels 
control the osmotic movement of water by fluxing ions, which results in the 
extension at the leading edge of migrant cells as a moving force (Schwab et 
al., 2007). Nav1.5 was reported to be up-regulated in metastatic breast 
cancer cells and tissues and there was a close link between its activity and the 
metastatic behaviours of cancer cells, such as endocytosis, directional 
motility and invasion. Moreover, the strong correlation was observed 
between Nav1.5 expression and lymph node metastasis in clinical samples 
(Fraser et al., 2005; Onkal et al., 2009).  
As mentioned in section 1.2.3.1-1.2.3.4, scorpion venoms contain 
abundant ion channel regulators and have the potential for the development 
of anti-metastasis drugs. As for BHV, a pool of small peptides were identified 
in gel filtration and SDS-PAGE (Fig 3.23 and Fig 3.24), which may be related to 
the ion channel regulation. Furthermore, using patch clamp 
electrophysiological approach, we investigated the existence of voltage gated 
potassium current in NUGC-3 cells (Supp. Fig 2) and various K+ and Na+ 
channels in NUGC-3 cells were also found to be differentially expressed 






that the channel toxins in BHV may be responsible for the inhibitory effects 
on NUGC-3 cell migration and invasion.  
in vivo: 
It is commonly recognized that the in vivo model plays a crucial role in 
translational cancer researches and the findings from animal model are more 
applicable to clinical applications. In this study, the NUGC-3 xenograft model 
was established on BALB/c-nu/nu mice to evaluate the antitumoral effects of 
BHV and examine its toxicity to mouse as well. First, 5 BHV venom doses 
were tested on mice with tumor, which were 100 µg, 50 µg, 25 µg, 12.5 µg 
and 6.25 µg per mouse, respectively, in a descending order. It was found that 
100 µg and 50 µg per mouse BHV injection would kill the mice and doses 
lower than 25 µg per mouse were safe. By monitoring the mice health 
conditions like body weight ( shown in supp. Table 1), it was confirmed that 
the doses of 12.5 µg and 6.25 µg per mouse for injection would not produce 
systemic toxicity to mice and could be applied to evaluate the antitumoral 
effects of BHV in vivo.  
The results showed that 12.5 µg/mouse BHV significantly inhibited the 
tumor growth and histologically disrupted the tumor structure with the 
formation of more cavities with tissue debris. What is more, the apoptosis 
was detected mainly in the disruptive tissue areas. Such observations 






However, there is certain limitation in the experiment setting. IACUC 
has a regulation that the tumor on mice cannot exceed 1.5 cm. When it was 
applicable to give intratumoral injection, the tumor diameter had already 
reached 0.7 - 1.0 cm and NUGC-3 was an aggressive and fast growing tumor. 
These two factors limited the observation period to only one week after 
venom injection. An alternative way to overcome this is to inject the venom 
intraperitoneally or intravenously when the tumor size is still small.  
4.1.2 The anticancer potential of LAAO from snake venom 
BHV has been partially purified and characterized by HPLC, SDS-PAGE 
and mass spectrum, with the identification of LAAO as one active component 
in BHV in small quantity. Unfortunately, all the available crude venom had 
been used up and the purification for single protein could not be completed. 
However, from the literature review, LAAOs are found to share more than 80% 
sequence similarity (Franca et al., 2007).  Therefore, in this study, a 
commercial source of LAAO purified from Crotalus adamanteus snake venom 
was used to be screened and evaluated for its anticancer effects in gastric 
cancer.  
To date, several snake venom LAAOs have been reported to exert 
anticancer effects, such as Ophiophagus hannah (King Cobra), Agkistrodon 
acutus, Bothrops jararaca, Bothrops atrox, Naja naja atra,  as well as a LAAO 
homolog from parasite-infected fish. ACTX-6, the LAAO isolated from 






cancer cells via the Fas pathway, probably triggered by the ROS initiated JNK 
and c-Jun phosphorylation (Zhang et al., 2007). Another study showed that 
LAAO from King Cobra exerted cytotoxicity to murine melanoma, 
fibrosarcoma, stomach, breast, colorectal and lung cancer cell lines (Ahn et 
al., 1997). More inspiringly, a new report revealed its relative low toxicity to 
non-tumourigenic cells (Lee et al., 2013). For in vivo study of the anticancer 
effect of LAAO, the enzyme isolated from Bothrops jararaca snake venom 
was shown to significantly inhibit the growth Ehrlich ascites tumor and 
prolong the survival time of mouse with tumor (de Vieira Santos et al., 2008). 
A recent publication demonstrated the antitumoral effects of LAAO from King 
cobra in PC-3 prostate tumor xenograft, as LAAO induced apoptosis in PC-3 
cells and PC-3 tumors, suppression of PC-3 tumor growth and no obvious 
damage to vital organs (Lee et al., 2014). These evidence suggest that LAAO 
could be a promising anticancer agent, which deserves further investigation 
for its application in cancer therapeutics.  
In this study, the anticancer potential of LAAO from Crotalus 
adamanteus snake venom was fully investigated. First, the anti-proliferative 
activity of LAAO to gastric and breast cancer cells was screened. It would 
appear that LAAO had certain selectivity regarding the cytotoxicity to various 
cancer cell lines. For instance, more reduction of cell viability was observed 
on NUGC-3 cells compared with MKN-74 and MKN-7 cells. Pathologically, 
MKN-74 and MKN-7 are well-differentiated while NUGC-3 is poorly-






cytotoxicity to MCF12A non-tumorigenic breast cells in comparison with 
MCF-7 (less invasive), T-47D (less invasive) and MDA-MB-231 (invasive) 
breast cancer cells. However, whether and why LAAO selectively has stronger 
cytotoxicity against poorly-differentiated cancer cells in gastric cancer are still 
not clear and need to be further determined.  
The toxicity of LAAO to mouse tissues was verified by evaluating liver 
damage with the measurement of alanine transaminase (ALT) activity in 
mouse serum one week after LAAO injection. The result demonstrated that 
there was no change in the ALT activity after LAAO injection, suggesting that 
LAAO did not cause any damage to mouse liver (supp Fig 3), and appear 
relatively safe.  
For the cell cycle study in NUGC-3 cells, it was found that the cell cycle 
was arrested at G2/M phase (27.3% vs 38.5%) after treatment with LAAO and 
there was no increase in sub-G1 phase, indicating that there was no small 
DNA fragmentation induced by LAAO treatment. This appears to be different 
from what happened in NUGC-3 cells after treatment with BHV, which 
induced a significant increase in sub-G1 phase. However, the involvement of 
G2/M arrest in apoptosis is in agreement with several other studies. Such 
examples can be the G2/M cell cycle arrest and apoptosis induced by 
Furanodiene in HepG2 hepatocellular carcinoma cells and Doxorubicin 
induced G2/M phase arrest in synchronized p388 leukemia cells (Ling et al., 






arrests induced by BHV and LAAO could be attributed to the different 
components in apoptosis inducers, as BHV is a mixture and may contain other 
factors that enhance small DNA fragmentation.  
 
4.2  Caspase-independent apoptosis, an alternative way to combat cancer 
4.2.1  General background 
During the past decade, there are accumulative data, which have 
confirmed caspase-independent apoptosis (CIA) as an alternative modality of 
cell death, which differs from classic apoptosis, necrosis and autophagy. CIA 
has been widely reported in cell culture and animal studies. Quite a few in 
vitro studies have indicated the occurrence of CIA, by inducing apoptosis in 
the presence of caspase inhibitors (e.g. z-VAD-fmk) or in cells genetically 
expressing caspase inactivation genes like XIAP or p35. For example, as early 
in 1996, Xiang et al. reported that the apoptosis induced by the expression of 
Bax in Jurkat cells was not prevented by caspase inhibitor z-VAD-fmk (Xiang 
et al., 1996). Another example is the cell death induced by nitric oxide (NO) in 
PC12 cells was found not to be inhibited by expression of p35, a baculvirus-
encoded caspase inhibitor, indicating the CIA occurred (Okuno et al., 1998). 
Additionally, a number of natural and synthetic compounds were shown to 
induce CIA, such as Selenocysteine in MCF-7 breast cancer cells, Ciglitazone in 
renal epithelial cells, and Artesunate in human myelodysplastic syndrome 






in vitro evidence, studies on mouse models also revealed the existence of CIA 
pathways. CHM-1, a synthetic quinolone, inhibited tumor growth and 
prolonged the survival of mice inoculated with HA22T hepatocellular 
carcinoma cells, via a CIA pathway mediated by AIF translocation (Wang et al., 
2008).  
The significance of caspase-independent apoptosis has been 
increasingly recognized in cancer research as it may unravel novel targets for 
cancer therapy. Cancer cells have developed diverse strategies to escape 
apoptosis by the inactivation of caspase-dependent pathway, which is critical 
for tumor development and adjuvant chemoresistance. For example, the 
gene mutation of tumor suppressor protein p53 is present in about half of 
cancer patients (Oren, 1999). In this context, CIA regulates an alternative 
pathway to kill cancer cells and provides novel targets for the design of more 
effective chemotherapeutic drugs (Mathiasen et al., 2002; Constantinou et al., 
2009). On the other hand, it was described in several experiments that 
induction of apoptosis by CIA exhibited selective antitumoral activity, with 
negligible or minor toxicity to noncancerous cells and tissues, indicating the 
potential clinical implications of CIA in the elimination of the side effects 
caused by chemotherapy drugs (Wang et al., 2008; Li-Weber, 2009).   
4.2.2 Mechanistic pathway in LAAO induced CIA 
In this work, the CIA induced in NUGC-3 cells by BHV and LAAO 






blot, absence of increased caspase-3 activity using DEVD-pNA substrate and 
the decrease in cell viability in the presence of caspase inhibitor z-VAD-fmk 
(section 3.2.6.2 and section 3.5.6).  
Like classical apoptosis, CIA is largely dependent on activation of other 
proteases and mitochondrial membrane permeabilization (MMp). Several 
proteases have been implicated in CIA, such as cathepsin B and D, calpains 
and serine proteases (Mathiasen et al., 2002). Cathepsins are lysosomal 
proteases, which participate in CIA by directly cleaving Bid and AIF or 
translocating Bax and Bid from cytosol to mitochondria (Bidere et al., 2003; 
Cirman et al., 2004). Calpains reside in cytosol and are activated in response 
to the elevation in intracellular calcium caused by ER stress (Muruganandan 
et al., 2006). Similar to cathepsins, calpains can cause the cleavage of AIF in 
the absence of caspase activation. The serine proteases that are responsible 
for CIA include granzymes A and B, Omi/Htra2 and apoptotic protease 24 
(AP24) (Constantinou et al., 2009).  
Numerous studies have indicated that mitochondria play a pivotal role 
in the control of CIA, given that the AIF translocation from mitochondria to 
nucleus occurs in most CIA processes. Furthermore, the above mentioned 
proteases can serve as the upstream triggers of MMp. AIF is a 62 kDa 
flavoprotein localized in the inner mitochondrial membrane, which has dual 
functions: mitochondrial oxydoreductase and nuclear proapoptotic factor. 






(truncated AIF, tAIF) and released into cytosol along with MMp. Subsequently, 
tAIF translocates into nucleus where it cooperates with Endonuclease G and 
induces DNA fragmentation and CIA (Delavallee et al., 2011).  
Several drugs that target AIF mediated CIA have been developed. 
BZL101 (Bezielle®), an extract from plant Scutellaria barbatae, is known to 
induce CIA by AIF translocation and ROS generation in breast and prostate 
cancer cells, and the results from a phase I clinical trial showed that BZL101 
was safe and had a favorable toxicity profile with encouraging clinical activity 
in patients (Rugo et al., 2007). Another study showed that Bobel-24 and 
derivatives triggered CIA in human pancreatic cancer cell lines via lysosomal 
and mitochondrial death pathway by activation of cathepsin B. Particularly, 
Bobel-24 was also active against NP9 apoptosis-resistant pancreatic cell line 
(Parreno et al., 2008).  
In this study, the exploration of mechanistic pathway was performed 
using NUGC-3 cells with LAAO treatment, as LAAO is one active component 
from BHV and the findings from LAAO should also be applied to BHV. The AIF 
translocation was first identified by immunofluorescence assay.  After 
treatment with LAAO for 12 h, AIF translocated from cytoplasm into nucleus 
in most of NUGC-3 cells and a merged blue and red color was clearly 
observed. However, in this assay, only the nucleus was labelled with DAPI 
and the mitochondria were not labelled, the original location of AIF in 






Since the mitochondrial membrane permeabilization is necessary for 
AIF release, the mitochondrial membrane potential (MMP) was examined by 
JC-1 staining, which acts as a sensitive indicator of low and high MMP. The 
results showed that, just after 6 h of LAAO treatment, more than 70% NUGC-
3 cells had lost MMP and were permeabilized in mitochondrial membrane. 
This finding is in line with the notion that AIF translocation is dependent on 
time. The Bcl-2 family members are important for maintaining the integrity of 
outer mitochondrial membrane. The pro-apoptotic proteins Bax and Bid are 
responsible for the pore formation in mitochondrial membrane and the 
initiation of CIA, whereas this may be counteracted by anti-apoptotic protein 
Bcl-2 (Cabon et al., 2012). Consistently, in this study LAAO was observed to 
up-regulate Bax expression and down-regulate the expression of Bcl-2 and 
Bcl-xl.  
Many studies have shown that oxidative stress or reactive oxygen or 
nitrogen species (ROS/RNS) can trigger programmed cell death and several 
antitumor drugs are known to induce apoptosis by elevating intracellular ROS 
and affecting mitochondria in cancer cells (Ryter et al., 2007; Guo et al., 2013; 
Poornima et al., 2013; Yang et al., 2013). More importantly, new emerging 
evidence indicates the implication of oxidative stress in the initiation of CIA. It 
is documented that the intracellular ROS eruption induces AIF translocation 
and triggers CIA in the presence of z-VAD-fmk, accompanied by loss of MMP 
and inhibition of Bcl-2 (Son et al., 2009; Franke et al., 2010; Yu et al., 2011). It 






mitochondria membrane dysfunction and permeabilization.  In turn, such a 
dysfunction increases the ROS level, which leads to further damage to 
mitochondria. Therefore, a positive feedback loop for ROS-induced 
mitochondrial membrane dysfunction is formed (Ma et al., 2014).   
In this present study, oxidative stress induced by LAAO treatment was 
verified by detecting MDA modified protein adducts in western blot and the 
increase of total intracellular ROS by DCF-DA staining. It was found that 3 h of 
LAAO treatment or longer can significantly increase the intracellular ROS in 
NUGC-3 cells, evidenced by increased expression of MDA protein adducts and 
the right shift of formed DCF fluorescence. However, at 6 h of treatment 
group, the DCF signal went back to baseline level, which was believed to be 
because the plasma membrane of NUGC-3 had become permeable at this 
time and the DCF dye leaked out (Maher et al., 2005).  
It is not difficult to understand how LAAO induces intracellular 
oxidative stress, as H2O2 is generated during the oxidation process of LAAO. 
To confirm the role of LAAO generated ROS in the apoptosis inducing activity 
of LAAO, a ROS scavenger catalase was applied to check if the apoptosis can 
be rescued. As shown in supp. Fig 5, reduction of NUGC-3 cell viability was 
neutralized by 40%. However, catalase cannot completely compensate the 
anti-proliferative effect of LAAO, indicating that the anticancer activity of 






reported that the direct interaction between LAAO and target cells may also 
play a role (Suhr et al., 1996).  
 
4.3  BHV and LAAO target MAPK/ERK pathway  
The mitogen-activated protein kinases (MAPKs) are evolutionarily 
conserved protein kinase family that transmit extracellular signals to 
intracellular effectors and regulate a variety of cellular processes, such as 
proliferation, differentiation, migration, survival  and apoptosis (Ravingerova 
et al., 2003). The diverse exogenous signals include cytokines, growth factors, 
neurotransmitters, cellular stress and others. The activation of MAPKs is a 
three-kinase sequential cascade consisting of MAPK kinase kinase (MKKK), 
MAPK kinase (MKK) and MAPK, which is achieved through the reversible 
phosphorylation of both threonine and serine residues of the TXY motif in the 
catalytic domain. MAPKs comprise at least five subfamilies, of which the best 
known are ERK (extracellular signal-regulated kinase), JNK (c-Jun NH2-
terminal kinase) and p38 (Widmann et al., 1999). It is generally described 
that ERK pathway links to cell proliferation and cell survival. Whereas, JNK 
and p38 pathways are associated with apoptosis, differentiation and 
inflammation (Pearson et al., 2001).  
 The MAPK/ERK pathway is among the most extensively studied MAPK 
signaling pathways.  This pathway starts from the GTP loading of Ras at 






kinases, namely Ras → Raf (MKKK) → MEK 1/2 (MKK) → ERK 1/2 (MAPK). 
Upon phosphorylated, ERK 1/2 activates a variety of downstream substrates 
that participate in various cell behaviors, such as cell growth, cell 
differentiation, cell apoptosis and cell motility (Lewis et al., 1998). This 
pathway can be negatively regulated by various proteins, such as dual-
specificity phosphatases (DUSPs), cytoplasmic Sprouty protein family, 
scaffolding/chaperonin proteins such as MEK partner 1 (MP-1), heat shock 
protein-90 (HSP90), as well as many tumor suppressor proteins (e.g. PTEN, 
PP2A, DUSP5, RKIP, etc.) (McCubrey et al., 2012). The dysregulation of ERK 
pathway has been implicated in several neurodegenerative diseases and 
various malignancies (Kim et al., 2010).   
A large number of evidence reveals the aberrant activation of ERK 
pathway and its role in tumorigenesis. The mutations in growth factor 
receptors and upstream kinases are widely reported in many neoplasms. For 
example, the overexpression or oncogenic mutation of epidermal growth 
factor receptor (EGFR) has been detected in cancers of lung, breast, colon, 
ovary, etc. (Arteaga, 2002). Ras mutations cover approximately 30% of 
human tumors and the frequency of K-RAS mutation is high in pancreatic 
cancer (~ 60%) (Prior et al., 2012). BRAF is frequently mutated in melanomas 
(66%) and papillary thyroid tumors (40%) (Davies et al., 2002; Puxeddu et al., 
2004). Previously, mutations of MEK and ERK genes were rarely reported 
while recent studies indicate the somatic mutation of MEK1 in non-small cell 






Abnormal activation driven by the mutation or up-regulation of certain 
components in ERK pathway has been  associated with the multiple steps of 
cancer progression, by regulations of cancer cell proliferation, cell cycle, cell 
apoptosis, cancer metastasis and angiogenesis, as well as drug resistance 
(Kohno et al., 2006; Steelman et al., 2010).  
In this current study, the inhibition of ERK pathway by BHV was 
discovered by screening the activity of ten important signaling pathways in 
cancer. This assay is based on the measurement of the expression of the 
transcription factor, a downstream target of each specific signaling pathway. 
The results indicate that MAPK/ERK pathway (Elk-1 as downstream 
transcription factor) was down-regulated by 34.8%, while no significant 
change was observed in the activity of MAPK/JNK pathway (AP-1 as 
transcription factor). To further confirm this notion, the gene expressions of 
members in ERK pathway were examined by RT-PCR. It was found that both 
BHV and LAAO significantly decreased the gene expressions of both upstream 
and downstream ERK members, including Raf-1, MEK-1, ERK-1, ERK-2, 
p90RSK. Furthermore, the phosphorylated protein expression of ERK 
members were assessed by western blot, given that only proteins in 
phosphorylated form work as active signal transducers. The results indicated 
the phosphorylation level of all members was down-regulated by 20%-40% in 
both BHV and LAAO treated groups. However, ERK 1/2 (with BHV and LAAO 
treatment) and p90RSK (with BHV treatment) showed a decrease with non-






of OD values between the triplicates. Collectively, these observations surely 
confirm that the MAPK/ERK pathway was inhibited by BHV and LAAO.  
There are two questions to be answered with regard to the inhibition 
of ERK signaling pathway in NUGC-3 by BHV and LAAO. The first one is how 
does ERK pathway participate in the regulation of various cellular processes 
observed in BHV and LAAO treated cells, such as inhibition of cell 
proliferation, cell migration and invasion and caspase-independent apoptosis? 
The second one is how does LAAO or BHV exert the inhibitory effect on ERK 
pathway?  
The first question can be addressed by analysing the downstream 
targets and networks of ERK pathway. After being activated as the final 
effectors, ERK 1/2 can phosphorylate dozens of substrates in different cell 
compartments (nucleus, cytoplasm, cytoskeleton). In the nucleus, ERK 1/2 
activate a set of transcription factors, such as ternary complex factors (TCFs, 
e.g. Elk-1, Sap-1), MSKs, ATF-1, c-Fos, c-Myc, Stat 1/3, estrogen receptor, 
etc.(Kohno et al., 2006). These transcription factors further regulate gene 
expression and promote cell growth and survival. Moreover, ERK 1/2 also 
phosphorylate cytoplasmic targets such as p90RSK, which regulates GSK3 and 
BAD. More importantly p90RSK will translocate into nucleus and 
phosphorylate SRF (serum response factor), CREB (Cyclic AMP Response 
Element-Binding protein) and other factors (Hauge et al., 2006). In 






and MSK-1, which could be responsible for the anti-proliferation effects of 
BHV and LAAO, as well as the cell cycle arrest.  
Apart from the role in cell proliferation and survival, ERK signaling 
pathway also mediates cell apoptosis and cell metastasis. The regulation of 
cell apoptosis by ERK pathway is mainly accomplished via interaction with 
Bcl-2 family in several ways (Balmanno et al., 2009). For example, p90RSK 
and MSK can inactivate pro-apoptotic protein BAD by phosphorylation at 
Ser112. The expressions anti-apoptotic proteins like Bcl-2 and Bcl-xl are also 
reported to be ERK pathway dependent, which is supported by the fact that 
MEK inhibitor PD98059 induced a decrease in Bcl-2 and Bcl-xl and promoted 
apoptosis in pancreatic cancer cells (Boucher et al., 2000). Additionally, ERK 
1/2 can target the proteasomal degradation of FOXO3A and thereby repress 
the FOXO3A-dependent expression of BIM (Yang et al., 2008). All these 
observations help considerably in understanding how LAAO induces 
inhibition of the ERK pathway, which participates in mitochondria-mediated 
caspase-independent apoptosis, associated with decreased expression of Bcl-
2 and Bcl-xl, accompanied by the down-regulation of ERK pathway.  
Several studies have also shown that the ERK pathway promotes 
cancer cell migration/invasion by modulating matrix metalloproteinase, 
myosine light-chain kinase (MLCK) as well as genes involved in epithelial 






1997; Welch et al., 2000; Chen et al., 2009a; Hong et al., 2011; Nagarajan et 
al., 2012). 
The relationship between LAAO and MAPK pathway has thus far 
remained elusive. However, some clues can be obtained by analyzing the 
responses of MAPK pathway towards intracellular ROS. It is commonly 
described that ROS can trigger the activation of JNK or p38-MAPK pathway, 
which can facilitate the ROS mediated cell apoptosis (Runchel et al., 2011). 
Nonetheless, several studies also indicate the role of ERK pathway in 
response to ROS induction. A non-aromatic B-ring flavonoid (DHEC), isolated 
from Macrothelypteris viridifrons, induced apoptosis in human colon HT-29 
tumor cells via ROS-mitochondrial dysfunction, activation of p38 and JNK and 
inhibition of phosphorylated ERK (Wei et al., 2011). Similar findings were 
observed in mycotoxin zearalenone induced apoptosis of RAW267.4 
macrophages (Yu et al., 2011). Krifka S et al. reviewed the adaptive 
mechanisms in cell responses to oxidative stress caused by dental resin 
monomers, finding that the downstream targets of ERK pathway were 
inhibited, including Elk-1, AFT-2, AFT-3 and c-Jun (Krifka et al., 2013). All 
these evidence suggest, at least partially, that ROS may result in the down-
regulation of ERK pathway. Therefore, it would seem that LAAO suppress the 
ERK pathway probably via the induction of intracellular ROS. Nevertheless, 








4.4  Application of cDNA microarray and SILAC to understand the biology of 
BHV and LAAO-treated NUGC-3 cancer cells 
During last two decades, with the advances in bioinformatics (i.e. 
genomics and proteomics), the systematic analysis of gene and protein 
expressions of cells or tissues in large scale become realised. Tens of 
thousands of genes or proteins can be analyzed in one set of experiment. 
Two such approaches applied in this study are cDNA microarray (gene chip) 
and SILAC (Stable Isotopic Labeling using Amino acids in Cell culture) 
techniques. Because of the advantage in time- and cost- efficiency, SILAC and 
gene chip are now widely used in cancer research to detect oncogenic and 
tumor suppressor genes/proteins, signaling transduction, biomarkers, 
treatment targets, and so on (Macgregor et al., 2002; Marimuthu et al., 2013).  
 
4.4.1  Altered genes in BHV  treated NUGC-3 gastric cancer cells 
In this study, the Affymetrix gene microarray was conducted in NUGC-
3 cells after treatment with partially purified BHV (BHV-F1). 69 genes were 
considered to be differentially regulated by BHV-F1 with the criteria fold 
change more than 2 and p value less than 0.05. These genes were grouped 
using DAVID, which helps researchers focus on the genes involved in 
interested cellular processes such as cell cycle and cell apoptosis. Moreover, 
these genes were further analyzed by Pathway Studio software to better 






and clearer regulation network was proposed. For example, the genes 
involved in cell cycle and cell apoptosis analyzed by Pathway Studio are 
shown in Fig 4.1 and Fig 4.2, respectively. In such networks, the cell processes, 
involved proteins, protein types and locations, as well as types of regulation 













All these gene targets identified from microarray, which are involved 
in the regulations of cell cycle, apoptosis, cytoskeleton, DNA repair and 
oxidation reduction, deserve further investigations for novel therapeutic 
targets. For instance, TOP2A, which encode DNA topoisomerase II, have been 
implicated in the development of several antitumor agents. A variety of 
mutations in this gene are associated with the acquirement of drug 
resistance (Fortune & Osheroff, 2000; Pommier et al., 2010). TUBB, the gene 
for beta-tubulin, is a major component to assemble microtubules and form 
cytoskeleton. The anticancer drugs like paclitaxel and vinca alkaloids can 
target tubulin and kill cancer cells (Hadfield et al., 2003; Pasquier  & Kavallaris, 








2008). ANAPC5 (anaphase promoting complex subunit 5), which was 15 folds 
decreased after BHV treatment, is a cell cycle related-E3 ubiquitin ligase that 
controls progression through mitosis and the G1 phase of the cell cycle 
(Peters & Jan-Michael, 2002).  
Furthermore, by literature review, several genes involved in 
MAPK/ERK pathway were identified. For example, the eukaryotic translation 
initiation factors (EIF3D, EIF3F and EIF4G2) are found to be regulated by MAP 
kinase interacting Ser/Thr kinase 1/2 (MNK 1/2), which are directly activated 
by ERK 1/2 (Jackson et al., 2010). EIF protein family can bind to 40S ribosome 
and help maintain 40S and 60S ribosomal subunits, which play an important 
role in mRNA translation and protein synthesis. Interestingly, EIF3 proteins 
can also be inhibited by tAIF in cytosol (Kim et al., 2006). Several genes from 
heterogeneous nuclear ribonucleoproteins (HNRNPA1, HNRNPD and HNRNPK) 
are also downstream targets of ERK 1/2. HNRNP proteins can function as the 
substrate of kinases and bind to DNA and RNA in a sequence specific manner, 
regulating gene translation and mRNA metabolism (Notari et al., 2006). All 
these gene changes are in agreement with functional observations and 
signaling studies and further provide new information about mechanisms of 
actions.  
4.4.2  Altered proteins in LAAO treated NUGC-3 gastric cancer cells 
In this study, SILAC experiment was performed to examine the protein 






showed that many of the differentially expressed proteins are related to 
mitochondria structures and functions (e.g. AFG3L2, ACAT1, ALDH18A1, DC1, 
HADHA, HDAHB, ACAA2, PMPCA, PMPCB, SDHA and SUCLG1 in Table 3.3), 
which may be responsible for the mitochondria mediated caspase-
independent apoptosis. For example, SDHA which is short for succinate 
dehydrogenase subunit A, flavoprotein, is involved in complex II of the 
mitochondrial electron transport chain. The decrease of SDHA was reported 
Hippi expression induced HeLa cell apoptosis, accompanied by AIF release 
(Majumder et al., 2006).  
Since the treatment agents and conditions are different, the SILAC 
data cannot be compared with microarray data directly. However, several 
similarities and consistence are identified. For example, a decreased 
expression of Ras GTPase-activating-like protein IQGAP3 was observed in 
SILAC data, which is described as an upstream activator of Ras/ERK pathway 
(Nojima et al., 2008; Yang et al., 2014). The EIF genes were found to be 
inhibited in microarray data by BHV and one EIF protein inhibitor EIF4EBP1 
(eukaryotic translation initiation factor 4E-binding protein 1) was up-
regulated by LAAO treatment. Another protein from HNRNP family (HNRNPM) 
was also down-regulated by LAAO treatment. Moreover, the down-regulation 
of heat shock protein family (HSP90AB1, HSPA8 and HSPH1) was observed in 
BHV treated NUGC-3 cells. A putative heat shock protein HSP90-beta 4 






reported to promote cell apoptosis, which was supported by Bengalin 
induced apoptosis in leukemic cells (Ravagnan et al., 2001; Gupta et al., 2010). 
Clearly, the DNA microarray and SILAC can identify a lot of 
differentially regulated genes and proteins, which provide valuable 
information to help researchers understand cancer responses to intervention, 
mechanisms of actions, novel biomarker and anticancer targets. However, 
how to analyse these hundreds of thousands of genes or proteins is still a 
challenging task. Nowadays, advanced bioinformatics software and tools 
have been developed to facilitate researchers to in the analysis of these large 
volumes of data, including DAVID, KEGG, GeneSpring, Pathway Studio and 
Partek Genomics Suite.   
4.5  Conclusions  
In the current study, the anticancer potential of scorpion venoms and 
snake venom L-amino acid oxidase (LAAO) were screened, evaluated and 
investigated in gastric cancer in vitro and in vivo. Particularly, the anticancer 
effects of Hottentotta hottentotta scorpion venoms (BHV) and LAAO from 
Crotalus adamanteus snake venom were extensively studied by various 
functional analysis and mechanisms detections.  
First, the anti-proliferative effects of several scorpion venoms were 
examined and compared. It was found that scorpion venom from 
Mesobuthus martensi karsch had limited anti-proliferative effects on NUGC-3 






Comparatively, scorpion venoms from Hottentotta hottentotta, Heterometrus 
longimanus and Pandinus imperator exerted stronger inhibition of NUGC-3 
cell proliferation, among which BHV was the most promising exhibiting a low 
IC50. 
Next, the anticancer activities of BHV were investigated in both 
NUGC-3 gastric cancer cell line and a xenograft tumor model. BHV decreased 
the cell viability/proliferation of NUGC-3 dose-dependently by cell cycle 
arrest at sub-G1 phase and induction of cell apoptosis, which was confirmed 
by Annexin V staining. Morphological characteristics of apoptosis such as 
membrane blebbing and chromatin condensation were observed under 
fluorescence microscope and TEM.  Interestingly, at low concentration, BHV 
also inhibited cell migration and invasion of NUGC-3 cells. In vivo, BHV 
inhibited the NUGC-3 tumor growth, with histological evidence of disruption 
of tissue homogeneity and induced apoptosis in situ.  
Subsequently, BHV crude venom was partially purified and 
characterized by HPLC, SDS-PAGE and mass spectrum, with the identification 
of L-amino acid oxidase (LAAO) as the active molecule in BHV. In view of the 
inability to produce LAAO in BHV from the supplier, a LAAO from Crotalus 
adamanteus snake venom was evaluated for its anticancer effects in NUGC-3 
cells. Similar findings including the decrease in cell viability, cell cycle arrest at 
G2/M phase, induction of apoptosis and the inhibition on cell migration were 
observed in both BHV and LAAO treated NUGC-3 cells. BHV and LAAO also 






western blot, caspase-3 activity assay as well as with the presence of pan 
caspase inhibitor z-VAD-fmk.  
The mechanisms and pathways in NUGC-3 gastric cancer cells in 
response to BHV and LAAO treatment are briefly summarized in as such:  
BHV/LAAO increases intracellular ROS, which causes mitochondria 
dysfunction and inhibits MAPK/ERK signaling pathway. Subsequently, AIF 
translocates from mitochondria to nucleus and initiates a caspase-
independent apoptosis. Concomitantly, the inhibition of ERK pathway results 
in the decrease in cell proliferation/viability, cell cycle arrest, suppression of 
cell migration and invasion, as well as contribution to cell apoptosis. The 










Fig 4.3  Diagram showing the possible mechanistic pathways of how 







The combination of transcriptomic and proteomic approaches have 
leaded to the identification of  several gene and protein candidates from the 
microarray data and SILAC analysis, such as EIF,  HNRNP and HSP families as 
well as TUBB, TOP2A and SDHA, which could be important and promising 
anticancer targets worthy of further studies.   
4.6  Future work 
The future directions of this study are: 
 Further investigation into the selectivity of LAAO to gastric cancer and 
normal cells. As it was found that LAAO had certain preference to 
target poorly differentiated gastric cancer cells, future work will 
include more gastric cancer and normal cell lines to compare the 
cytotoxicity of LAAO to poorly differentiated and well differentiated 
gastric cancer cells, and cytotoxicity to cancerous and normal gastric 
cells.  
 Elucidating the mechanism by which LAAO inhibits NUGC-3 cell 
motility. One interesting finding in this project is the inhibitory effect 
of LAAO to NUGC-3 cell motility at low concentration. The Cell 
Motility RT2 Profiler PCR Array could be employed to elucidate how 
LAAO may regulate the selected 84 genes involved in NUGC-3 cell 
migration and invasion.  
 Verifying the role of ROS in LAAO induced caspase independent 






treatment appears to play an important role in the regulation of 
MAPK/ERK pathway, mitochondria dysfunction and AIF translocation. 
Further confirmation could be performed by abrogating ROS 
formation with catalase. 
 Assessing the safety and antitumor activity of LAAO in NUGC-3 
xenograft tumor model. The mouse xenograft tumor model is of great 
importance in the evaluation of LAAO`s anticancer potential. 
Therefore, this study will continue to assess the safety and efficacy of 
LAAO in NUGC-3 xenografts. As the present animal model used is a 
subcutaneous model, an orthotopic model can be employed.  
 Validating targeted candidates from the microarray and SILAC data. 
Several gene/protein candidates have been identified as potential 
therapeutic targets of gastric cancer from microarray and SILAC assays, 
including EIFs, HNRNPs, HSPs, TUBB, TOP2A, and SDHA. These 
candidates will be further validated by RT-PCR, western blot and 
approaches such as siRNA-mediated silencing of the genes and small 
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Supp. Fig 1 Image of Hottentotta hottentotta scorpion. The copyright 
belongs to František Kovařík and the permission is obtained.  
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Supp. Fig 2  Identification of voltage-gated potassium channels in NUGC-3 
cells by path clamp. 4-AP, 4-aminopyridine (1mM), as inhibitor of voltage 
















Supp. Fig 3  Gene expression of voltage gated ion channels in NUGC-3 
cells by real time PCR. The fold change was normalized with the gene 
expression in HeLa cells. Data are presented as means + SEM. N=3. 
  
 
Supp. Fig 4  Measurement of mouse serum alanine transaminase (ALT) 
activity. Alanine Transaminase Activity Assay Kit was applied in this experiment 















Group Labeling body weight (g) 
control 
G1-- 19 19 20 20 
G5++ 17 18 18 19 
G4L 18 17 18 17 
G2++ 18 19 19 18 
G4 R 17 19 18 18 
6.25 ug/mouse 
BHV 
G5 L 17 17 18 17 
G6 R 19 19 20 20 
G4 ++ 18 18 18 18 
G1 L 18 17 18 18 
G3 L 17 17 17 17 
12.5 ug/mouse 
BHV 
G6 -- 19 20 20 19 
G3 ++ 18 17 18 17 
G6 L 19 18 19 19 
G1 R 18 17 18 18 
G3 R 19 19 20 20 




Supp. Fig 5 Role of catalase in LAAO induced reduction of cell viability of 
NUGC-3 cells. NUGC-3 cells were treated with 1 ug/ml LAAO and various 
concentrations of catalase for 24 h. Cell viability was analyzed by 
alamarBlue assay. Data are presented as means + SEM. N=3. 
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Supp. Table 1  Record of body weight of mice after BHV injection 
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Abstract
Scorpions and their venoms have been used in traditional medicine for thousands of years in China, India and Africa. The scorpion
venom is a highly complex mixture of salts, nucleotides, biogenic amines, enzymes, mucoproteins, as well as peptides and
proteins (e.g. neurotoxins). One of the recently observed biological properties of animal venoms and toxins is that they possess
anticancer potential. An increasing number of studies have shown that scorpion venoms and toxins can decrease cancer growth,
induce apoptosis and inhibit cancer progression and metastasis in vitro and in vivo. Several active molecules with anticancer
activities, ranging from inhibition of proliferation and cell cycle arrest to induction of apoptosis and decreasing cell migration and
invasion, have been isolated from scorpion venoms. These observations have shed light on the application of scorpion venoms
and toxins as potential novel cancer therapeutics. This mini-review focuses on the anticancer potential of scorpion venoms and
toxins and the possible mechanisms for their antitumor activities.
Keywords: Scorpion, venoms and toxins, anticancer potential, apoptosis
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Introduction
The scorpion, which is one of the oldest creatures known,
has existed on earth for more than 400 million years.
Scorpions are known to be widely distributed all over the
world, and there are over 1500 species that have been
reported thus far.1 Scorpions have developed a negative
reputation due to their stings and envenomation, usually
resulting in pain, swelling, hypertension, cardiac arrhyth-
mia and other systemic manifestations.2 Scorpion envenom-
ation is a public health hazard in tropical and subtropical
regions. More than 1,200,000 scorpion stings are reported to
occur yearly with the number of deaths possibly exceeding
3250 per year worldwide. There is therefore, the need for
improvement in specific (antivenom) and systematic
treatments.3
However, human beings have also derived benefits from
the scorpion. In China, fried scorpions are popularly con-
sumed as food, and scorpion or snake wines are used to
strengthen the immune system.4 The scorpion and its
venom have been applied in traditional medicine for thou-
sands of years in China, India and Africa. For example, in
China, the dried whole bodies of scorpions have been
widely used as an antiepilepsy and analgesic agent since
the Song Dynasty (A.D. 960-1279).5,6 The Buthidae family of
scorpions has been widely studied for medical applications.
The scorpion venom is a highly complex mixture produced
from the venom gland to immobilize/paralyze the prey or to
defend against predators. The venom which is found in
the telson contains salts, nucleotides, biogenic amines,
enzymes such as phospholipase, hyaluronidase, L-amino
acid oxidase, metalloproteinase, serine protease, mucopro-
teins, as well as small peptides which are known to interact
with various ion channels in excitable cell membranes,
making them good candidates for drug design in
the pharmaceutical industry.7,8 A number of antimicrobial
peptides have also been isolated and reported to be bio-
active against bacteria, fungi, yeasts and viruses
including Mucroporin-M1 which inhibits the amplification
of hepatitis virus B and Kn2-7 which possesses anti-HIV-1
activity.9,10
This mini-review explores the significance of scorpion
venoms as anticancer agents and provides biological
insights into their mechanism (s) of action.
Scorpion venoms as potential cancer
therapeutics
According to the World Health Organization, cancer has
replaced heart disease to become the leading cause of
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mortality worldwide, leading to 7.6 million deaths
(around 13% of all deaths) in 2008.11 Cancers of the
lung, stomach, liver, colon and breast are known to be
the highest contributors to cancer mortality each year.
Even though treatment for cancer improved considerably
over the past decade resulting in increased patient sur-
vival and better quality of life, early screening and diag-
nosis still play a very important role in improving the
patient’s survival rate, since many cancers have a high
chance of cure if detected early and treated adequately.12
Surgical resection of the primary tumor and regional
lymph nodes is the main and most effective way to
treat most patients with solid tumors.13 Adjuvant and
neo-adjuvant therapies (chemotherapy and radiotherapy)
are known to benefit patients by increasing their survival
remarkably. However, the side effects and risks of treat-
ment resistance and toxicity are of major concern. Newly
emerging targeted therapy opens a novel avenue for sur-
gical oncologists and clinicians to better understand the
molecular mechanism of cancer and provide alternative
and effective approaches to combat cancer.14
One of the recently discovered biological properties of
scorpion venom and toxin is that they possess anticancer
potential. An increasing number of experimental and pre-
clinical investigations have demonstrated that crude scor-
pion venom and some purified proteins and peptides can
impair cancer proliferation, arrest cell cycle, induce cell
apoptosis and inhibit cancer metastasis in in vitro or
in vivo setting. The anticancer effect and efficacy of scorpion
venoms have been tested in glioma, neuroblastoma, leuke-
mia, lymphoma, breast, lung and prostate cancer.15,16
Chinese red scorpion (Buthus martensii
Karsch) venom
Buthus martensii Karsch (BmK) (Figure 1), also known as
Chinese red scorpion, belongs to the Buthidea family and
can be extensively found from north western China to
Mongolia and Korea. The medical use of BmK scorpion
dates back to the Song Dynasty of China (A.D. 960-1279).
To date, this scorpion venom has been well described as
having antiepileptic, analgesic, anti-rheumatic and antican-
cer potential.5,6,15,16 Among all the scorpions used in cancer
research, BmK is probably the first to have been reported to
possess antitumor properties.16 BMK scorpion venom has
been well studied in China, with several active molecules
having been isolated and characterized, making this scor-
pion venom a good source for the development of antic-
ancer agents.
In 1987, Zhang Futong, extracted a solution from the
dried whole body of the BmK scorpion (Quan Xie in
traditional Chinese medicine) and administered the extract
subcutaneously to mice with reticulum cell sarcoma and
MA-737 mammary carcinoma at a dose of 0.04 g/mouse
every other day for five times.17 On the 8th day following
administration, the inhibitory rate of growth was 55.5% in
reticulum cell sarcoma and 30.4% in mammary carcinoma,
respectively. There was a decrease in DNA content in the
tumor tissues after BmK venom treatment. This seminal
finding formed the basis for the escalating reports on the
anticancer potential of BmK scorpion venom.
Several groups later described the anticancer effects of
the crude scorpion venom of BmK in vitro or in vivo.
However, scientific literatures on the BMK venom which
are published in Chinese will not be included in this
review. Wang and Ji observed that the crude venom extract
from BmK induced apoptosis of malignant glioma U251-
MG cells in vitro especially at a dose of 10mg/mL but
was not cytotoxic to BEL7404 hepatocellular carcinoma
cells and C400 Chinese hamster ovary cells.18 For the
in vivo study, BmK venom was assessed using severe com-
bined immunodeficiency mice bearing U251-MG tumor
xenografts. Both tumor volumes and weights were signifi-
cantly reduced compared with the control group after
20mg/kg BmK venom treatment for 21 days. The authors
proposed ion channels as targets for BmK venom in glioma
cells. Another study by Gao et al.19 found that BmK
venom could also inhibit growth of human Jurkat and
Raji lymphoma cells by arresting the cell cycle and inducing
apoptosis as evidenced by Annexin-V and propidium
iodide staining and flow cytometry assay. Treatment with
the BmK venom has been demonstrated to inactivate the
PI3K/Akt signal pathway by increasing phosphatase and
tensin homolog (PTEN) expression in Raji cells, whereas, in
Jurkat cells, a PTEN-negative cell line, up-regulation of p27
(a cell cycle inhibitor) may partially account for the antic-
ancer effect.19
In light of several reports on the anticancer potential of
BmK crude venom, researchers attempted to purify and
isolate the anticancer agent in BmK venom with techniques
such as size-exclusive gel filtration, ion exchange chroma-
tography and high-performance liquid chromatography.20
Polypeptide extract from the scorpion venom (PESV), a
group of polypeptides comprising 50–60 amino acids
extracted from crude venom of BmK, was reported to
induce growth inhibition and apoptosis of DU 145 human
prostate cancer cell.21 PESV treatment on DU 145 cells
resulted in a significantly dose-dependent inhibition of pro-
liferation with G1 phase arrest in cell cycle, accompanied by
enhanced expression of p27 and a decrease in cyclin E.
PESV treatment also induced a high apoptosis index,
which was verified by the TdT-mediated dUTP-biotin
nick-end labeling (TUNEL) assay and probably due to an
Figure 1 Buthus martensii Karsch (Chinese red scorpion). Specimen from
Jiangsu Province, PR China. Arrow indicates telson, the venom-producing gland.
(A color version of this figure is available in the online journal)
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increase in pro-apoptotic protein Bax. A recent study
reported that another partially purified component from
BmK scorpion venom (SVCIII), obtained after gel filtration
with a molecular weight of approximate 70–80 kDa, could
inhibit cell proliferation of THP-1 and Jurkat human leuke-
mia cells and caused cell cycle arrest at G1 phase.22
A decrease of cyclin D1 expression was observed in a
dose-dependent manner after SVCIII treatment. The anti-
proliferative effect has been attributed to the suppression
of NF-kB activation.
Two anticancer peptides have been purified and charac-
terized from BmK scorpion venom. Early in 2002, Liu and
colleagues first isolated an analgesic-antitumor peptide
(AGAP) from BmK scorpion venom with a series of purifi-
cation steps.23 This peptide had a relative molecular mass of
6280 Da and exerted antitumor effects in the mouse S-180
fibro sarcoma model and Ehrlich ascites tumor model. The
AGAP gene was determined, cloned and expressed in the
Escherichia coli system in 2003 by the same group (GeneBank
No. AF464898) and the protein showed effective analgesic
and antitumor activities.24 Subsequently, BmK AGAP was
classified as a voltage-gated sodium channel scorpion
toxin and three transcription regulatory elements were elu-
cidated in the BmK AGAP intron.25 A recombinant fusion
protein SUMO-AGAP which combined a small ubiquitin-
related modifier to AGAP was proven to have antitumor
activity.26 Further study showed that SUMO-AGAP inhib-
ited cell proliferation and migration of SHG-44 human
malignant glioma cells by inducing cell cycle arrest and
interfering with the p-Akt, NF-kB, Bcl-2 and MAPK signal-
ing pathways.27
BmKCT, another purified anticancer peptide from BmK
with 68% homology to chlorotoxin (a promising antiglioma
toxin that will be discussed later), was cloned from a cDNA
library made from the venom glands of the BmK scorpion.28
BmKCT contains 59 amino acid residues and comprises a
mature toxin of 35 residues with four disulfide bridges and
a signal peptide of 24 residues. Subsequently, the recombin-
ant peptide of BmKCT was shown to inhibit the growth of
glioma cells (SGH-44) dose-dependently with IC50 value of
approximately 0.28 mMwhile showing no toxicity to normal
astrocytes under the same condition.29 Whole-cell patch-
clamp technique indicated that the chloride current in
SHG-44 glioma cells was inhibited by BmKCT in a vol-
tage-dependent manner (up to 55.86% inhibition at
0.14 mM treatment) and histological analysis of tissues
from BmKCT-treated mice showed that the brain was one
of the targets of this toxin. Furthermore, in vivo evidence
from Fan et al. using the glioma/SD rat model30 demon-
strated that BmKCT toxin inhibited glioma proliferation
and tumor metastasis and 131I-labeled or Cy5.5-conjugated
BmKCT selectively targeted the glioma in situ. All these
observations provide evidence for the potential therapeutic
application of BmKCT for glioma diagnosis and treatment.
Two scorpion enzymes, isolated by our research group
from BmK scorpion venom, have also been reported to pos-
sess anticancer potential. One is the serine proteinase-like
protein named BmK-CBP, which can dose-dependently
bind with human breast cancer cells MCF-7.31 The other,
BmHYA1, a homogeneous hyaluronidase from the BmK
scorpion, was shown to modulate the expression of CD44,
a cell surface marker in the MDA-MB-231 breast cancer
cell line.32
Scorpion venom targeted ion channels
A novel and promising field of cancer research is targeting
Naþ, Kþ, Ca2þ and Cl- ion channels in cancer, given that
altered or abnormal expression and activity of ion channels
are related to cancer processes and pathology including cell
volume and motility, cell proliferation and death, as well as
cell adhesion, migration and invasion. Moreover, blocking
ion channel activity can impair cancer growth and
metastasis.33,34
Functional expression of voltage-gated sodium channels
has been reported to be associated with several strongly
metastatic carcinomas, such as breast and prostate cancer,
as evidenced by their over-expression in aggressive cancer-
derived cell lines and biopsies as well as its role in control-
ling multiple steps of metastatic cascades.35 Fraser and
co-workers36 observed that functional expression of
Nav1.5 was up-regulated in metastatic human breast
cancer cells and tissues, and its activity could potentiate
cellular behaviours linked to metastasis, such as directional
motility, endocytosis and invasion. Also, a strong correl-
ation was found between Nav1.5 expression and lymph
node metastasis in a clinical study. Similar findings were
also observed for the involvement of Nav1.7 in prostate
cancer.37–39
Compared to Naþ channels, Kþ channels are mainly
implicated in cancer cell proliferation and survival. There
is a tight relationship between Kv expression and cell pro-
liferation and apoptosis, but the underlying mechanism is
still not clear. Generally, by regulating the membrane poten-
tial, Kv channels can control the Ca
2þ fluxes and cell
volume, and therefore exert their role in cell cycle regula-
tion and cell death.40 A number of Kv channels have been
detected to be abnormally expressed in many primary can-
cers. Kv1.3 has been analyzed in gliomas, colon, prostate
and breast cancers.41 The aberrant expression of Kv1.3
was observed to promote cancer cell growth. The roles of
Kv 1.5, Kv10.1 and KCa3.1 have been studied in gliomas,
colon cancer and melanoma. Kv11.1, also known as hERG,
is expressed in several cancers, including leukemia, neuro-
blastoma, stomach and colorectal cancers. The blockage of
Kv11.1 with a channel inhibitor or siRNA interference can
impair cell proliferation in vitro and reduce cell invasive-
ness, making it a novel therapeutic target for cancer.42
Among the peptides found in scorpion venoms, the most
well-studied are the long-chain toxins with 60–70 amino
acid residues cross-linked by four disulfide bridges,
which interact with Naþ channels. Short-chain toxins with
30–40 amino acid residues are known to modulate Kþ or
Cl (chloride ion) channels.43 Compared to massive Naþ or
Kþ channel toxins, only few calcium channel-related toxins
(with a variable number of amino acids) have been purified
or cloned from scorpion venoms.44
Chlorotoxin (CTX), a 36–amino acid small peptide, first
purified from the Leiurus quinquestriatus scorpion venom in
1993, contains a single tyrosine residue that is available for
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radioiodination, eight cysteine residues, and four disulfide
bonds.45 Originally, CTX was described as a Cl channel
blocker that acts as a paralytic agent for small insects and
other arthropods. CTX had been largely applied as a tool in
the study of voltage-gated chloride channel until the sem-
inal findings of Ullrich and co-workers in cancer
research.46,47 They adapted the whole cell patch-clamp rec-
ording technique to identify and characterize the voltage-
activated outwardly-rectifying Cl currents in human
astrocytoma/glioblastoma cells. Cl currents were
observed in all tumor cells of glial origin (primary cultures
of six freshly resected brain tumors and seven established
human astrocytoma cell lines), while interestingly they
were absent in normal non-malignant glial cells or non-
glial tumors such as melanoma, breast, rhabdomyosarcoma
and neuroblastoma. Their study also demonstrated that
CTX could block the Cl current and inhibit cell prolifer-
ation of astrocytoma cells.
The specifically expressed Cl channel in glioma and its
high affinity and sensitivity to CTX led to the use of this
peptide by Soroceanu and colleagues to target gliomas in
1989.48 They showed that biotinylated and fluorescence-
tagged CTX and CTX-conjugated molecules had specific
staining for glioma cells in vitro, in situ and in patient biop-
sies. Another survey of over 200 tissue biopsies from
patients with various malignancies also suggest that CTX
bind to the surface of gliomas and other embryologically
related tumors of neuroectodermal origin but not to normal
brain.49 Furthermore, CTX has been reported to signifi-
cantly reduce the glioma cell migration dose-dependently
and inhibited cell invasion into fetal brain aggregates at
5 mM concentration.50
The receptor of CTX was initially believed to be related
to the Cl channel from electrophysiological evidence (as
described above). Further studies with a recombinant His-
CTX revealed that the principal receptor is matrix metallo-
proteinase-2 (MMP-2), a proteinase that is present on the
surface of glioma cells, and specifically over-expressed in
gliomas and related cancers, but normally not expressed in
brain.51 CTX could inhibit the enzymatic activity and
reduce the expression of MMP-2, causing disruption of
chloride channels and Cl currents. A synthetic CTX
coupled with radioactive iodine isotope (131I-TM-601), pro-
duced by Transmolecular, Inc. (Cambridge, MA) has been
approved by the US Food and Drug Administration for
tumor imaging and diagnosis. Preclinical and Phase I clin-
ical trials have been completed in recurrent glioma patients,
with the conclusion that intracavitary dose of 131I-TM-601 is
safe and minimally toxic, and that 131I-TM-601 binds malig-
nant glioma with high specificity and for long duration.52 A
Phase II trial using a higher dose of radioactivity and
repeated local administrations is currently in progress.
Because CTX binds tumor with high affinity and specificity
and shows low toxicity, it represents a promising diagnostic
agent for imaging and targeted therapies for gliomas and
other cancers.
Apart fromCTX, several other scorpion toxins associated
with ion channels have been purified and investigated in
cancer research. Iberiotoxin (IbTX), a 37-amino acid neuro-
toxin from the Indian red scorpion Mesobuthus tamulus, has
been reported to block the large conductance Ca2þ activated
Kþ (BK) channel and induce a slight depolarization inMCF-
7 human breast cancer cells. Cells treated with IbTX
(500nM) were observed to accumulate in S phase of the
cell cycle but did not alter the cell proliferation rate.53
Another experiment showed that blockade of the BK chan-
nels by IbTX inhibited Kþ currents and growth of PC-3
prostate cancer cells.54 Margatoxin (MgTX), which is iso-
lated from the venom of Centruroides margartatus scorpion,
sharing a sequence homology and structural similarity with
IbTX, has a high affinity and specificity against Kv1.3. Jang
et al. found that MgTX can significantly inhibit the prolif-
eration of A549 human lung adenocarcinoma cells by reg-
ulating the G1/S cell cycle progression. Western blot
analysis showed increased expression of p21Waf1/Cip1
and decreased levels of CdK4 after 1 nM MgTX treatment.
The antiproliferative effect of MgTX was also verified in a
nude mice xenograft model, as confirmed by a reduction of
tumor volume after injectingMgTX into the tumor tissues.55
Charybdotoxin (ChTX), another peptide isolated from
Leiurus quinquestriatus scorpion venom, is structurally
similar to IbTX and MgTX and acts as an inhibitor of
Ca2þ-activated Kþ channel. Studies revealed that ChTX
can inhibit the migration of NIH3T3 fibroblasts and
human melanoma cells dose-dependently by up to 61%,
possibly by depolarizing the cell membrane potential and
reducing the electrochemical driving force for Ca2þ entry,
which is important in the cell migration process.56 However,
in the same study, it was also observed that ChTX did not
influence the disruption of the epithelial layer of renal cells
by human melanoma cells, suggesting that Kþ channel
activity was not involved in melanoma invasion.
Recent studies on the anticancer potential of
scorpion venoms and toxins
Research on animal venoms and toxins has attracted greater
interest because of advances in genomic and proteomic
approaches such as the venomous systems genome pro-
ject.57 In addition, new emerging research regarding the
relationship between ion channels and cancer progression
and therapy has paved the way for novel clinical applica-
tions for scorpion venoms and toxins, given that scorpion
venoms contain many disulfide-rich peptides and proteins
which display high specificity, good permeability and sta-
bility against cancer cells.58 In the last decade, more evi-
dence has accumulated regarding the anticancer effect of
scorpion venoms and toxins from different species and tar-
geting assorted cancers.
In 2007, Gupta et al.59 reported the antiproliferative and
apoptogenic activities induced by Heterometrus bengalensis
Koch (Indian black scorpion) against human leukemic U937
and K562 cell lines, characterized by cell cycle arrest, mem-
brane blebbing, chromatin condensation and DNA degrad-
ation. The molecule of interest was subsequently purified
and named Bengalin, a 72-kDa protein with an N-terminal
sequence that shared no similarity with any protein in the
scorpion toxin database. The IC50 of Bengalin was deter-
mined as 3.7mg/mL and 4.1 mg/mL for U937 and K562
human leukemic cells, respectively, without affecting
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normal human lymphocytes. Bengalin induced apoptosis
as confirmed by damaged nuclei, sub G1 peak, DNA frag-
mentation as well as decreased telomerase activity.
Furthermore, Bengalin caused the loss of mitochondrial
membrane potential, decreased the expression of heat
shock protein (HSP) 70 and 90, activated caspase-3, 9 and
induced cleavage of poly (ADP-ribose) polymerase.60 These
observations indicated activation of a mitochondrial death
cascade, involving inhibition of HSPs by Bengalin.
Two peptides named neopladine 1 and neopladine 2, iso-
lated from Tityus discrepans scorpion venom, were reported
to be effective in inducing apoptosis and necrosis of SKBR3
breast cancer cells with negligible effect on non-malignant
MA104 monkey kidney cells.61 Immunohistochemistry
showed that neopladines bind to the surface of SKBR3 cell
and triggered FasL and Bcl-2 expression. We have also
found that the Indian red scorpion (Mesobuthus tamulus)
venom decreased the cell viability of human breast cancer
cells dose-dependently with minimal cytotoxic effect on
normal breast epithelial cells in vitro (unpublished data).
Another research finding showed that scorpion venom
from Odontobuthus doriae inhibited cell growth and induced
apoptosis in SH-SY5Y human neuroblastoma cells and
MCF-7 breast cancer cells.62,63 Moreover, Odontobuthus
doriae venom increased intracellular oxidative stress as evi-
denced by an increase in reactive nitrogen intermediates
and depression of glutathione and catalases in MCF-7
cells, which may contribute to the induction of apoptosis.
The cytotoxicity of another scorpion venom Androctonus
crassicauda was also screened using MCF-7 and SH-SY5Y
cell lines.64 Similarly, Androctonus crassicauda venom
caused the suppression of cell growth by S-phase cell
cycle arrest and induced apoptosis by increasing nitric
oxide production, thereby, activating caspase-3 and depo-
larizing mitochondrial membrane. The above findings sug-
gest that the Odontobuthus doriae and Androctonus
crassicauda scorpion venoms may be potential sources for
isolating effective anticancer molecules.
Cytotoxic proteins such as Bengalin and Neopladine 1
and 2 with molecular weight more than 10 kDa are able to
inhibit cell viability and induce apoptosis or necrosis in
cancer cells while showing negligible cytotoxicity to
normal cells. Hence, such proteins are promising for
developing as anticancer drugs.
Besides cancer therapy, scorpion venoms have also been
applied in diagnostic imaging of tumor, mainly based on
the conjugates of CTX and its homological peptides (e.g.
BmKCT) to delineate the tumor margins. Researchers
have combined CTX with other radioactive or fluorescence
molecules, such as 131I, Cy5.5, and iron oxide nanoparticles
coated with polyethylene glycol, and synthesized various
probes that can be detected by g-camera, single photon
emission computed tomography or magnetic resonance
imaging.52,65,66 Due to the binding specificity of CTX and
the use of nanovectors, the CTX-conjugated probes can
cross the blood-brain barrier and work as imaging agents
in tumors of the central nervous system. In addition, the
CTX-conjugated nanoparticles are now being developed
as a carrier of DNA in gene therapy in glioma.67
Conclusion
In summary, the anticancer effects of scorpion venoms and
toxins have been reported for several scorpion species and
in different cancer types, in both in vitro and in vivo settings.
Scorpion venoms with anticancer properties and possible
mechanisms of action are summarized in Table 1. It can be
clearly seen that the anticancer effects are achieved mainly
via targeting ion channels on cell membrane, or exerting
antiproliferative or apoptotic activities by cell cycle arrest
or induction of caspase-dependent apoptosis pathways.
Currently, only a few scorpion species have been inves-
tigated for anticancer effects. As many of the studies have
been carried out in the in vitro setting, testing the antitumor
potential of scorpion venoms/toxins in animal models is
important for preclinical research work and drug design.
Although purification and characterization of the active
components which exert anticancer effects from crude
venoms still remain a challenge, there is potential for the
use of scorpion venoms as novel cancer therapeutics.
Table 1 Summary of the important molecules with anticancer potential and possible mechanisms
Molecules Scorpion species Tested cancer models Possible mechanisms References
BmK AGAP Buthus martensii Karsch Mouse fibro sarcoma, Rhrlich ascites
tumor, SHG-44 glioma cells
Voltage gated sodium channel toxin,
interfering p-AKT, NF-kB, Bcl-2 and
MAPK signaling pathway
23–27
BmKCT Buthus martensii Karsch SHG-44 glioma cells, glioma/SD rat Inhibit chloride current and selectively
target glioma
28–30
Chlorotoxin Leiurus quinquestriatus Glioma cells, animal models and clin-
ical trials
Inhibit chloride current, bind to matrix
metalloproteinase-2 (MMP-2)
48–52
Iberiotoxin Mesobuthus tamulus MCF-7 breast cancer cells Block large conductance Ca2þ activated
Kþ (BK) channel
53, 54
Magatoxin Centruroides margartatus A549 human lung adenocarcinoma
cells and xenograft model
Inhibit Kv 1.3, increase expression of
p21Waf1/Cip1 and decrease CdK4
55
Charybdotoxin Leiurus quinquestriatus NIH3T3 fibroblasts and human melan-
oma cells
Inhibit cell migration does-dependently 56
Bengalin Heterometrus bengalensis Koch human leukemic U937 and K562 cells Induce caspase apoptosis pathway by
loss of mitochondrial membrane
potential and decreased HSP 70 and 90
59, 60
Neopladine 1 and 2 Tityus discrepans SKBR3 breast cancer cell line Trigger FasL and BcL-2 expression 61
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